10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

Commission file number 001-15925

COMMUNITY HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware	13-3893191
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)
4000 Meridian Boulevard Franklin, Tennessee	37067
(Address of principal executive offices)	(Zip Code)

615-465-7000

(Registrant’s telephone number)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  þ    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ             Accelerated filer ¨        Non-accelerated filer ¨        Smaller reporting company ¨
	(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨    No þ

As of April 29, 2015, there were outstanding 118,034,114 shares of the Registrant’s Common Stock, $0.01 par value.

Community Health Systems, Inc.

Form 10-Q

For the Three Months Ended March 31, 2015

Part I.	Financial Information		Page
	Item 1.	Financial Statements:
		Condensed Consolidated Statements of Income (Loss) - Three Months Ended March 31, 2015 and March 31, 2014 (Unaudited)	2
		Condensed Consolidated Statements of Comprehensive Income (Loss) - Three Months Ended March 31, 2015 and March 31, 2014 (Unaudited)	3
		Condensed Consolidated Balance Sheets - March 31, 2015 and December 31, 2014 (Unaudited)	4
		Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2015 and March 31, 2014 (Unaudited)	5
		Notes to Condensed Consolidated Financial Statements (Unaudited)	6
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	44
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	66
	Item 4.	Controls and Procedures	66
Part II.	Other Information
	Item 1.	Legal Proceedings	66
	Item 1A.	Risk Factors	72
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	72
	Item 3.	Defaults Upon Senior Securities	73
	Item 4.	Mine Safety Disclosures	73
	Item 5.	Other Information	73
	Item 6.	Exhibits	74
Signatures			75
Index to Exhibits			76

1

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(In millions, except share and per share data)

(Unaudited)

	Three Months Ended
	March 31,
	2015		2014
Operating revenues (net of contractual allowances and discounts)	$	5,646	$	4,875
Provision for bad debts		735		699
Net operating revenues		4,911		4,176
Operating costs and expenses:
Salaries and benefits		2,257		1,992
Supplies		762		632
Other operating expenses		1,099		1,019
Government settlement and related costs		8		-
Electronic health records incentive reimbursement		(26)		(40)
Rent		116		98
Depreciation and amortization		296		255
Amortization of software to be abandoned		-		42
Total operating costs and expenses		4,512		3,998
Income from operations		399		178
Interest expense, net		241		224
Loss from early extinguishment of debt		8		73
Equity in earnings of unconsolidated affiliates		(18)		(11)
Impairment of long-lived assets		-		24
Income (loss) from continuing operations before income taxes		168		(132)
Provision (benefit) for income taxes		56		(56)
Income (loss) from continuing operations		112		(76)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		(11)		(4)
Impairment of hospitals sold or held for sale		(1)		(18)
Loss on sale, net		(1)		-
Loss from discontinued operations, net of taxes		(13)		(22)
Net income (loss)		99		(98)
Less: Net income attributable to noncontrolling interests		20		14
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$	79	$	(112)
Basic earnings (loss) per share attributable to Community
Health Systems, Inc. common stockholders:
Continuing operations	$	0.80	$	(0.84)
Discontinued operations		(0.11)		(0.21)
Net income (loss)	$	0.69	$	(1.05)
Diluted earnings (loss) per share attributable to Community
Health Systems, Inc. common stockholders:
Continuing operations	$	0.79	$	(0.84)
Discontinued operations		(0.11)		(0.21)
Net income (loss)	$	0.68	$	(1.05)
Weighted-average number of shares outstanding:
Basic		114,419,590		106,601,997
Diluted		115,057,668		106,601,997

See accompanying notes to the condensed consolidated financial statements.

2

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In millions)

(Unaudited)

	Three Months Ended
	March 31,
	2015		2014
Net income (loss)	$	99	$	(98)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		9
Net change in fair value of available-for-sale securities, net of tax		1		-
Amortization and recognition of unrecognized pension cost components, net of tax		1		-
Other comprehensive (loss) income		(7)		9
Comprehensive income (loss)		92		(89)
Less: Comprehensive income attributable to noncontrolling interests		20		14
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	$	72	$	(103)

See accompanying notes to the condensed consolidated financial statements.

3

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except share data)

(Unaudited)

	March 31, 2015		December 31, 2014
ASSETS
Current assets:
Cash and cash equivalents	$	222	$	509
Patient accounts receivable, net of allowance for doubtful accounts of $3,628 and $3,504 at March 31, 2015 and December 31, 2014, respectively		3,606		3,409
Supplies		561		557
Prepaid income taxes		-		30
Deferred income taxes		341		341
Prepaid expenses and taxes		189		192
Other current assets (including assets of hospitals held for sale of $7 and $38 at March 31, 2015 and December 31, 2014, respectively)		507		528
Total current assets		5,426		5,566
Property and equipment		14,400		14,264
Less accumulated depreciation and amortization		(4,309)		(4,095)
Property and equipment, net		10,091		10,169
Goodwill		8,954		8,951
Other assets, net (including assets of hospitals held for sale of $36 and $90 at March 31, 2015 and December 31, 2014, respectively)		2,648		2,735
Total assets	$	27,119	$	27,421
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	229	$	235
Accounts payable		1,192		1,293
Income tax payable		13		-
Deferred income taxes		23		23
Accrued interest		157		227
Accrued liabilities (including liabilities of hospitals held for sale of $2 and $10 at March 31, 2015 and December 31, 2014, respectively)		1,547		1,811
Total current liabilities		3,161		3,589
Long-term debt		16,740		16,681
Deferred income taxes		844		845
Other long-term liabilities		1,694		1,692
Total liabilities		22,439		22,807
Redeemable noncontrolling interests in equity of consolidated subsidiaries		520		531
EQUITY
Community Health Systems, Inc. stockholders’ equity:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued		-		-
Common stock, $.01 par value per share, 300,000,000 shares authorized; 119,000,326 shares issued and 118,024,777 shares outstanding at March 31, 2015, and 117,701,087 shares issued and 116,725,538 shares outstanding at December 31, 2014		1		1
Additional paid-in capital		2,101		2,095
Treasury stock, at cost, 975,549 shares at March 31, 2015 and December 31, 2014		(7)		(7)
Accumulated other comprehensive loss		(70)		(63)
Retained earnings		2,056		1,977
Total Community Health Systems, Inc. stockholders’ equity		4,081		4,003
Noncontrolling interests in equity of consolidated subsidiaries		79		80
Total equity		4,160		4,083
Total liabilities and equity	$	27,119	$	27,421

See accompanying notes to the condensed consolidated financial statements.

4

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

	Three Months Ended
	March 31,
	2015		2014
Cash flows from operating activities:
Net income (loss)	$	99	$	(98)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		296		302
Government settlement and related costs		8		-
Stock-based compensation expense		14		11
Loss on sale, net		1		-
Impairment of long-lived assets and hospitals sold or held for sale		2		42
Loss from early extinguishment of debt		8		73
Excess tax benefit relating to stock-based compensation		-		(3)
Other non-cash expenses, net		(7)		6
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable		(202)		(171)
Supplies, prepaid expenses and other current assets		14		14
Accounts payable, accrued liabilities and income taxes		(284)		(83)
Other		(10)		(28)
Net cash (used in) provided by operating activities		(61)		65
Cash flows from investing activities:
Acquisitions of facilities and other related equipment		(13)		(2,774)
Purchases of property and equipment		(241)		(181)
Proceeds from disposition of hospitals and other ancillary operations		62		-
Proceeds from sale of property and equipment		3		-
Purchases of available-for-sale securities		(59)		(78)
Proceeds from sales of available-for-sale securities		56		76
Increase in other investments		(39)		(99)
Net cash used in investing activities		(231)		(3,056)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		6
Repurchase of restricted stock shares for payroll tax withholding requirements		(20)		(11)
Deferred financing costs and other debt-related costs		(20)		(269)
Excess tax benefit relating to stock-based compensation		-		3
Redemption of noncontrolling investments in joint ventures		(7)		(5)
Distributions to noncontrolling investors in joint ventures		(23)		(19)
Borrowings under credit agreements		1,251		7,079
Issuance of long-term debt		-		4,000
Proceeds from receivables facility		75		133
Repayments of long-term indebtedness		(1,268)		(7,686)
Net cash provided by financing activities		5		3,231
Net change in cash and cash equivalents		(287)		240
Cash and cash equivalents at beginning of period		509		373
Cash and cash equivalents at end of period	$	222	$	613
Supplemental disclosure of cash flow information:
Interest payments	$	(300)	$	(175)
Income tax (payments) refunds, net	$	(1)	$	79

See accompanying notes to the condensed consolidated financial statements.

5

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2015 and December 31, 2014 and for the three-month periods ended March 31, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of Health Management Associates, Inc. (“HMA”) are included from January 27, 2014, the date of the HMA merger. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2015. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2014, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2015.

Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets.

During the three months ended March 31, 2014, the Company made the decision to sell several smaller hospitals and entered into definitive agreements to sell two hospitals. Since March 31, 2014, the Company made the decision to sell two additional hospitals. The condensed consolidated statement of income for the three months ended March 31, 2014 has been restated to reclassify the results of operations for these hospitals that were owned or leased in 2014 to discontinued operations.

Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses.

The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. For all other non-self-pay payor categories, the Company reserves 100% of all accounts aging over 365 days from the date of discharge. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

6

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2015 and 2014, were as follows (in millions):

	Three Months Ended
	March 31,
	2015		2014
Medicare	$	1,398	$	1,261
Medicaid		586		459
Managed Care and other third-party payors		2,946		2,450
Self-pay		716		705
Total	$	5,646	$	4,875

Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

The Company recognized approximately $26 million and $40 million for the three months ended March 31, 2015 and 2014, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology. These incentive reimbursements are presented as a reduction of operating costs and expenses on the condensed consolidated statements of income. The Company received cash related to the incentive reimbursement for HITECH incentives of approximately $54 million and $62 million for the three months ended March 31, 2015 and 2014, respectively. The Company recorded $75 million and $93 million as deferred revenue in connection with the receipt of these cash payments at March 31, 2015 and March 31, 2014, respectively, as all criteria for gain recognition had not been met.

7

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently decided to defer the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows.

2. ACCOUNTING FOR STOCK-BASED COMPENSATION

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. 2009 Stock Option and Award Plan, amended and restated as of March 19, 2014 (the “2009 Plan”).

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock. Persons eligible to receive grants under the 2000 Plan include the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 have a 10-year contractual term, options granted in 2005 through 2007 have an eight-year contractual term and options granted in 2008 through 2011 have a 10-year contractual term. The Company has not granted stock option awards under the 2000 Plan since 2011. Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan.

The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term. As of March 31, 2015, 3,192,176 shares of unissued common stock were reserved for future grants under the 2009 Plan.

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date.

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

	Three Months Ended
	March 31,
	2015		2014
Effect on income from continuing operations before income taxes	$	(14)	$	(11)
Effect on net income	$	(8)	$	(7)

At March 31, 2015, $103 million of unrecognized stock-based compensation expense related to outstanding unvested restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 29 months. There is no expense to be recognized related to stock options. There were no modifications to awards during the three months ended March 31, 2015 and 2014.

8

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows (in millions, except share and per share data):

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value as of March 31, 2015
Outstanding at December 31, 2014		1,953,727	$	32.94
Granted		-		-
Exercised		(452,959)		38.77
Forfeited and cancelled		-		-
Outstanding at March 31, 2015		1,500,768	$	31.18	4.7 years	$	32
Exercisable at March 31, 2015		1,498,764	$	31.19	4.7 years	$	37

No stock options were granted during the three months ended March 31, 2015 and 2014. The aggregate intrinsic value (the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($52.28) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on March 31, 2015. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the three months ended March 31, 2015 and 2014 was $5 million and $1 million, respectively. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options.

The Company has also awarded restricted stock under the 2000 Plan and the 2009 Plan to its directors and employees of certain subsidiaries. The restrictions on these shares generally lapse in one-third increments on each of the first three anniversaries of the award date. Certain of the restricted stock awards granted to the Company’s senior executives contain a performance objective that must be met in addition to any time-based vesting requirements. If the performance objective is not attained, the awards will be forfeited in their entirety. Once the performance objective has been attained, restrictions will lapse in one-third increments on each of the first three anniversaries of the award date. In addition, 835,000 restricted stock awards granted March 1, 2014 have a performance objective that is measured based on the realization of synergies related to the HMA merger over a two-year period that began on February 1, 2014. The performance objective could be met in part in the first year or in whole or in part over such two-year period. Depending on the degree of attainment of the performance objective, restrictions may lapse on a portion of the award grant over the first three anniversaries of the award date at a level dependent upon the amount of synergies realized. If the synergies related to the HMA merger did not reach a certain level, then the awards would have been forfeited in their entirety. Based on the synergy levels attained in the first annual measurement period ending on January 31, 2015, the performance objective for the first measurement period was met, and one-third of the awards vested on March 1, 2015. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2000 Plan and the 2009 Plan will lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance standards that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied.

Restricted stock outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows:

	Shares		Weighted- Average Grant Date Fair Value
Unvested at December 31, 2014		2,760,639	$	39.82
Granted		1,223,500		47.72
Vested		(1,115,006)		37.45
Forfeited		-		-
Unvested at March 31, 2015		2,869,133		44.11

9

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2000 Plan and the 2009 Plan. On February 27, 2013, each of the Company’s outside directors received a grant under the 2009 Plan of 3,596 RSUs. On March 1, 2014, each of the Company’s outside directors received a grant under the 2009 Plan of 3,614 RSUs. On March 1, 2015, each of the Company’s outside directors received a grant under the 2009 Plan of 3,504 RSUs. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date.

RSUs outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows:

	Shares		Weighted- Average Grant Date Fair Value
Unvested at December 31, 2014		49,362	$	36.07
Granted		21,024		47.70
Vested		(27,708)		31.76
Forfeited		-		-
Unvested at March 31, 2015		42,678		44.59

3. COST OF REVENUE

Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office and Naples, Florida office, (which was the headquarters of HMA prior to the closing of the HMA merger), which collectively were $77 million for both the three months ended March 31, 2015 and 2014. During the three months ended March 31, 2015, corporate office costs from the Naples, Florida office were significantly lower than the three months ended March 31, 2014 due to the integration of the HMA corporate functions. Included in these corporate office costs is stock-based compensation of $14 million and $11 million for the three months ended March 31, 2015 and 2014, respectively.

4. USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

5. ACQUISITIONS AND DIVESTITURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition. Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

Approximately $3 million and $57 million of acquisition and related integration costs related to prospective and closed acquisitions were expensed during the three months ended March 31, 2015 and 2014, respectively, and are included in other operating expenses on the condensed consolidated statements of income.

10

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Effective November 1, 2014, the Company entered into and closed on a restructuring agreement related to the joint venture between an affiliate of the Company and an affiliate of Novant Health, Inc. (“Novant”), the non-profit joint venture partner. Through this joint venture, Novant owned an indirect noncontrolling interest in Lake Norman Regional Medical Center (“Lake Norman”), one of the former HMA hospitals. The HMA merger triggered a change in control provision in the operating agreement of this joint venture, requiring the Company to purchase the 30% noncontrolling interest in Lake Norman held by Novant for the higher of fair value or $150 million. As part of the restructuring agreement, on November 3, 2014, the Company paid Novant (1) $150 million for its 30% noncontrolling interest in Lake Norman, (2) approximately $4 million to acquire Upstate Carolina Medical Center (125 licensed beds) in Gaffney, South Carolina, and (3) approximately $5 million to settle prior claims with Novant. The amounts paid to Novant to acquire the noncontrolling interest in Lake Norman and to settle prior claims were recognized as part of the opening balance sheet in the purchase accounting for HMA. Based upon our preliminary purchase price allocation relating to this acquisition as of March 31, 2015, no goodwill has been recorded related to the acquisition of Upstate Carolina Medical Center. The preliminary allocation of the purchase price has been determined by us based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material.

On October 1, 2014, one or more subsidiaries of the Company completed the acquisition of Natchez Regional Medical Center (179 licensed beds) in Natchez, Mississippi. The total cash consideration paid at closing for long-lived assets was $10 million. As part of the closing, the Company also paid $8 million as a prepayment for future property taxes that will be applied to the tax liability for the next 17 years. Based upon our preliminary purchase price allocation relating to this acquisition as of March 31, 2015, no goodwill has been recorded. The preliminary allocation of the purchase price has been determined by us based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material.

Effective April 1, 2014, one or more subsidiaries of the Company completed the acquisition of Sharon Regional Health System in Sharon, Pennsylvania. This healthcare system includes Sharon Regional (258 licensed beds) and other outpatient and ancillary services. The total cash consideration paid for long-lived assets and working capital was approximately $67 million and $1 million, respectively, with additional consideration of $9 million assumed in liabilities, for a total consideration of $77 million. Based upon the Company’s purchase price allocation relating to this acquisition as of March 31, 2015, approximately $8 million of goodwill has been recorded.

Effective April 1, 2014, one or more subsidiaries of the Company completed the acquisition of a 95% interest in Munroe Regional Medical Center (421 licensed beds) in Ocala, Florida and its other outpatient and ancillary services through a joint venture arrangement with an affiliate of a regional not-for-profit healthcare system, which acquired the remaining 5% interest. The total cash consideration paid for long-lived assets plus prepaid rent on the leased property and working capital was approximately $192 million and $4 million, respectively, with additional consideration of $11 million assumed in liabilities, for a total consideration of $207 million. The value of the noncontrolling interest at acquisition was $10 million. Based upon the Company’s purchase price allocation relating to this acquisition as of March 31, 2015, approximately $11 million of goodwill has been recorded.

HMA Merger

On January 27, 2014, the Company completed the HMA merger by acquiring all the outstanding shares of HMA’s common stock for approximately $7.3 billion, including the assumption of approximately $3.8 billion of existing indebtedness, for consideration for each share of HMA’s common stock consisting of $10.50 in cash, 0.06942 of a share of the Company’s common stock, and one contingent value right (“CVR”). The CVR entitles the holder to receive a cash payment of up to $1.00 per CVR (subject to downward adjustment but not below zero), subject to the final resolution of certain legal matters pertaining to HMA, as defined in the CVR agreement. At the time of the completion of the HMA merger, HMA owned and operated 71 hospitals in 15 states in non-urban communities located primarily in the southeastern United States.

In connection with the HMA merger, the Company and CHS/Community Health Systems, Inc. (“CHS”) entered into a third amendment and restatement of its credit facility, providing for additional financing and recapitalization of certain of the Company’s term loans. In addition, the Company and CHS also issued in connection with the HMA merger: (i) $1.0 billion aggregate principal amount of 5.125% Senior Secured Notes due 2021 and (ii) $3.0 billion aggregate principal amount of 6.875% Senior Notes due 2022.

11

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The total consideration of the HMA merger has been allocated to the assets acquired and liabilities assumed based upon their respective fair values, resulting in $4.5 billion of goodwill resulting from the final purchase price allocation at December 31, 2014. The purchase price represented a premium over the fair value of the net tangible and identifiable intangible assets acquired for reasons such as:

● the expansion of the number of markets in which the Company operates in existing states;

● the extension and strengthening of the Company’s hospital and physician networks;

● the centralization of many support functions; and

● the elimination of duplicate corporate functions.

Other Acquisitions

During the three months ended March 31, 2015, the Company paid approximately $12 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during 2015, the Company allocated approximately $8 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill.

Discontinued Operations

Effective January 1, 2015, one or more subsidiaries of the Company sold Carolina Pines Regional Medical Center (116 licensed beds) in Hartsville, South Carolina and related outpatient services to Capella Healthcare for approximately $74 million in cash, which was received at the closing on December 31, 2014. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

Effective February 1, 2015, one or more subsidiaries of the Company sold Harris Hospital (133 licensed beds) in Newport, Arkansas and related healthcare services to White County Medical Center in Searcy, Arkansas for approximately $5 million in cash.

Effective March 1, 2015, one or more subsidiaries of the Company sold Riverview Regional Medical Center (281 licensed beds) in Gadsden, Alabama to Prime Healthcare Services, LLC. (“Prime”) for approximately $25 million in cash. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

Effective March 1, 2015, one or more subsidiaries of the Company sold Dallas Regional Medical Center (202 licensed beds) in Mesquite, Texas to Prime for approximately $25 million in cash.

During the year ended December 31, 2014, the Company made the decision to sell and began actively marketing several smaller hospitals, which are classified as held for sale at March 31, 2015. In addition, HMA entered into a definitive agreement to sell Williamson Memorial Hospital (76 licensed beds) located in Williamson, West Virginia prior to the HMA merger. In connection with management’s decision to sell these facilities and the sale of the four hospitals noted above during 2015, the Company has classified the results of operations of the above mentioned hospitals as discontinued operations in the accompanying condensed consolidated statements of income, and classified these hospitals as held for sale in the accompanying condensed consolidated balance sheet.

12

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions):

	Three Months Ended
	March 31,
	2015		2014
Net operating revenues	$	56	$	89
Loss from operations of entities sold or held for sale before income taxes		(17)		(7)
Impairment of hospitals sold or held for sale		(1)		(22)
Loss on sale, net		(1)		-
Loss from discontinued operations, before taxes		(19)		(29)
Income tax benefit		(6)		(7)
Loss from discontinued operations, net of taxes	$	(13)	$	(22)

Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment.

In April 2014, FASB issued ASU 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that are recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. The Company adopted this ASU on January 1, 2015 and the adoption did not have a material impact on the Company’s consolidated financial position, results of operations and cash flows as of and for the three months ended March 31, 2015.

6. INCOME TAXES

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $5 million as of March 31, 2015. A total of approximately $2 million of interest and penalties is included in the amount of the liability for uncertain tax positions at March 31, 2015. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its condensed consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position.

The Company, or one of its subsidiaries, files income tax returns in the United States federal jurisdiction and various state jurisdictions. The Company has extended the federal statute of limitations through December 31, 2015 for Triad Hospitals, Inc. for the tax periods ended December 31, 1999, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, the Company is no longer subject to state income tax examinations for years prior to 2011. The Company’s federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2015 for Community Health Systems, Inc. for the tax periods ended December 31, 2007 and 2008, through June 30, 2015 for the tax periods ended December 31, 2009 and 2010, and through September 6, 2016 for the tax period ended December 31, 2011.

13

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The Company’s effective tax rates were 33.2% and 42.5% for the three months ended March 31, 2015 and 2014, respectively. The decrease in the Company’s effective tax rate for the three months ended March 31, 2015 is primarily impacted by the increase in income from continuing operations before income taxes, and the impact of non-deductible transaction costs associated with the HMA merger affecting the tax provision for the three months ended March 31, 2014.

Cash paid for income taxes, net of refunds received, resulted in net cash paid of $1 million and a net cash refund of $79 million during the three months ended March 31, 2015 and 2014, respectively.

7. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2015 are as follows (in millions):

Balance as of December 31, 2014	$	8,951
Goodwill acquired as part of acquisitions during current year		4
Consideration and purchase price allocation adjustments for prior year’s acquisitions and other adjustments		(1)
Balance as of March 31, 2015	$	8,954

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2015, the hospital operations reporting unit, the home care agency operations reporting unit, and the hospital management services reporting unit had approximately $8.9 billion, $44 million and $33 million, respectively, of goodwill.

Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2014. No impairment was indicated by this evaluation. The next annual goodwill evaluation will be performed during the fourth quarter of 2015.

The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.

Intangible Assets

No intangible assets other than goodwill were acquired during the three months ended March 31, 2015. The gross carrying amount of the Company’s other intangible assets subject to amortization was $76 million at both March 31, 2015 and December 31, 2014, and the net carrying amount was $35 million at March 31, 2015 and $39 million at December 31, 2014. The carrying amount of the Company’s other intangible assets not subject to amortization was $128 million and $131 million at March 31, 2015 and December 31, 2014, respectively. Other intangible assets are included in other assets, net on the Company’s condensed consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions.

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately four years. There are no expected residual values related to these intangible assets. Amortization expense on these intangible assets was $3 million and $1 million during the three months ended March 31, 2015 and 2014, respectively. Amortization expense on intangible assets is

14

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

estimated to be $10 million for the remainder of 2015, $13 million in 2016, $3 million in 2017, $2 million in 2018, $2 million in 2019, $2 million in 2020 and $3 million thereafter.

The gross carrying amount of capitalized software for internal use was approximately $1.4 billion and $1.5 billion at March 31, 2015 and December 31, 2014, respectively, and the net carrying amount considering accumulated amortization was approximately $769 million and $790 million at March 31, 2015 and December 31, 2014, respectively. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, which is generally eight to ten years. There is no expected residual value for capitalized internal-use software. At March 31, 2015, there was approximately $33 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $53 million and $84 million during the three months ended March 31, 2015 and 2014, respectively. Amortization expense on capitalized internal-use software is estimated to be $146 million for the remainder of 2015, $167 million in 2016, $103 million in 2017, $75 million in 2018, $68 million in 2019, $65 million in 2020 and $145 million thereafter.

In connection with the HMA merger, the Company further analyzed its intangible assets related to internal-use software used in certain of its hospitals for patient and clinical systems, including software required to meet criteria for meaningful use attestation and ICD-10 compliance. This analysis resulted in management reassessing its usage of certain software products and rationalizing that, with the addition of the HMA hospitals in the first quarter of 2014, those software applications were going to be discontinued and replaced with new applications that better integrate meaningful use and ICD-10 compliance, are more cost effective and can be implemented at a greater efficiency of scale over future implementations. During the three months ended March 31, 2014, the Company recorded an impairment charge of approximately $24 million related to software in-process that was abandoned at March 31, 2014 and the acceleration of amortization of approximately $42 million related to shortening the remaining useful life of software abandoned by July 1, 2014.

8. EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of basic and diluted earnings per share for income (loss) from continuing operations, discontinued operations and net income attributable to Community Health Systems, Inc. common stockholders (in millions, except share data):

	Three Months Ended
	March 31,
	2015		2014
Numerator:
Income (loss) from continuing operations, net of taxes	$	112	$	(76)
Less: Income from continuing operations attributable to noncontrolling interests, net of taxes		20		14
Income (loss) from continuing operations attributable to Community Health Systems, Inc. common stockholders — basic and diluted	$	92	$	(90)
Loss from discontinued operations, net of taxes	$	(13)	$	(22)
Less: Loss from discontinued operations attributable to noncontrolling interests, net of taxes		-		-
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders — basic and diluted	$	(13)	$	(22)
Denominator:
Weighted-average number of shares outstanding — basic		114,419,590		106,601,997
Effect of dilutive securities:
Restricted stock awards		181,120		-
Employee stock options		452,659		-
Other equity-based awards		4,299		-
Weighted-average number of shares outstanding — diluted		115,057,668		106,601,997

15

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The Company generated a loss from continuing operations attributable to Community Health Systems, Inc. common stockholders for the three months ended March 31, 2014, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income from continuing operations during the three months ended March 31, 2014, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 578,587 shares.

	Three Months Ended
	March 31,
	2015		2014
Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:
Employee stock options and restricted stock awards		-		1,891,000

9. STOCKHOLDERS’ EQUITY

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of March 31, 2015, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

On December 10, 2014, the Company adopted a new open market repurchase program for up to 5,000,000 shares of the Company’s common stock, not to exceed $150 million in repurchases. The repurchase program will expire at the earliest of three years from the commencement date, when the maximum number of shares has been repurchased, or when the maximum dollar amount of repurchases has been expended. During the three months ended March 31, 2015, the Company did not repurchase and retire any shares under this program.

With the exception of a cash dividend of $0.25 per share paid by the Company in December 2012, historically, the Company has not paid any cash dividends. The Company’s Credit Facility limits the Company’s ability to pay dividends and/or repurchase stock to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing the senior and senior secured notes also limit the Company’s ability to pay dividends and/or repurchase stock. As of March 31, 2015, under the most restrictive test under these agreements, the Company has approximately $461 million remaining available with which to pay permitted dividends and/or repurchase shares of stock or its senior and senior secured notes.

16

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company, and equity attributable to the noncontrolling interests for the three-month period ended March 31, 2015 (in millions):

			Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interest		Common Stock		Additional Paid-In Capital		Treasury   Stock		Accumulated Other Comprehensive Income (Loss)		Retained   Earnings		Noncontrolling  Interest		Total  Stockholders’  Equity
Balance, December 31, 2014	$	531	$	1	$	2,095	$	(7)	$	(63)	$	1,977	$	80	$	4,083
Comprehensive income		16		-		-		-		(7)		79		4		76
Distributions to noncontrolling interests, net of contributions		(17)		-		-		-		-		-		(6)		(6)
Purchase of subsidiary shares from noncontrolling interests		(7)		-		-		-		-		-		-		-
Disposition of less-than-wholly owned hospital		(8)		-		-		-		-		-		-		-
Other reclassifications of noncontrolling interests		(1)		-		-		-		-		-		1		1
Adjustment to redemption value of redeemable noncontrolling interests		6		-		(6)		-		-		-		-		(6)
Issuance of common stock in connection with the exercise of stock options		-		-		18		-		-		-		-		18
Cancellation of restricted stock for tax withholdings on vested shares		-		-		(20)		-		-		-		-		(20)
Share-based compensation		-		-		14		-		-		-		-		14
Balance, March 31, 2015	$	520	$	1	$	2,101	$	(7)	$	(70)	$	2,056	$	79	$	4,160

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ equity (in millions):

	Three Months Ended
	March 31, 2015
Net income attributable to Community Health Systems,
Inc. stockholders	$	79
Transfers to the noncontrolling interests:
Net decrease in Community Health Systems, Inc. paid-in capital for purchase of subsidiary partnership interests		-
Net transfers to the noncontrolling interests		-
Change to Community Health Systems, Inc. stockholders’ equity from net income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$	79

17

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

10. EQUITY INVESTMENTS

As of March 31, 2015, the Company owned equity interests of 27.5% in four hospitals in Las Vegas, Nevada, and 26.1% in one hospital in Las Vegas, Nevada, in which Universal Health Systems, Inc. owns the majority interest, and an equity interest of 38.0% in three hospitals in Macon, Georgia, in which HCA Holdings Inc. owns the majority interest.

Summarized combined financial information for these unconsolidated entities in which the Company owns an equity interest is as follows (in millions):

	Three Months Ended
	March 31,
	2015		2014
Revenues	$	375	$	332
Operating costs and expenses		315		294
Income from continuing operations before taxes		60		39

The summarized financial information was derived from the unaudited financial information provided to the Company by those unconsolidated entities.

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As part of the HMA merger, the Company acquired HMA’s ownership in HealthTrust. As of March 31, 2015, the Company had a 25.1% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $488 million and $470 million at March 31, 2015 and December 31, 2014, respectively, and is included in other assets, net in the accompanying condensed consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $18 million and $11 million for the three months ended March 31, 2015 and 2014, respectively.

11. LONG-TERM DEBT

Long-term debt consists of the following (in millions):

	March 31,		December 31,
	2015		2014
Credit Facility:
Term A Loan	$	925	$	950
Term D Loan		4,544		4,555
Term E Loan		-		1,660
Term F Loan		1,700		-
Revolving credit loans		62		-
8% Senior Notes due 2019		2,017		2,018
7 1⁄8% Senior Notes due 2020		1,200		1,200
5 1⁄8% Senior Secured Notes due 2018		1,600		1,600
5 1⁄8% Senior Secured Notes due 2021		1,000		1,000
6 7⁄8% Senior Notes due 2022		3,000		3,000
Receivables Facility		623		614
Capital lease obligations		215		228
Other		83		91
Total debt		16,969		16,916
Less current maturities		(229)		(235)
Total long-term debt	$	16,740	$	16,681

18

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Credit Facility

The Company’s wholly-owned subsidiary, CHS, has senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, the Company and CHS entered into a third amendment and restatement of its credit facility (the “Credit Facility”), providing for additional financing and recapitalization of certain of the Company’s term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019 (the “Revolving Facility”), (ii) the addition of a new $1.0 billion Term A facility due 2019 (the “Term A Facility”), (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which includes certain term C loans that were converted into such Term D facility (collectively, the “Term D Facility”)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the Company’s post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility included a subfacility for letters of credit. On March 9, 2015, CHS entered into a first amendment and incremental term loan assumption agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion dollars.

The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term D Facility and the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term D Facility will be subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on the Company’s leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to the Company’s EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements.

The borrower under the Credit Facility is CHS. All of the obligations under the Credit Facility are unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries.

CHS has agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. CHS is obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility.

19

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s and its subsidiaries’ ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of the Company’s businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change the Company’s fiscal year. The Company is also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants.

Events of default under the Credit Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility.

As of March 31, 2015, the availability for additional borrowings under the Credit Facility, after consideration of the $62 million outstanding at that date, was approximately $1.0 billion pursuant to the Revolving Facility, of which $83 million was set aside for outstanding letters of credit. CHS has the ability to amend the Credit Facility to provide for one or more tranches of term loans or increases in the Revolving Facility in an aggregate principal amount of $1.5 billion, which CHS has not yet accessed. As of March 31, 2015, the weighted-average interest rate under the Credit Facility, excluding swaps, was 4.4%.

8% Senior Notes due 2019

On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019 (the “8% Senior Notes”), which were issued in a private placement. The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8 ⁷⁄₈% Senior Notes and related fees and expenses. On March 21, 2012, CHS completed the secondary offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%). The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8 ⁷⁄₈% Senior Notes, to pay related fees and expenses and for general corporate purposes. The 8% Senior Notes bear interest at 8% per annum, payable semiannually in arrears on May 15 and November 15, commencing May 15, 2012. Interest on the 8% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months.

Except as set forth below, CHS is not entitled to redeem the 8% Senior Notes prior to November 15, 2015.

Prior to November 15, 2015, CHS may redeem some or all of the 8% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 8% Senior Notes indenture. On and after November 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
November 15, 2015 to November 14, 2016		104.000 %
November 15, 2016 to November 14, 2017		102.000 %
November 15, 2017 to November 15, 2019		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 8% Senior Notes, as a result of an exchange offer made by CHS, substantially all of the 8% Senior Notes issued in November 2011 and March 2012 were exchanged in May 2012 for new notes (the “8% Exchange Notes”) having terms substantially identical in all material respects to the 8% Senior Notes (except that the 8% Exchange Notes were issued under a registration statement pursuant to the Securities Act of 1933, as amended (the “1933 Act”)). References to the 8% Senior Notes shall also be deemed to include the 8% Exchange Notes unless the context provides otherwise.

20

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

7 ¹⁄₈% Senior Notes due 2020

On July 18, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7 ¹⁄₈% Senior Notes due 2020 (the “7 ¹⁄₈% Senior Notes”). The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount plus accrued interest of CHS’ outstanding 8 ⁷⁄₈% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes. The 7 ¹⁄₈% Senior Notes bear interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15, commencing January 15, 2013. Interest on the 7 ¹⁄₈% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months.

Except as set forth below, CHS is not entitled to redeem the 7 ¹⁄₈% Senior Notes prior to July 15, 2016.

Prior to July 15, 2015, CHS is entitled, at its option, to redeem a portion of the 7 ¹⁄₈% Senior Notes (not to exceed 35% of the outstanding principal amount) at a redemption price equal to 107.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to July 15, 2016, CHS may redeem some or all of the 7 ¹⁄₈% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 7 ¹⁄₈% Senior Notes indenture. On and after July 15, 2016, CHS is entitled, at its option, to redeem all or a portion of the 7 ¹⁄₈% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
July 15, 2016 to July 14, 2017		103.563 %
July 15, 2017 to July 14, 2018		101.781 %
July 15, 2018 to July 15, 2020		100.000 %

5 ¹⁄₈% Senior Secured Notes due 2018

On August 17, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5 ¹⁄₈% Senior Secured Notes due 2018 (the “2018 Senior Secured Notes”). The net proceeds from this issuance, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses. The 2018 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on August 15 and February 15, commencing February 15, 2013. Interest on the 2018 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2018 Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2018 Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility.

Except as set forth below, CHS is not entitled to redeem the 2018 Senior Secured Notes prior to August 15, 2015.

Prior to August 15, 2015, CHS is entitled, at its option, to redeem a portion of the 2018 Senior Secured Notes (not to exceed 35% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to August 15, 2015, CHS may redeem some or all of the 2018 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2018 Senior Secured Notes indenture. On and after August 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 2018 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

21

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Period	Redemption Price
August 15, 2015 to August 14, 2016		102.563 %
August 15, 2016 to August 14, 2017		101.281 %
August 15, 2017 to August 15, 2018		100.000 %

5 ¹⁄₈% Senior Secured Notes due 2021

On January 27, 2014, CHS issued $1.0 billion aggregate principal amount of 5 ¹⁄₈% Senior Secured Notes due 2021 (the “2021 Senior Secured Notes”) in connection with the HMA merger, which were issued in a private placement. The net proceeds from this issuance were used to finance the HMA merger. The 2021 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 2021 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2021 Senior Secured Notes are secured by a first-priority lien, subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2021 Senior Secured Notes, on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility.

Except as set forth below, CHS is not entitled to redeem the 2021 Senior Secured Notes prior to February 1, 2017.

Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 2021 Senior Secured Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain equity offerings. Prior to February 1, 2017, CHS may redeem some or all of the 2021 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2021 Senior Secured Notes indenture. On and after February 1, 2017, CHS is entitled, at its option, to redeem all or a portion of the 2021 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2017 to January 31, 2018		103.844 %
February 1, 2018 to January 31, 2019		102.563 %
February 1, 2019 to January 31, 2020		101.281 %
February 1, 2020 to January 31, 2021		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 2021 Senior Secured Notes, as a result of an exchange offer made by CHS, all of the 2021 Senior Secured Notes issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 2021 Senior Secured Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 2021 Senior Secured Notes shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise.

6 ⁷⁄₈% Senior Notes due 2022

On January 27, 2014, CHS issued $3.0 billion aggregate principal amount of 6 ⁷⁄₈% Senior Notes due 2022 (the “6 ⁷⁄₈% Senior Notes”) in connection with the HMA merger, which were issued in a private placement. The net proceeds from this issuance were used to finance the HMA merger. The 6 ⁷⁄₈% Senior Notes bear interest at 6.875% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 6 ⁷⁄₈% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months.

Except as set forth below, CHS is not entitled to redeem the 6 ⁷⁄₈% Senior Notes prior to February 1, 2018.

22

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Prior to February 1, 2018, CHS is entitled, at its option, to redeem a portion of the 6 ⁷⁄₈% Senior Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 106.875% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings. Prior to February 1, 2018, CHS may redeem some or all of the 6 ⁷⁄₈% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 6 ⁷⁄₈% Senior Notes indenture. On and after February 1, 2018, CHS is entitled, at its option, to redeem all or a portion of the 6 ⁷⁄₈% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2018 to January 31, 2019		103.438 %
February 1, 2019 to January 31, 2020		101.719 %
February 1, 2020 to January 31, 2022		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 6 ⁷⁄₈% Senior Notes, as a result of an exchange offer made by CHS, all of the 6 ⁷⁄₈% Senior Notes issued in January 2014 were exchanged in October 2014 for new notes (the “6 ⁷⁄₈% Exchange Notes”) having terms substantially identical in all material respects to the 6 ⁷⁄₈% Senior Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 6 ⁷⁄₈% Senior Notes shall be deemed to be the 6 ⁷⁄₈% Exchange Notes unless the context provides otherwise.

Receivables Facility

On March 21, 2012, CHS and certain of its subsidiaries entered into an accounts receivable loan agreement (the “Receivables Facility”) with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent. On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries of the Company also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries of the Company also agreed to participate in the Receivables Facility as of that date. The existing and future non-self pay patient-related accounts receivable (the “Receivables”) for certain of the Company’s hospitals serves as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread. Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on March 21, 2017, subject to customary termination events that could cause an early termination date. The Company maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of the Company’s subsidiaries to CHS, which then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS. The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to the Company or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan. The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2015 totaled $623 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2015, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.3 billion and is included in patient accounts receivable on the condensed consolidated balance sheet.

Loss from Early Extinguishment of Debt

The financing transactions discussed above resulted in a loss from early extinguishment of debt of $8 million and $73 million for the three months ended March 31, 2015 and 2014, respectively, and an after-tax loss of $5 million and $45 million for the three months ended March 31, 2015 and 2014, respectively.

23

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Other Debt

As of March 31, 2015, other debt consisted primarily of the mortgage obligation on the Company’s corporate headquarters and other obligations maturing in various installments through 2020.

To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to seven separate interest swap agreements in effect at March 31, 2015, with an aggregate notional amount for currently effective swaps of $1.3 billion, and six forward-starting swap agreements with an aggregate notional amount of $1.7 billion. On each of these swaps, the Company receives a variable rate of interest based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. The Company currently pays, on a quarterly basis, interest on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 275 basis points. Loans in respect of the Term D Facility and the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 325 basis points. The Term D Facility is also subject to a 100 basis point LIBOR floor and a 200 basis point Alternate Base Rate floor. See Note 12 for additional information regarding these swaps.

The Company paid interest of $300 million and $175 million on borrowings during the three months ended March 31, 2015 and 2014, respectively. Subsequent to the issuance of the Company’s 2014 Quarterly Report on Form 10-Q for the three-month period ended March 31, 2014, the Company determined that it had incorrectly reported cash paid for interest during the three months ended March 31, 2014 of $280 million instead of the correct amount of $175 million. The Company concluded that this error was immaterial to its previously reported consolidated financial statements and had no impact on its consolidated financial position, results of operations, or cash flows. Correct amounts were reported in all subsequent quarterly and annual financial reports during 2014.

12. FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of March 31, 2015 and December 31, 2014, and valuation methodologies considered appropriate. The estimates presented are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions):

	March 31, 2015				December 31, 2014
	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets:
Cash and cash equivalents	$	222	$	222	$	509	$	509
Available-for-sale securities		285		285		280		280
Trading securities		58		58		55		55
Liabilities:
Contingent Value Right		6		6		6		6
Credit Facility		7,231		7,249		7,165		7,143
8% Senior Notes		2,017		2,129		2,018		2,139
7 1⁄8% Senior Notes		1,200		1,277		1,200		1,282
2018 Senior Secured Notes		1,600		1,655		1,600		1,655
2021 Senior Secured Notes		1,000		1,034		1,000		1,041
6 7⁄8% Senior Notes		3,000		3,211		3,000		3,194
Receivables Facility and other debt		706		706		705		705

The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 13. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant.

Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

24

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Available-for-sale securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities. Estimated fair value is based on closing price as quoted in public markets.

Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded.

Credit Facility. Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions.

8% Senior Notes. Estimated fair value is based on the closing market price for these notes.

7 ¹⁄₈% Senior Notes. Estimated fair value is based on the closing market price for these notes.

2018 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes.

2021 Senior Secured Notes. Estimated fair value is based on the closing market price for these notes.

6 ⁷⁄₈% Senior Notes. Estimated fair value is based on the closing market price for these notes.

Receivables Facility and other debt. The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations.

Interest rate swaps. The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements.

The Company assesses the effectiveness of its hedge instruments on a quarterly basis. For the three months ended March 31, 2015 and 2014, the Company completed an assessment of the cash flow hedge instruments and determined the hedges to be highly effective. The Company has also determined that the ineffective portion of the hedges do not have a material effect on the Company’s consolidated financial position, operations or cash flows. The counterparties to the interest rate swap agreements expose the Company to credit risk in the event of nonperformance. However, at March 31, 2015, all of the swap agreements entered into by the Company were in a net liability position such that the Company would be required to make the net settlement payments to the counterparties; the Company does not anticipate nonperformance by those counterparties. The Company does not hold or issue derivative financial instruments for trading purposes.

25

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Interest rate swaps consisted of the following at March 31, 2015:

Swap #	Notional Amount   (in millions)		Fixed Interest     Rate		Termination Date	Fair Value (in     millions)
1	$	300		3.447%	August 6, 2016	$	12
2		100		3.401%	August 19, 2016		4
3		200		3.429%	August 19, 2016		8
4		200		3.500%	August 30, 2016		8
5		100		3.005%	November 30, 2016		4
6		200		2.055%	July 25, 2019		5
7		200		2.059%	July 25, 2019		5
8		400		1.882%	August 30, 2019		1	(1)
9		200		2.515%	August 30, 2019		5	(1)
10		200		2.613%	August 30, 2019		6	(2)
11		300		2.041%	August 30, 2020		1	(1)
12		300		2.738%	August 30, 2020		10	(1)
13		300		2.892%	August 30, 2020		12	(2)

(1) This interest rate swap becomes effective August 28, 2015.

(2) This interest rate swap becomes effective August 30, 2015.

The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Interest rate swaps are entered into to manage interest rate fluctuation risk associated with the term loans in the Credit Facility. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the condensed consolidated statement of financial position. The Company designates its interest rate swaps as cash flow hedges. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

Assuming no change in March 31, 2015 interest rates, approximately $48 million of interest expense resulting from the spread between the fixed and floating rates defined in each interest rate swap agreement will be recognized during the next 12 months. If interest rate swaps do not remain highly effective as a cash flow hedge, the derivatives’ gains or losses resulting from the change in fair value reported through OCI will be reclassified into earnings.

The following tabular disclosure provides the amount of pre-tax loss recognized as a component of OCI during the three months ended March 31, 2015 and 2014 (in millions):

	Amount of Pre-Tax Loss Recognized in OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Three Months Ended March 31,
	2015		2014
Interest rate swaps	$	(22)	$	(3)

26

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the condensed consolidated statements of income during the three months ended March 31, 2015 and 2014 (in millions):

	Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion)
Location of Loss Reclassified from AOCL into Income (Effective Portion)	Three Months Ended March 31,
	2015		2014
Interest expense, net	$	9	$	18

The fair values of derivative instruments in the condensed consolidated balance sheets as of March 31, 2015 and December 31, 2014 were as follows (in millions):

Asset Derivatives

Liability Derivatives

March 31, 2015

December 31, 2014

March 31, 2015

December 31, 2014

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

-

Other long- term liabilities

$

81

Other long- term liabilities

$

73

13. FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1:	Quoted market prices in active markets for identical assets or liabilities.
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3:	Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during 2015 or 2014.

27

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 (in millions):

	March 31, 2015		Level 1		Level 2		Level 3
Available-for-sale securities	$	285	$	156	$	129	$	-
Trading securities		58		58		-		-
Total assets	$	343	$	214	$	129	$	-
Contingent Value Right (CVR)	$	6	$	6	$	-	$	-
CVR-related liability		256		-		-		256
Fair value of interest rate swap agreements		81		-		81		-
Total liabilities	$	343	$	6	$	81	$	256
	December 31, 2014		Level 1		Level 2		Level 3
Available-for-sale securities	$	280	$	151	$	129	$	-
Trading securities		55		55		-		-
Total assets	$	335	$	206	$	129	$	-
Contingent Value Right (CVR)	$	6	$	6	$	-	$	-
CVR-related liability		265		-		-		265
Fair value of interest rate swap agreements		68		-		68		-
Total liabilities	$	339	$	6	$	68	$	265

Available-for-sale Securities

Available-for-sale securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale securities primarily consisted of: (i) bonds and notes issued by the United States government and its agencies, domestic and foreign corporations and foreign governments; and (ii) preferred securities issued by domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Contingent Value Right (CVR)

The CVR represents the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVR is listed on the NASDAQ and the valuation at March 31, 2015 is based on the quoted trading price for the CVR on the last day of the period. Changes in the estimated fair value of the CVR are recorded through the condensed consolidated statement of income.

28

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

CVR-related Liability

The CVR-related legal liability represents the Company’s estimate of fair value at March 31, 2015 of the liability associated with the legal matters assumed in the HMA merger that were not previously accrued by HMA. In addition, a liability of $24 million is recorded in accrued liabilities in the accompanying condensed consolidated balance sheet in respect of claims that were previously recorded by HMA as a probable contingency. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability. The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company has classified the fair value measurement as a Level 3 measurement in the fair value hierarchy.

The fair value of the CVR-related legal liability will be measured each reporting period using similar measurement techniques, updated for the assumptions and facts existing at that date for each of the underlying legal matters. Changes in the fair value of the CVR related legal liability are recorded in future periods through the condensed consolidated statement of income.

Fair Value of Interest Rate Swap Agreements

The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged.

The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements at March 31, 2015 resulted in a decrease in the fair value of the related liability of $5 million and an after-tax adjustment of $3 million to OCI. The CVA on the Company’s interest rate swap agreements at December 31, 2014 resulted in a decrease in the fair value of the related liability of $4 million and an after-tax adjustment of $2 million to OCI.

The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy.

14. SEGMENT INFORMATION

The Company operates in two distinct operating segments, represented by hospital operations (which includes its general acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services) and home care agency operations (which provide in-home outpatient care).

Only the hospital operations segment meets the criteria as a separate reportable segment. The financial information for the home care agency segment does not meet the quantitative thresholds for a separate identifiable reportable segment and is combined into the corporate and all other reportable segment.

29

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The distribution between reportable segments of the Company’s net operating revenues and income (loss) from continuing operations before income taxes is summarized in the following tables (in millions):

	Three Months Ended March 31,
	2015		2014
Net operating revenues:
Hospital operations	$	4,857	$	4,124
Corporate and all other		54		52
Total	$	4,911	$	4,176
Income (loss) from continuing operations before income taxes:
Hospital operations	$	273	$	38
Corporate and all other		(105)		(170)
Total	$	168	$	(132)

15. OTHER COMPREHENSIVE INCOME

The following tables present information about items reclassified out of accumulated other comprehensive income (loss) by component for the three months ended March 31, 2015 and 2014 (in millions, net of tax):

	Change in Fair Value of Interest Rate Swaps		Change in Fair Value of Available for Sale Securities		Change in Unrecognized Pension Cost Components		Accumulated Other Comprehensive Income (Loss)
Balance as of December 31, 2014	$	(43)	$	7	$	(27)	$	(63)
Other comprehensive (loss) income before reclassifications		(15)		1		-		(14)
Amounts reclassified from accumulated other comprehensive income (loss)		6		-		1		7
Net current-period other comprehensive income		(9)		1		1		(7)
Balance as of March 31, 2015	$	(52)	$	8	$	(26)	$	(70)
	Change in Fair Value of Interest Rate Swaps		Change in Fair Value of Available for Sale Securities		Change in Unrecognized Pension Cost Components		Accumulated Other Comprehensive Income (Loss)
Balance as of December 31, 2013	$	(56)	$	7	$	(18)	$	(67)
Other comprehensive (loss) income before reclassifications		(2)		-		-		(2)
Amounts reclassified from accumulated other comprehensive income (loss)		11		-		-		11
Net current-period other comprehensive income		9		-		-		9
Balance as of March 31, 2014	$	(47)	$	7	$	(18)	$	(58)

30

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

The following tables present a subtotal for each significant reclassification to net income out of accumulated other comprehensive income (loss) and the line item affected in the accompanying condensed consolidated statement of income for the three months ended March 31, 2015 and 2014 (in millions):

	Amount reclassified from AOCL		Affected line item in the
Details about accumulated other comprehensive income (loss) components	Three Months Ended            March 31, 2015		statement where net income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(9)	Interest expense, net
		3	Tax benefit
	$	(6)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		(1)	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax
	Amount reclassified from AOCL		Affected line item in the
Details about accumulated other comprehensive income (loss) components	Three Months Ended March 31, 2014		statement where net income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(18)	Interest expense, net
		7	Tax benefit
	$	(11)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		-	Salaries and benefits
		-	Total before tax
		-	Tax benefit
	$	-	Net of tax

16. CONTINGENCIES

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

31

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

HMA Legal Matters and Related CVR

The CVR agreement entitles the holder to receive a one-time cash payment of up to $1.00 per CVR, subject to downward adjustment based on the final resolution of certain litigation, investigations (whether formal or informal, including subpoenas), or other actions or proceedings related to HMA or its affiliates existing on or prior to July 29, 2013 (the date of the Company’s merger agreement with HMA) as more specifically provided in the CVR agreement (all such matters are referred to as the “HMA Legal Matters”), which include, but are not limited to, investigation and litigation matters as previously disclosed by HMA in public filings with the SEC and described in more detail below. The adjustment reducing the ultimate amount paid to holders of the CVR is determined based on the amount of losses incurred by the Company in connection with the HMA Legal Matters as more specifically provided in the CVR agreement, which generally includes the amount paid for damages, costs, fees and expenses (including, without limitation, attorneys’ fees and expenses), and all fines, penalties, settlement amounts, indemnification obligations and other liabilities (all such losses are referred to as “HMA Losses”). If the aggregate amount of HMA Losses exceeds a deductible of $18 million, then the amount payable in respect of each CVR shall be reduced (but not below zero) by an amount equal to the quotient obtained by dividing: (a) the product of (i) all losses in excess of the deductible and (ii) 90%; by (b) the number of CVRs outstanding on the date on which final resolution of the existing litigation occurs. There are 264,544,053 CVRs outstanding as of the date hereof. If total HMA Losses (including HMA Losses that have occurred to date as noted in the table below) exceed approximately $312 million, then the holders of the CVRs will not be entitled to any payment in respect of the CVRs.

The CVRs do not have a finite payment date. Any payments the Company makes under the CVR agreement will be payable within 60 days after the final resolution of the HMA Legal Matters. The CVRs are unsecured obligations of CHS and all payments under the CVRs will be subordinated in right of payment to the prior payment in full of all of the Company’s senior obligations (as defined in the CVR agreement), which include outstanding indebtedness of the Company (subject to certain exceptions set forth in the CVR agreement) and the HMA Losses. The CVR agreement permits the Company to acquire all or some of the CVRs, whether in open market transactions, private transactions or otherwise. As of March 31, 2015, the Company had acquired no CVRs.

The following table represents the impact of legal expenses paid or incurred to date and settlements paid or deemed final as of March 31, 2015 on the amounts owed to CVR holders (in millions):

			Allocation of Expenses and Settlement Costs
	Total Expenses and Settlement Cost		Deductible		CHS Responsibility at 10%		Reduction to Amount Owed to CVR Holders at 90%
As of December 31, 2014	$	24	$	18	$	-	$	6
Settlements paid		-		-		-		-
Legal expenses incurred and/or paid during the three months ended March 31, 2015		3		-		1		2
As of March 31, 2015	$	27	$	18	$	1	$	8

Amounts owed to CVR holders are dependent on the ultimate resolution of the HMA Legal Matters and determination of HMA Losses incurred. The settlement of any or all of the claims and expenses incurred on behalf of the Company in defending itself will (subject to the deductible) reduce the amounts owed to the CVR holders.

32

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Underlying the CVR agreement are a number of claims included in the HMA Legal Matters asserted against HMA. The Company has recorded a liability in connection with those claims as part of the acquired assets and liabilities at the date of acquisition pursuant to the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 805 “Business Combinations.” For the estimate of the Company’s liabilities associated with the HMA Legal Matters that will be covered by the CVR and were not previously accrued by HMA, the Company recorded a liability of $284 million as part of the acquisition accounting for the HMA merger based on the Company’s estimate of fair value of such liabilities as of the date of acquisition. The decrease in this liability during the three months ended March 31, 2015 was approximately $9 million and the fair value of $256 million is recorded in other long-term liabilities on the accompanying condensed consolidated balance sheet. The remaining portion of the estimated liability for claims underlying the CVR agreement had been previously recorded by HMA, as a probable contingency, and was reflected in the purchase accounting for HMA as an acquired liability. This amount is $24 million at March 31, 2015 and is recorded in accrued liabilities on the accompanying condensed consolidated balance sheet. In addition, although legal fees are not included in the amounts currently accrued, such legal fees are taken into account in determining HMA Losses under the CVR agreement. Certain significant HMA Legal Matters underlying these liabilities are discussed in greater detail below.

HMA Matters Recorded at Fair Value

Medicare/Medicaid Billing Lawsuits

Beginning during the week of December 16, 2013, eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act. Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was recently settled; U.S. ex rel. Sandra Simmons, v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was recently partially settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions. On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation. On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, and again extended until May 27, 2015. The Company intends to defend against the allegations in these matters, but will also be cooperating with the government in the ongoing investigation of these allegations. The Company has been in discussions with the Civil Division of the United States Department of Justice (“DOJ”) regarding the resolutions of these matters. The Company has recently been told that the Criminal Division is continuing to investigate former executive-level employees of HMA, as well as considering whether any HMA entities should be held criminally liable for the acts of the former HMA employees. The Company is voluntarily cooperating with these inquiries and has not been served with any subpoenas or other legal process.

During September 2010, HMA received a letter from the DOJ indicating that an investigation was being conducted to determine whether certain HMA hospitals improperly submitted claims for the implantation of implantable cardioverter defibrillators (“ICDs”). The DOJ’s investigation covers the period commencing with Medicare’s expansion of coverage for ICDs in 2003 to the present. The letter from the DOJ further indicates that the claims submitted by HMA’s hospitals for ICDs and related services need to be reviewed to determine if Medicare coverage and payment was appropriate. During 2010, the DOJ sent similar letters and other requests to a large number of unrelated hospitals and hospital operators across the country as part of a nation-wide review of ICD billing under the Medicare program. The Company is cooperating with the DOJ in its ongoing investigation, which could potentially give rise to claims against HMA and/or certain of its subsidiary hospitals under the False Claims Act or other statutes, regulations or laws. Additionally, the Company is conducting an internal review of hospital medical records related to ICDs that are the subject of the DOJ investigation. The Company has reached an agreement in principle to settle this matter.

33

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Probable Contingencies – HMA

OIG Investigation of Certain HMA Hospitals’ Relationships with Allegiance

On February 22, 2012 and February 24, 2012, the United States Department of Health and Human Services office of the Inspector General (“OIG”) served subpoenas on certain HMA hospitals relating to those hospitals’ relationships with Allegiance Health Management, Inc. (“Allegiance”). Allegiance, which is unrelated to HMA, is a post-acute healthcare management company that provides intensive outpatient psychiatric (“IOP”) services to patients. The HMA hospitals that were served subpoenas were: (i) Central Mississippi Medical Center in Jackson, Mississippi; (ii) Crossgates River Oaks Hospital in Brandon, Mississippi; (iii) Davis Regional Medical Center in Statesville, North Carolina; (iv) Lake Norman Regional Medical Center in Mooresville, North Carolina; (v) the Medical Center of Southeastern Oklahoma in Durant, Oklahoma; and (vi) Natchez Community Hospital in Natchez, Mississippi. Each of those hospitals has or had a contract with Allegiance. Among other things, the subpoenas seek: (i) documents related to the hospitals’ financial relationships with Allegiance; (ii) documents related to patients who received IOP services from Allegiance at the HMA hospitals, including their patient medical records; (iii) documents relating to complaints or concerns regarding Allegiance’s IOP services at the HMA hospitals; (iv) documents relating to employees, physicians and therapists who were involved with the IOP services provided by Allegiance at the HMA hospitals; and (v) other documents related to Allegiance, including leases, contracts, policies and procedures, training documents, budgets and financial analyses. The period of time covered by the subpoenas is January 1, 2008 through the date of subpoena compliance. The Company will continue to cooperate with the investigations. Prior to the HMA merger, HMA determined that a liability for this claim was probable and a liability was recorded by HMA during the quarter ended December 31, 2013, which liability was assumed as part of the HMA merger. The Company has reached an agreement in principle to settle this matter.

Department of Justice Investigation of Kyphoplasty Procedures at Certain HMA Hospitals

Several HMA hospitals received letters during 2009 requesting information in connection with a DOJ investigation relating to kyphoplasty procedures. Kyphoplasty is a minimally invasive spinal procedure used to treat vertebral compression fractures. The DOJ is currently investigating hospitals and hospital operators in multiple states to determine whether certain Medicare claims for kyphoplasty were incorrect when billed as an inpatient service rather than as an outpatient service. The DOJ’s investigation originated with a False Claims Act lawsuit against Kyphon, Inc., the company that developed the kyphoplasty procedure. The requested information has been provided to the DOJ and the Company is continuing to cooperate with the investigation. Prior to the HMA merger, HMA determined that a liability for this claim was probable and an incremental liability was recorded by HMA during the quarter ended December 31, 2013, which liability was assumed as part of the HMA merger.

Probable Contingencies - CHS

Implantable Cardioverter Defibrillators (“ICDs”). The Company was first made aware of this investigation in September 2010, when the Company received a letter from the Civil Division of the DOJ. The letter advised the Company that an investigation was being conducted to determine whether certain hospitals have improperly submitted claims for payment for ICDs. The period of time covered by the investigation was 2003 to 2010. The Company continues to fully cooperate with the government in this investigation and has provided requested records and documents. On August 30, 2012, the DOJ issued a document entitled, “Medical Review Guidelines/Resolution Model,” which sets out, for the purposes of this investigation, the patient conditions and criteria for the medical necessity of the implantation of ICDs in Medicare beneficiaries and how the DOJ will enforce the repayment obligations of hospitals. The Company has reached an agreement in principle to settle this matter.

34

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the three months ended March 31, 2015 with respect to the Company’s fair value determination in connection with HMA Legal Matters that were not previously accrued by HMA, the estimated liability in connection with HMA Legal Matters that were previously recorded by HMA as a probable contingency, and the remaining contingencies of the Company in respect of which an accrual has been recorded. In addition, future legal fees (which are expensed as incurred) and costs related to possible indemnification and criminal investigation matters associated with the HMA Legal Matters have not been accrued or included in the table below. Furthermore, although not accrued, such costs, if incurred, will be taken into account in determining the total amount of reductions applied to the amounts owed to CVR holders.

	CVR Related Liability at Fair Value		CVR Related Liability for Probable Contingencies		Other Probable Contingencies
Balance as of December 31, 2014	$	265	$	29	$	125
Expense		(9)		(5)		15
Cash payments		-		-		(92)
Balance as of March 31, 2015	$	256	$	24	$	48

With respect to the “Other Probable Contingencies” referenced in the chart above, in accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the condensed consolidated balance sheet and are included in the table above in the “Other Probable Contingencies” column. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount.

In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $4 million and $3 million for the three months ended March 31, 2015 and 2014, respectively, and are included in other operating expenses in the accompanying condensed consolidated statements of income.

Matters for which an Outcome Cannot be Assessed

For all of the legal matters below, the Company cannot at this time assess what the outcome may be and is further unable to determine any estimate of loss or range of loss. Because the matters below are at a preliminary stage and other factors, there are not sufficient facts available to make these assessments.

Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. The Company’s motion to dismiss this case has been fully briefed and remains pending before the court. Case management has been set for May 11, 2015. The Company believes this consolidated matter is without merit and will vigorously defend this case.

Shareholder Derivative Actions. Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. The Company’s motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part the Company’s motion to dismiss. On October 14, 2013, the Company filed for a Motion for Reconsideration of the Order Granting in Part and Denying in Part the Motion to Dismiss, a Motion to Stay Discovery, and an unopposed Motion for Extension of Time to File an Answer. The Company’s motion to stay

35

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

was denied and the Company’s motion for reconsideration was denied on December 12, 2014. An initial case management order was entered on November 11, 2014, but no trial date has been set. The Company believes all of the plaintiffs’ claims are without merit and will vigorously defend them.

17. SUBSEQUENT EVENTS

The Company evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the condensed consolidated financial statements.

Effective April 1, 2015, one or more subsidiaries of the Company sold Chesterfield General Hospital (59 licensed beds) in Cheraw, South Carolina and Marlboro Park Hospital (102 licensed beds) in Bennettsville, South Carolina, and related outpatient services to M/C Healthcare, LLC for approximately $4 million in cash, which was received at the closing on March 31, 2015.

18. SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Senior Notes due 2019, 2020 and 2022, which are senior unsecured obligations of CHS, and the 5 ¹⁄₈% Senior Secured Notes due 2018 and 2021 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries. The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below:

• Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets.

• Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net.

• Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes.

• Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances.

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 11. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation.

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods are revised to reflect the status of guarantors or non-guarantors as of March 31, 2015.

36

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Income

Three Months Ended March 31, 2015

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual allowances and discounts)	$	-	$	(5)	$	3,488	$	2,163	$	-	$	5,646
Provision for bad debts		-		-		447		288		-		735
Net operating revenues		-		(5)		3,041		1,875		-		4,911
Operating costs and expenses:
Salaries and benefits		-		-		1,222		1,035		-		2,257
Supplies		-		-		492		270		-		762
Other operating expenses		-		-		708		391		-		1,099
Government settlement and related costs		-		-		8		-		-		8
Electronic health records incentive reimbursement		-		-		(17)		(9)		-		(26)
Rent		-		-		61		55		-		116
Depreciation and amortization		-		-		200		96		-		296
Total operating costs and expenses		-		-		2,674		1,838		-		4,512
Income from operations		-		(5)		367		37		-		399
Interest expense, net		-		21		211		9		-		241
Loss from early extinguishment of debt		-		8		-		-		-		8
Equity in earnings of unconsolidated affiliates		(79)		(104)		(5)		-		170		(18)
Income from continuing operations before income taxes		79		70		161		28		(170)		168
Provision for (benefit from) income taxes		-		(9)		61		4		-		56
Income from continuing operations		79		79		100		24		(170)		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		-		(11)		-		(11)
Impairment of hospitals sold or held for sale		-		-		(1)		-		-		(1)
Loss on sale, net		-		-		2		(3)		-		(1)
Loss from discontinued operations, net of taxes		-		-		1		(14)		-		(13)
Net income		79		79		101		10		(170)		99
Less: Net income attributable to noncontrolling interests		-		-		-		20		-		20
Net income attributable to Community Health Systems, Inc. stockholders	$	79	$	79	$	101	$	(10)	$	(170)	$	79

37

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Loss

Three Months Ended March 31, 2014

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual allowances and discounts)	$	-	$	(4)	$	3,119	$	1,760	$	-	$	4,875
Provision for bad debts		-		-		476		223		-		699
Net operating revenues		-		(4)		2,643		1,537		-		4,176
Operating costs and expenses:
Salaries and benefits		-		-		1,147		845		-		1,992
Supplies		-		-		417		215		-		632
Other operating expenses		-		-		663		356		-		1,019
Electronic health records incentive reimbursement		-		-		(30)		(10)		-		(40)
Rent		-		-		54		44		-		98
Depreciation and amortization		-		-		189		66		-		255
Amortization of software to be abandoned		-		-		26		16		-		42
Total operating costs and expenses		-		-		2,466		1,532		-		3,998
Income from operations		-		(4)		177		5		-		178
Interest expense, net		-		40		172		12		-		224
Loss from early extinguishment of debt		-		73		-		-		-		73
Equity in earnings of unconsolidated affiliates		112		27		23		-		(173)		(11)
Impairment of long-lived assets		-		-		24		-		-		24
Income from continuing operations before income taxes		(112)		(144)		(42)		(7)		173		(132)
Provision for (benefit from) income taxes		-		(32)		(16)		(8)		-		(56)
Income from continuing operations		(112)		(112)		(26)		1		173		(76)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		(3)		(1)		-		(4)
Impairment of hospitals sold or held for sale		-		-		-		(18)		-		(18)
Loss from discontinued operations, net of taxes		-		-		(3)		(19)		-		(22)
Net loss		(112)		(112)		(29)		(18)		173		(98)
Less: Net income attributable to noncontrolling interests		-		-		-		14		-		14
Net loss attributable to Community Health Systems, Inc. stockholders	$	(112)	$	(112)	$	(29)	$	(32)	$	173	$	(112)

38

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended March 31, 2015

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net income	$	79	$	79	$	101	$	10	$	(170)	$	99
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		(9)		-		-		9		(9)
Net change in fair value of available-for-sale securities, net of tax		1		1		1		-		(2)		1
Amortization and recognition of unrecognized pension cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(7)		(7)		2		-		5		(7)
Comprehensive income		72		72		103		10		(165)		92
Less: Comprehensive income attributable to noncontrolling interests		-		-		-		20		-		20
Comprehensive income (loss) attributable to Community
Health Systems, Inc. stockholders	$	72	$	72	$	103	$	(10)	$	(165)	$	72

Condensed Consolidating Statement of Comprehensive Loss

Three Months Ended March 31, 2014

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net loss	$	(112)	$	(112)	$	(29)	$	(18)	$	173	$	(98)
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		9		9		-		-		(9)		9
Net change in fair value of available-for-sale securities, net of tax		-		-		-		-		-		-
Amortization and recognition of unrecognized pension cost components, net of tax		-		-		-		-		-		-
Other comprehensive income (loss)		9		9		-		-		(9)		9
Comprehensive loss		(103)		(103)		(29)		(18)		164		(89)
Less: Comprehensive income attributable to noncontrolling interests		-		-		-		14		-		14
Comprehensive loss attributable to Community
Health Systems, Inc. stockholders	$	(103)	$	(103)	$	(29)	$	(32)	$	164	$	(103)

39

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Balance Sheet

March 31, 2015

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	37	$	185	$	-	$	222
Patient accounts receivable, net of allowance for doubtful accounts		-		-		1,430		2,176		-		3,606
Supplies		-		-		377		184		-		561
Deferred income taxes		341		-		-		-		-		341
Prepaid expenses and taxes		-		-		131		58		-		189
Other current assets		-		-		329		178		-		507
Total current assets		341		-		2,304		2,781		-		5,426
Intercompany receivable		1,257		16,512		3,314		6,131		(27,214)		-
Property and equipment, net		-		-		6,613		3,478		-		10,091
Goodwill		-		-		5,483		3,471		-		8,954
Other assets, net		6		303		1,817		1,164		(642)		2,648
Net investment in subsidiaries		3,361		18,435		7,643		-		(29,439)		-
Total assets	$	4,965	$	35,250	$	27,174	$	17,025	$	(57,295)	$	27,119
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	163	$	54	$	12	$	-	$	229
Accounts payable		-		1		873		318		-		1,192
Income tax payable		13		-		-		-		-		13
Deferred income taxes		23		-		-		-		-		23
Accrued interest		-		155		1		1		-		157
Accrued liabilities		4		-		1,051		492		-		1,547
Total current liabilities		40		319		1,979		823		-		3,161
Long-term debt		-		15,885		127		728		-		16,740
Intercompany payable		-		14,822		20,071		14,117		(49,010)		-
Deferred income taxes		844		-		-		-		-		844
Other long-term liabilities		-		862		1,113		361		(642)		1,694
Total liabilities		884		31,888		23,290		16,029		(49,652)		22,439
Redeemable noncontrolling interests in equity of consolidated subsidiaries		-		-		-		520		-		520
Equity:
Community Health Systems, Inc. stockholders’ equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,101		1,294		1,471		523		(3,288)		2,101
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(70)		(70)		(17)		-		87		(70)
Retained earnings		2,056		2,138		2,430		(126)		(4,442)		2,056
Total Community Health Systems, Inc. stockholders’ equity		4,081		3,362		3,884		397		(7,643)		4,081
Noncontrolling interests in equity of consolidated subsidiaries		-		-		-		79		-		79
Total equity		4,081		3,362		3,884		476		(7,643)		4,160
Total liabilities and equity	$	4,965	$	35,250	$	27,174	$	17,025	$	(57,295)	$	27,119

40

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Balance Sheet

December 31, 2014

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	368	$	141	$	-	$	509
Patient accounts receivable, net of allowance for doubtful accounts		-		-		1,272		2,137		-		3,409
Supplies		-		-		373		184		-		557
Prepaid income taxes		30		-		-		-		-		30
Deferred income taxes		341		-		-		-		-		341
Prepaid expenses and taxes		-		-		138		54		-		192
Other current assets		-		-		356		172		-		528
Total current assets		371		-		2,507		2,688		-		5,566
Intercompany receivable		1,199		16,560		2,532		7,877		(28,168)		-
Property and equipment, net		-		-		6,548		3,621		-		10,169
Goodwill		-		-		5,480		3,471		-		8,951
Other assets, net		15		302		1,874		1,179		(635)		2,735
Net investment in subsidiaries		3,290		18,229		7,399		-		(28,918)		-
Total assets	$	4,875	$	35,091	$	26,340	$	18,836	$	(57,721)	$	27,421
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	163	$	61	$	11	$	-	$	235
Accounts payable		-		-		909		384		-		1,293
Deferred income taxes		23		-		-		-		-		23
Accrued interest		-		225		2		-		-		227
Accrued liabilities		4		-		1,249		558		-		1,811
Total current liabilities		27		388		2,221		953		-		3,589
Long-term debt		-		15,820		139		722		-		16,681
Intercompany payable		-		14,752		19,066		15,795		(49,613)		-
Deferred income taxes		845		-		-		-		-		845
Other long-term liabilities		-		841		1,140		346		(635)		1,692
Total liabilities		872		31,801		22,566		17,816		(50,248)		22,807
Redeemable noncontrolling interests in equity of consolidated subsidiaries		-		-		-		531		-		531
Equity:
Community Health Systems, Inc. stockholders’ equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,095		1,208		1,369		528		(3,105)		2,095
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(63)		(63)		(25)		5		83		(63)
Retained earnings		1,977		2,145		2,430		(124)		(4,451)		1,977
Total Community Health Systems, Inc. stockholders’ equity		4,003		3,290		3,774		409		(7,473)		4,003
Noncontrolling interests in equity of consolidated subsidiaries		-		-		-		80		-		80
Total equity		4,003		3,290		3,774		489		(7,473)		4,083
Total liabilities and equity	$	4,875	$	35,091	$	26,340	$	18,836	$	(57,721)	$	27,421

41

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2015

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating activities	$	(10)	$	(123)	$	23	$	49	$	-	$	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related equipment		-		-		(11)		(2)		-		(13)
Purchases of property and equipment		-		-		(199)		(42)		-		(241)
Proceeds from disposition of hospitals and other ancillary operations		-		-		4		58		-		62
Proceeds from sale of property and equipment		-		-		-		3		-		3
Purchases of available-for-sale securities		-		-		(22)		(37)		-		(59)
Proceeds from sales of available-for-sale securities		-		-		19		37		-		56
Increase in other investments		-		-		(30)		(9)		-		(39)
Net cash used in investing activities		-		-		(239)		8		-		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		-		-		-		-		17
Repurchase of restricted stock shares for payroll tax withholding requirements		(20)		-		-		-		-		(20)
Deferred financing costs and other debt-related costs		-		(20)		-		-		-		(20)
Redemption of noncontrolling investments in joint ventures		-		-		-		(7)		-		(7)
Distributions to noncontrolling investors in joint ventures		-		-		-		(23)		-		(23)
Changes in intercompany balances with affiliates, net		13		77		(101)		11		-		-
Borrowings under credit agreements		-		1,250		1		-		-		1,251
Issuance of long-term debt		-		-		-		-		-		-
Proceeds from receivables facility		-		-		-		75		-		75
Repayments of long-term indebtedness		-		(1,184)		(15)		(69)		-		(1,268)
Net cash provided by (used in) financing activities		10		123		(115)		(13)		-		5
Net change in cash and cash equivalents		-		-		(331)		44		-		(287)
Cash and cash equivalents at beginning of period		-		-		368		141		-		509
Cash and cash equivalents at end of period	$	-	$	-	$	37	$	185	$	-	$	222

42

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) – (Continued)

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2014

	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating activities	$	73	$	298	$	62	$	(368)	$	-	$	65
Cash flows from investing activities:
Acquisitions of facilities and other related equipment		-		-		(2,760)		(14)		-		(2,774)
Purchases of property and equipment		-		-		(143)		(38)		-		(181)
Purchases of available-for-sale securities		-		-		-		(78)		-		(78)
Proceeds from sales of available-for-sale securities		-		-		-		76		-		76
Increase in other investments		-		-		(75)		(24)		-		(99)
Net cash used in investing activities		-		-		(2,978)		(78)		-		(3,056)
Cash flows from financing activities:
Proceeds from exercise of stock options		6		-		-		-		-		6
Repurchase of restricted stock shares for payroll tax withholding requirements		(11)		-		-		-		-		(11)
Deferred financing costs and other debt-related costs		-		(269)		-		-		-		(269)
Excess tax benefit relating to stock-based compensation		3		-		-		-		-		3
Redemption of noncontrolling investments in joint ventures		-		-		-		(5)		-		(5)
Distributions to noncontrolling investors in joint ventures		-		-		-		(19)		-		(19)
Changes in intercompany balances with affiliates, net		(71)		(3,417)		3,117		371		-		-
Borrowings under credit agreements		-		7,062		17		-		-		7,079
Issuance of long-term debt		-		4,000		-		-		-		4,000
Proceeds from receivables facility		-		-		-		133		-		133
Repayments of long-term indebtedness		-		(7,674)		(7)		(5)		-		(7,686)
Net cash provided by (used in) financing activities		(73)		(298)		3,127		475		-		3,231
Net change in cash and cash equivalents		-		-		211		29		-		240
Cash and cash equivalents at beginning of period		-		-		239		134		-		373
Cash and cash equivalents at end of period	$	-	$	-	$	450	$	163	$	-	$	613

43

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read this discussion together with our unaudited condensed consolidated financial statements and the accompanying notes included herein.

Throughout this Quarterly Report on Form 10-Q, we refer to Community Health Systems, Inc., or the Parent Company, and its consolidated subsidiaries in a simplified manner and on a collective basis, using words like “we,” “our,” “us” and the “Company”. This drafting style is suggested by the Securities and Exchange Commission, or SEC, and is not meant to indicate that the publicly-traded Parent Company or any particular subsidiary of the Parent Company owns or operates any asset, business or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Executive Overview

We are one of the largest publicly-traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. We provide healthcare services through the hospitals that we own and operate and affiliated businesses in non-urban and selected urban markets throughout the United States. We generate revenues by providing a broad range of general and specialized hospital healthcare services and other outpatient services to patients in the communities in which we are located. As of March 31, 2015, we owned or leased 197 hospitals included in continuing operations, comprised of 193 general acute care hospitals and four stand-alone rehabilitation or psychiatric hospitals. In addition to our hospitals and related businesses, we own and operate home care agencies, located primarily in markets where we also operate a hospital. Also, through our wholly-owned subsidiary, Quorum Health Resources, LLC, or QHR, we provide management and consulting services to non-affiliated general acute care hospitals located throughout the United States. For the hospitals and home care agencies that we own and operate, we are paid for our services by governmental agencies, private insurers and directly by the patients we serve. For our management and consulting services, we are paid by the non-affiliated hospitals utilizing our services.

On January 27, 2014, we and one of our wholly-owned subsidiaries completed the acquisition of Health Management Associates, Inc., or HMA, by acquiring through a merger all the outstanding shares of common stock of HMA, or HMA common stock, for approximately $7.3 billion, including the assumption of approximately $3.8 billion of indebtedness, consisting of a combination of cash and Parent Company common stock. During the three months ended March 31, 2015 and 2014, we recognized approximately less than $1 million and $56 million of acquisition and integration expenses related to the HMA merger, respectively.

We believe the HMA merger has benefited us since it has expanded the number of markets we serve and reduced our concentration of credit risk and other risks in any one state. We have also achieved synergies, and believe that we will achieve additional synergies, from eliminating duplicate corporate functions and centralizing many support functions, which we believe will allow us to continue to improve HMA’s margins. We believe this merger has extended and strengthened our hospital and physician networks.

Operating results and statistical data for the three months ended March 31, 2015, include information for the operations of the acquired HMA hospitals from January 27, 2014, the date of the HMA merger. Throughout this executive overview and management’s discussion and analysis, same-store operating results and statistical data for the three months ended March 31, 2015 and 2014 includes the hospitals acquired in the HMA merger. For the hospitals acquired in the HMA merger, this same-store information reflects the periods from January 1 through March 31, 2015 and 2014, as if such hospitals were owned during both comparable periods. For all hospitals owned throughout both periods, the same-store operating results and statistical data reflects the indicated periods. In addition, the same-store comparisons exclude our hospitals that have previously been classified as discontinued operations for accounting purposes.

In addition, during the three months ended March 31, 2015, we divested four hospitals previously recorded in discontinued operations. Two of these hospitals were required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

44

Our net operating revenues for the three months ended March 31, 2015, increased approximately $735 million to approximately $4.9 billion compared to approximately $4.2 billion for the three months ended March 31, 2014. We had income from continuing operations before noncontrolling interests of $112 million during the three months ended March 31, 2015, compared to a loss from continuing operations before noncontrolling interests of $76 million for the three months ended March 31, 2014. Income from continuing operations before noncontrolling interests for the three months ended March 31, 2015 included an after-tax charge of $5 million for loss from early extinguishment of debt, less than $1 million after-tax expense for acquisition and integration expenses from the HMA merger and $5 million after-tax expense for government settlement and related costs for several qui tam matters settled in principle during the three months ended March 31, 2015. These after-tax charges were partially offset by income of $4 million from fair value adjustments, net of legal expenses, related to the HMA legal proceedings underlying the CVR agreement. Included in income from continuing operations for the three months ended March 31, 2014, was a $45 million after-tax charge for loss from early extinguishment of debt, $32 million after-tax expense for acquisition and integration expenses from the HMA merger, an after-tax charge of $26 million for the acceleration of amortization on software to be abandoned, an after-tax charge of $15 million for impairment of long-lived assets related to internal-use software and an after-tax charge of $2 million for legal expenses related to the HMA legal proceedings underlying the CVR agreement. Consolidated inpatient admissions for the three months ended March 31, 2015, increased 15.7%, compared to the three months ended March 31, 2014, and consolidated adjusted admissions for the three months ended March 31, 2015 increased 17.0%, compared to the three months ended March 31, 2014. Same-store inpatient admissions for the three months ended March 31, 2015, increased 0.4%, compared to the three months ended March 31, 2014, and same-store adjusted admissions for the three months ended March 31, 2015 increased 2.5%, compared to the three months ended March 31, 2014.

Self-pay revenues represented approximately 12.6% and 14.5% of our net operating revenues, net of contractual allowances and discounts (but before provision for bad debts), for the three months ended March 31, 2015 and 2014, respectively. The amount of foregone revenue related to providing charity care services as a percentage of net operating revenues was approximately 2.2% and 4.0% for the three months ended March 31, 2015 and 2014, respectively. Direct and indirect costs incurred in providing charity care services were approximately 0.3% and 0.6% of net operating revenues for the three months ended March 31, 2015 and 2014, respectively.

The U.S. Congress and certain state legislatures have introduced and passed a large number of proposals and legislation designed to make major changes in the healthcare system, including changes that increased access to health insurance. The Patient Protection and Affordable Care Act of 2010 as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Reform Legislation, mandates that substantially all U.S. citizens maintain medical insurance coverage and expands health insurance coverage through a combination of public program expansion and private sector health insurance reforms. Based on projections issued by the CBO, in March 2015, the incremental insurance coverage due to the Reform Legislation could result in 27 million formerly uninsured Americans gaining coverage by the end of 2025.

As the number of persons with access to health insurance in the U.S. increases, there may be a resulting increase in the number of patients using our facilities who have health insurance coverage. We operate hospitals in nine of the 10 states that, prior to enactment of the Reform Legislation, had the highest percentage of nonelderly uninsured people from among the state’s nonelderly population. More broadly, the 28 states in which we operate hospitals that are included in continuing operations include 25 of the 30 states with the highest percentage of nonelderly uninsured people from among the state’s nonelderly population.

States may opt out of the Medicaid coverage expansion provisions of the Reform Legislation without losing existing federal Medicaid funding. A number of states have opted out of the Medicaid coverage expansion provisions, but could ultimately decide to expand their programs at a later date. At our hospitals in these states, the number of uninsured patients will likely decline by a smaller margin than we initially expected when the Reform Legislation was first adopted. Of the 28 states in which we operate hospitals that are included in continuing operations, 13 states are expanding their Medicaid programs. At this time, the other 15 states are not, including Florida, Tennessee and Texas, where we operated a significant number of hospitals as of March 31, 2015. Some states that have opted out are evaluating options such as waiver plans to operate an alternative Medicaid expansion plan.

Our hospitals are well positioned to participate in the provider networks of various qualified health plans, or QHPs, offering plan options on the health insurance exchanges created pursuant to the Reform Legislation. For the 2015 plan year, all of our hospitals in continuing operations have arrangements to participate in at least one health insurance exchange agreement, approximately 90% of our hospitals participate in two or more contracts, approximately 90% of our hospitals participate in the first or second lowest cost bronze plan networks (QHPs with a 60% actuarial value) and approximately 90% of our hospitals participate in the first or second lowest cost silver plan networks (QHPs with a 70% actuarial value).

45

The Reform Legislation also makes a number of changes to Medicare and Medicaid, such as reductions to the Medicare annual market basket update for federal fiscal years 2010 through 2019, a productivity offset to the Medicare market basket update, and a reduction to the Medicare and Medicaid disproportionate share payments, each of which could adversely impact the reimbursement received under these programs.

Also included in the Reform Legislation are provisions aimed at reducing fraud, waste and abuse in the healthcare industry. These provisions allocate significant additional resources to federal enforcement agencies and expand the use of private contractors to recover potentially inappropriate Medicare and Medicaid payments. The Reform Legislation amends several existing federal laws, including the federal anti-kickback statute and the False Claims Act making it easier for government agencies and private plaintiffs to prevail in lawsuits brought against healthcare providers. These amendments also make it easier for potentially severe fines and penalties to be imposed on healthcare providers that violate applicable laws and regulations.

We believe the expansion of private sector health insurance and Medicaid coverage will, over time, increase our reimbursement related to providing services to individuals who were previously uninsured, which should reduce our expense from uncollectible accounts receivable. The various provisions in the Reform Legislation that directly or indirectly affect reimbursement take effect over a number of years. In addition, we believe that the Reform Legislation has had a positive impact on net operating revenues during 2014 and 2015 as the result of the expansion of private sector and Medicaid coverage that has already occurred from the Reform Legislation and we believe the impact on our net operating revenues will continue to be positive. Other provisions of the Reform Legislation, such as requirements related to employee health insurance coverage, have increased and will continue to increase our operating costs.

The Reform Legislation, however, remains subject to legislative efforts to repeal or modify the law and a number of court challenges to its constitutionality and interpretation. For example, the United States Supreme Court heard King v. Burwell during the 2015 session, which challenges the extension of premium subsidies to health insurance policies purchased through federally-operated health insurance exchanges. If decided in favor of the plaintiffs, who contend that subsidies must be limited to state-operated health insurance exchanges, the case could make it more difficult for uninsured individuals in states that do not operate an exchange to purchase coverage and otherwise significantly affect implementation of the Reform Legislation, in a manner that results in less than projected numbers of newly insured individuals. Because of the many variables involved, including clarifications and modifications resulting from the rule-making process, legislative efforts to repeal or modify the law, court challenges, the development of agency guidance and future judicial interpretations, whether and how many states ultimately decide to expand Medicaid coverage, the number of uninsured who elect to purchase health insurance coverage, budgetary issues at federal and state levels, and the potential for delays in the implementation of the Reform Legislation, we may not be able to fully realize the positive impact the Reform Legislation may otherwise have on our business, results of operations, cash flow, capital resources and liquidity. Furthermore, we cannot predict whether we will be able to modify certain aspects of our operations to offset any potential adverse consequences from the Reform Legislation.

The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records, or EHR, technology and pursuant to the Health Information Technology for Economic and Clinical Health Act, or HITECH, established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. These payments are intended to incentivize the meaningful use of EHR. Our hospital facilities have been implementing EHR technology on a facility-by-facility basis since 2011. We recognize incentive reimbursement related to the Medicare or Medicaid incentives as we are able to implement the certified EHR technology and meet the defined “meaningful use criteria,” and information from completed cost report periods is available from which to calculate the incentive reimbursement. The timing of recognizing incentive reimbursement will not correlate with the timing of recognizing operating expenses and incurring capital costs in connection with the implementation of EHR technology which may result in material period-to-period changes in our future results of operations. Beginning in 2015, eligible hospitals and professionals that have not demonstrated meaningful use of certified EHR technology and have not applied and qualified for a hardship exception are subject to penalties. Eligible hospitals are subject to a reduced market basket update to the inpatient prospective payment system standardized amount in 2015 and each subsequent fiscal year. Eligible professionals are subject to a 1% per year cumulative reduction applied to the Medicare physician fee schedule amount for covered professional services, subject to a cap of 5%.

Although we believe that our hospital facilities will be in compliance with the meaningful use standards during 2015, there can be no assurance that all of our facilities will remain in compliance and therefore not be subject to the HITECH penalty provisions. We recognized approximately $26 million and $40 million during the three months ended March 31, 2015 and 2014, respectively, for HITECH incentive reimbursements from Medicare and Medicaid related to certain of our hospitals and for certain of our employed physicians, which are presented as a reduction of operating expenses.

46

As a result of our current levels of cash, available borrowing capacity, long-term outlook on our debt repayments, the refinancing of our term loans and our continued projection of our ability to generate cash flows, we anticipate that we will be able to invest the necessary capital in our business over the next twelve months. We believe there continues to be ample opportunity for growth in substantially all of our markets by decreasing the need for patients to travel outside their communities for healthcare services. Furthermore, we continue to benefit from synergies from our acquisitions and will continue to strive to improve operating efficiencies and procedures in order to improve our profitability at all of our hospitals.

Sources of Revenue

The following table presents the approximate percentages of operating revenues, net of contractual allowances and discounts (but before provision for bad debts), by payor source for the periods indicated. The data for the periods presented are not strictly comparable due to the effect that hospital acquisitions have had on these statistics.

	Three Months Ended
	March 31,
	2015		2014
Medicare		24.8 %		25.8 %
Medicaid		10.4		9.4
Managed Care and other third-party payors		52.2		50.3
Self-pay		12.6		14.5
Total		100.0 %		100.0 %

As shown above, we receive a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect revenues received from the Medicare and Medicaid programs to increase due to the general aging of the population. In addition, the Reform Legislation has increased and should continue to increase the number of insured patients, which, in turn, has reduced and should continue to reduce revenues from self-pay patients and reduce our provision for bad debts. The Reform Legislation, however, imposes significant reductions in amounts the government pays Medicare managed care plans. The trend toward increased enrollment in Medicare managed care may adversely affect our operating revenue growth. Other provisions in the Reform Legislation impose minimum medical-loss ratios and require insurers to meet specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. The trend toward increased enrollment in managed care may adversely affect our operating revenue growth. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than the standard billing rates. We account for the differences between the estimated program reimbursement rates and the standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net income (loss) by an insignificant amount in each of the three month periods ended March 31, 2015 and 2014.

47

The payment rates under the Medicare program for hospital inpatient and outpatient acute care services are based on a prospective payment system, depending upon the diagnosis of a patient’s condition. These rates are indexed for inflation annually, although increases have historically been less than actual inflation. On August 22, 2014, the Centers for Medicare & Medicaid Services, or CMS, issued the final rule to adjust this index by 2.9% for hospital inpatient acute care services that are reimbursed under the prospective payment system. The final rule also made other payment adjustments that, coupled with the 0.5% multifactor productivity reduction and a 0.2% reduction to hospital inpatient rates implemented pursuant to the Reform Legislation, yielded an estimated net 0.6% decrease in reimbursement for hospital inpatient acute care services beginning October 1, 2014. CMS also implemented new admission and medical review criteria for inpatient services commonly known as the “two midnight rule.” Under the rule, Medicare beneficiaries are only to be admitted as inpatients when there is a reasonable expectation that the hospital care is medically necessary and will be required across two midnights, absent unusual circumstances. Compliance with the two midnight rule was required beginning October 1, 2013 and will become subject to Recovery Audit Contractor audits for admissions on or after October 1, 2015. Reductions in the rate of increase or overall reductions in Medicare reimbursement may cause a decline in the growth of our net operating revenues.

Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Similar programs are also being considered by other states. The programs are generally authorized for a specified period of time and require CMS’s approval to be extended. The Florida limited income pool supplemental program is scheduled to expire in 2015, unless extended by CMS. CMS has indicated that it will take into account a state’s status with respect to expanding its Medicaid program in considering whether to extend these supplemental programs. Certain of the states in which we operate, including Florida and Texas, have opted out of the Medicaid expansion under the Reform Legislation. We are unable to predict whether or on what terms CMS will extend the supplemental programs in which our hospitals participate. After these supplemental programs are signed into law, we recognize revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and included as Medicaid revenue in the table above, and fees, taxes or other program related costs are reflected in other operating expenses.

Results of Operations

Our hospitals offer a variety of services involving a broad range of inpatient and outpatient medical and surgical services. These include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic services, psychiatric and rehabilitation services. The strongest demand for hospital services generally occurs during January through April and the weakest demand for these services occurs during the summer months. Accordingly, eliminating the effect of new acquisitions, our net operating revenues and earnings are historically highest during the first quarter and lowest during the third quarter. Same-store operating results include the hospitals acquired in the HMA merger. For the hospitals acquired in the HMA merger, this same-store information reflects the periods from January 1 through March 31, 2015 and 2014, as if such hospitals were owned during both comparable periods. For all hospitals owned throughout both periods, the same-store information reflects the indicated periods. The same store information reflected below does not reflect the application of purchase accounting adjustments as if the HMA merger had been completed on January 1, 2014. Therefore, this information is not intended to present pro forma information prepared under the guidelines of Articles 3-05 and 11 of the Securities and Exchange Commission. However, management believes the information provides investors with useful information about hospital admissions, adjusted admissions and net operating revenues had the HMA facilities been owned for the indicated periods. This same-store information for the hospitals acquired in the HMA merger for 2014 is non-GAAP financial information and may not be comparable to the information provided for 2015 due to the aforementioned purchase accounting adjustments not having been applied.

48

The following tables summarize, for the periods indicated, selected operating data.

	Three Months Ended
	March 31,
	2015		2014
	(Expressed as a percentage of net operating revenues)
Consolidated (a):
Net operating revenues		100.0 %		100.0 %
Operating expenses (b)		(85.9)		(88.6)
Depreciation and amortization		(6.0)		(7.1)
Income from operations		8.1		4.3
Interest expense, net		(4.9)		(5.4)
Loss from early extinguishment of debt		(0.2)		(1.7)
Equity in earnings of unconsolidated affiliates		0.4		0.3
Impairment of long-lived assets		-		(0.6)
Income (loss) from continuing operations before income taxes		3.4		(3.1)
(Provision) benefit for income taxes		(1.1)		1.3
Income (loss) from continuing operations		2.3		(1.8)
Loss from discontinued operations, net of taxes		(0.3)		(0.5)
Net income (loss)		2.0		(2.3)
Less: Net income attributable to noncontrolling interests		(0.4)		(0.4)
Net income (loss) attributable to Community Health Systems, Inc. stockholders		1.6 %		(2.7)%
			Three Months Ended
			March 31, 2015
Percentage increase from same period prior year (a):
Net operating revenues				17.6 %
Admissions				15.7
Adjusted admissions (c)				17.0
Average length of stay				-
Net income attributable to Community Health Systems, Inc. (d)				170.5
Same store percentage increase from same period prior year (a)(e):
Net operating revenues				5.2 %
Admissions				0.4
Adjusted admissions (c)				2.5

(a) We have restated our prior period financial statements and statistical results to reflect the reclassification as discontinued operations for two hospitals held for sale at December 31, 2014 and subsequently sold or held for sale during the three months ended March 31, 2015.

(b) Operating expenses include salaries and benefits, supplies, other operating expenses, government settlement and related costs, electronic health records incentive reimbursement and rent.

(c) Adjusted admissions is a general measure of combined inpatient and outpatient volume. We computed adjusted admissions by multiplying admissions by gross patient revenues and then dividing that number by gross inpatient revenues.

(d) Includes loss from discontinued operations.

(e) Includes former HMA hospitals for the periods from January 1 through March 31, 2015 and 2014, as if they were owned during both comparable periods. For all hospitals owned throughout both periods, the same-store operating results and statistical data reflects the indicated periods. In addition, same-store comparisons exclude our hospitals that have previously been classified as discontinued operations for accounting purposes.

49

Three Months Ended March 31, 2015 Compared to Three Months Ended March 31, 2014

Net operating revenues increased by 17.6% to approximately $4.9 billion for the three months ended March 31, 2015, from approximately $4.2 billion for the three months ended March 31, 2014. The $735 million increase in net operating revenues consisted of $401 million of revenues due to having an additional 26 days of operations for the hospitals acquired in the HMA merger, as well as $130 million of non-same store net operating revenue primarily from the other four hospitals acquired in 2014. Net operating revenues from hospitals owned throughout both periods increased $204 million. On a same-store basis, net operating revenues increased 5.2% during the three months ended March 31, 2015. The increase in same-store net operating revenues was attributable to favorable changes in payor mix with corresponding reductions in charity care and self-pay discounts as a percentage of revenue. On a consolidated basis, inpatient admissions increased by 15.7% and adjusted admissions increased by 17.0% during the three months ended March 31, 2015. On a same-store basis, inpatient admissions increased by 0.4% and adjusted admissions increased by 2.5% during the three months ended March 31, 2015. The increase in same-store adjusted admissions was impacted by an increase in flu-based admissions, as well as an increase in Medicaid adjusted admissions of 7.5%, offset by a decrease in self-pay adjusted admissions of 12.0%.

Operating expenses, excluding depreciation and amortization, as a percentage of net operating revenues, decreased from 88.6% for the three months ended March 31, 2014 to 85.9% for the three months ended March 31, 2015. Salaries and benefits, as a percentage of net operating revenues, decreased from 47.7% for the three months ended March 31, 2014 to 46.0% for the three months ended March 31, 2015. This decrease in salaries and benefits, as a percentage of net operating revenues, was primarily due to increased productivity, elimination of certain of HMA’s corporate overhead costs and productivity improvement from integrating HMA into our operations during 2014. Supplies, as a percentage of net operating revenues, increased from 15.1% for the three months ended March 31, 2014 to 15.5% for the three months ended March 31, 2015. Other operating expenses, as a percentage of net operating revenues, decreased from 24.4% for the three months ended March 31, 2014 to 22.4% for the three months ended March 31, 2015. This decrease in other operating expenses, as a percentage of net operating revenues, was primarily due to decreases in expenses related to achieving meaningful use compliance and acquisition and integration-related expenses, primarily related to the HMA merger. Government settlement and related costs, as a percentage of net revenues, was 0.1% for the three months ended March 31, 2015 from the several qui tam matters settled in principle. Rent, as a percentage of net operating revenues, remained consistent at 2.4% for the three months ended March 31, 2015 and 2014.

Electronic health records incentive reimbursements represent those incentives under the HITECH Act for which the recognition criterion has been met. We recognized approximately $26 million and $40 million of incentive reimbursements, or 0.5% and 1.0% of net operating revenues, for the three months ended March 31, 2015 and 2014, respectively. We received cash payments of $54 million and $62 million for these incentives during the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015 and 2014, $75 million and $93 million, respectively, was recorded as deferred revenue in connection with the receipt of these cash payments as all criteria for gain recognition had not been met. Operating expenses incurred related to the installation and adoption of electronic health records totaled approximately 0.1% and 0.4% of net operating revenues for the three months ended March 31, 2015, and 2014, respectively.

Depreciation and amortization, including $42 million of amortization of software to be abandoned recognized during the three months ended March 31, 2014, as a percentage of net operating revenues, decreased from 7.1% for the three months ended March 31, 2014 to 6.0% for the three months ended March 31, 2015. This decrease was due primarily to the shortening of the remaining useful life of software that was previously in use and impaired during the three months ended March 31, 2014.

Interest expense, net, increased by $17 million to $241 million in the three months ended March 31, 2015 compared to $224 million for the three months ended March 31, 2014. An increase in our average outstanding debt during the three months ended March 31, 2015, primarily due to the additional debt incurred at the end of January 2014 to acquire HMA, resulted in an increase in interest expense of $50 million. These increases in interest expense were partially offset by a decrease in interest rates during the three months ended March 31, 2015, compared to the same period in 2014, which resulted in a decrease in interest expense of $32 million and a decrease in interest expense of $1 million as a result of more interest being capitalized during the three months ended March 31, 2015, as compared to the same period in 2014, due to an increase in major construction projects in the current year.

The loss from early extinguishment of debt of $8 million was recognized during the three months ended March 31, 2015 after the repayment of certain outstanding term loans as part of the amendment of the Credit Facility. The loss from early extinguishment of debt of $73 million was recognized during the three months ended March 31, 2014 after the repayment of the term loans due 2014.

50

Equity in earnings of unconsolidated affiliates, as a percentage of net operating revenues, increased from 0.3% for the three months ended March 31, 2014 to 0.4% for the three months ended March 31, 2015.

In connection with the HMA merger, we further analyzed our intangible assets related to internal-use software used in certain of our hospitals for patient and clinical systems, including software required to meet criteria for meaningful use attestation and ICD-10 compliance. This analysis resulted in management reassessing its usage of certain software products and rationalizing that, with the addition of the HMA hospitals in the first quarter of 2014, those software applications were going to be discontinued and replaced with new applications that better integrate meaningful use and ICD-10 compliance, are more cost effective and can be implemented at a greater efficiency of scale over future implementations. Because of this decision by management, an impairment charge of approximately $24 million was recorded during the three months ended March 31, 2014.

The net results of the above mentioned changes resulted in income (loss) from continuing operations before income taxes increasing $300 million from a loss of $132 million for the three months ended March 31, 2014 to income of $168 million for the three months ended March 31, 2015.

Provision for (benefit) from income taxes from continuing operations increased from an income tax benefit of $56 million for the three months ended March 31, 2014 to an income tax provision of $56 million for the three months ended March 31, 2015 due to the increase in income from continuing operations before income taxes. Our effective tax rates were 33.2% and 42.5% for the three months ended March 31, 2015 and 2014, respectively. The decrease in the Company’s effective tax rate for the three months ended March 31, 2015 is primarily impacted by the increase in income from continuing operations before income taxes, and the impact of non-deductible transaction costs associated with the HMA merger affecting the tax provision for the three months ended March 31, 2014.

Income (loss) from continuing operations, as a percentage of net operating revenues, increased from (1.8)% for the three months ended March 31, 2014 to 2.3% for the three months ended March 31, 2015.

Discontinued operations for these periods include the results of operations of certain hospitals owned or leased by us as of March 31, 2015 and 2014, which were classified as being held for sale or sold. The operation of these hospitals resulted in a loss, net of taxes, of $11 million included in discontinued operations during the three months ended March 31, 2015, compared to a loss, net of taxes, of $4 million included in discontinued operations during the three months ended March 31, 2014. An after-tax impairment charge of $1 million was recorded during the three months ended March 31, 2015, based on the difference between the estimated fair value and the carrying value of the assets held for sale, including an allocation of reporting unit goodwill, compared to an impairment charge of $18 million during the three months ended March 31, 2014. In addition, a loss on the sale of hospitals, net of tax, was recorded of $1 million for the three months ended March 31, 2015. Overall, discontinued operations during the three months ended March 31, 2015, consisted of a loss, net of taxes, of $13 million, compared to a loss, net of taxes, of $22 million during the three months ended March 31, 2014.

Net income (loss), as a percentage of net operating revenues, increased from a loss of (2.3)% for the three months ended March 31, 2014 to income of 2.0% for the three months ended March 31, 2015.

Net income attributable to noncontrolling interests, as a percentage of net operating revenues, remained consistent at 0.4% for the three months ended March 31, 2015 and 2014.

Net income (loss) attributable to Community Health Systems, Inc. was $79 million for the three months ended March 31, 2015 compared to a loss of $(112) million for the three months ended March 31, 2014. The increase in net income attributable to Community Health Systems, Inc. is primarily due to a decrease in the loss from early extinguishment of debt, impairment of long-lived assets and discontinued operations, as a percentage of net operating revenues, as discussed above.

51

Liquidity and Capital Resources

Net cash (used in) provided by operating activities decreased $126 million, from approximately $65 million in cash provided by operating activities for the three months ended March 31, 2014, to approximately $61 million in cash used in operating activities for the three months ended March 31, 2015. Cash from operating activities reflected the net impact of the increase in net income of $197 million, offset by a $6 million decrease to depreciation and amortization and a decrease of $103 million in the non-cash charges to income primarily related to the loss from early extinguishment of debt and the impairment of hospitals sold or held for sale. Cash from operating activities decreased as a result of net growth in operating assets and liabilities of approximately $214 million, primarily the result of an increase in patient accounts receivable coupled with a decrease in accounts payable, accrued liabilities and income taxes paid. Contributing to the decrease in accrued liabilities is the cash outflow for payment of the previously accrued government settlement and related legal costs of $87 million during the three months ended March 31, 2015. Total cash paid for interest during the three months ended March 31, 2015 was approximately $300 million compared to $175 million for the three months ended March 31, 2014. Approximately $1 million was paid for income taxes for the three months ended March 31, 2015, compared to a net tax refund of $79 million for the three months ended March 31, 2014. Included in net cash provided by operating activities for the three months ended March 31, 2015 was $54 million of cash received for HITECH incentive reimbursements, compared to $62 million received for the three months ended March 31, 2014.

The cash used in investing activities decreased $2.8 billion, from approximately $3.1 billion for the three months ended March 31, 2014 to approximately $231 million for the three months ended March 31, 2015. The decrease in cash used in investing activities was primarily due to a decrease in cash paid for acquisitions of facilities and other related equipment of $2.8 billion as a result of the acquisition of HMA (which owned and operated 71 hospitals at the time of the completion of the HMA merger) during the three months ended March 31, 2014, compared to no hospital acquisitions during the three months ended March 31, 2015, as well as an increase in proceeds from the disposition of hospitals and other ancillary operations of $62 million, an increase in proceeds from the sale of property and equipment of $3 million and a decrease in cash used for other investments of $60 million for the three months ended March 31, 2015. These decreases were offset by an increase in the cash used for the purchase of property and equipment of $60 million and the net impact of the purchases and sales of available-for-sale securities of $1 million. Included in cash outflows for other investments for the three months ended March 31, 2015 is approximately $3 million of capital expenditures related to the purchase and implementation of certified EHR technology, including implementation of Cerner software at several hospital locations. The remaining cash outflows for other investments for the three months ended March 31, 2015 consists primarily of purchases and development of other internal-use software and payments made under non-employee physician recruiting agreements of $36 million. We anticipate being able to fund future routine capital expenditures with cash flows generated from operations.

Our net cash provided by financing activities was $5 million for the three months ended March 31, 2015, compared to $3.2 billion for the three months ended March 31, 2014. The decrease in cash provided by financing activities, in comparison to the prior year, is primarily due to a reduction in our long-term borrowings and issuance of long-term debt totaling $9.8 billion, which was mostly offset by a reduction in the repayments of our long-term debt of $6.4 billion during the three months ended March 31, 2015 as a result of financing transactions in 2014 related to the HMA merger. These decreases were offset by an increase in the proceeds from the exercise of stock options of $11 million and a reduction in cash paid for deferred financing costs and other debt-related costs of $249 million.

  Capital Expenditures

Cash expenditures for purchases of facilities and other related equipment were $13 million for the three months ended March 31, 2015 compared to $3 billion for the three months ended March 31, 2014. Our expenditures during the three months ended March 31, 2015 were primarily related to the purchase of several physician practices and other ancillary services. Our expenditures during the three months ended March 31, 2014 were primarily related to the purchase price paid by us in the acquisition of HMA (which owned and operated 71 hospitals at the time of the completion of the HMA merger) and the purchase of several surgery centers, physician practices and other ancillary services.

Excluding the cost to construct replacement hospitals, our cash expenditures for routine capital for the three months ended March 31, 2015 totaled $207 million compared to $179 million for the three months ended March 31, 2014. These capital expenditures related primarily to the purchase of additional equipment, minor renovations and information systems infrastructure. Costs to construct replacement hospitals totaled $34 million for the three months ended March 31, 2015, compared to $2 million for the three months ended March 31, 2014. The costs to construct replacement hospitals for both the three months ended March 31, 2015 and 2014 represent both planning and construction costs for two replacement hospitals discussed below.

52

Pursuant to a hospital purchase agreement in effect as of March 31, 2015, we have committed to build a replacement facility in York, Pennsylvania by July 2017. Construction costs, including equipment costs, for the York replacement facility are currently estimated to be approximately $125 million. In addition, in October 2008, after the purchase of the noncontrolling owner’s interest in our Birmingham, Alabama facility, we initiated the purchase of a site, which includes a partially constructed hospital structure, for a potential replacement to our existing Birmingham facility. In September 2010, we received approval of our request for a certificate of need, or CON, from the Alabama Certificate of Need Review Board. This CON was challenged in the Alabama state circuit and appellate courts, but the CON was upheld by the Supreme Court of Alabama in May 2013, eliminating any further appeals. Our estimated construction costs, including the acquisition of the site and equipment costs, are approximately $280 million for the Birmingham replacement facility. We anticipate completion of this replacement hospital at the end of 2015.

  Capital Resources

Net working capital was approximately $2.3 billion at March 31, 2015, compared to $2.0 billion at December 31, 2014, an increase of $288 million, primarily the result of an increase in patient accounts receivable, decreases in accounts payable, accrued interest and employee compensation liabilities, and partially offset by decreases in cash.

We have senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, we and CHS entered into a third amendment and restatement of its Credit Facility, providing for additional financing and recapitalization of certain of our term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019, or Revolving Facility, (ii) the addition of a new $1.0 billion Term A facility due 2019, or the Term A Facility, (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which includes certain term C loans that were converted into such Term D facility (collectively, the Term D Facility)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the our post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility included a subfacility for letters of credit. On March 9, 2015, CHS entered into a first amendment and incremental term loan assumption agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion dollars.

The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at our option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.5% or (3) the adjusted LIBOR rate on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term D Facility and the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term D Facility will be subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by us and our subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by us and our subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on our leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to our EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements.

The borrower under the Credit Facility is CHS. All of our obligations under the Credit Facility are unconditionally guaranteed by Community Health Systems, Inc. and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of Community Health Systems, Inc., CHS and each subsidiary guarantor, including equity interests held

53

by us or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries.

We have agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. We are obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon our leverage ratio), on the unused portion of the Revolving Facility.

The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting our and our subsidiaries’ ability, subject to certain exception, to, among other things, (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of our businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change our fiscal year. We and our subsidiaries are also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants.

Events of default under the Credit Facility include, but are not limited to, (1) our failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility.

As of March 31, 2015, the availability for additional borrowings under our Credit Facility, after consideration of the $62 million outstanding at that date, was $1.0 billion pursuant to the Revolving Facility, of which $83 million was set aside for outstanding letters of credit. We believe that these funds, along with internally generated cash and continued access to the bank credit and capital markets, will be sufficient to finance future acquisitions, capital expenditures and working capital requirements during the next 12 months.

In connection with the consummation of the HMA merger, CHS issued: (i) $1.0 billion aggregate principal amount of 5.125% Senior Secured Notes due 2021, or the 2021 Senior Secured Notes, pursuant to an indenture, as supplemented, dated as of January 27, 2014, collectively, the Secured Indenture, by and among CHS, the Parent Company, the other guarantors from time to time party thereto, Regions Bank, as trustee, and Credit Suisse AG, as collateral agent, or the Collateral Agent and (ii) $3.0 billion aggregate principal amount of 6.875% Senior Notes due 2022, or the 6 ⁷⁄₈% Senior Notes, pursuant to an indenture, as supplemented, dated as of January 27, 2014, collectively, the Unsecured Indenture, by and among CHS, the Parent Company, the other guarantors from time to time party thereto, and Regions Bank, as trustee, or the Unsecured Indenture.

The 2021 Senior Secured Notes are senior secured obligations of CHS and are guaranteed on a senior secured basis by us, CHS and certain of CHS’s subsidiaries. The 2021 Senior Secured Notes mature on August 1, 2021, and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning on August 1, 2014. CHS is entitled to redeem some or all of the 2021 Senior Secured Notes at any time on or after February 1, 2017 at the redemption prices set forth in the Secured Indenture, plus accrued and unpaid interest, if any. In addition, prior to February 1, 2017, CHS may redeem some or all of the 2021 Senior Secured Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a “make-whole” premium, as set forth in the Secured Indenture. CHS is entitled to redeem up to 40% of the aggregate principal amount of the 2021 Senior Secured Notes until February 1, 2017 with the net proceeds from certain equity offerings at the redemption price set forth in the Secured Indenture. The Secured Indenture also contains covenants that, among other things, subject to various qualifications and exceptions, limit the ability of CHS and certain of CHS’s subsidiaries to: incur or guarantee additional indebtedness; pay dividends or make other restricted payments; make certain investments; create or incur certain liens; sell assets and subsidiary stock; transfer all or substantially all of their assets or enter into merger or consolidation transactions; and enter into transactions with affiliates.

The 6 ⁷⁄₈% Senior Notes are senior unsecured obligations of CHS and are guaranteed on a senior basis by the Parent Company, CHS and certain of CHS’s subsidiaries. The 6 ⁷⁄₈% Senior Notes mature on February 1, 2022, and bear interest at a rate of 6.875% per annum, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning on August 1, 2014. CHS is entitled to redeem some or all of the 6 ⁷⁄₈% Senior Notes at any time on or after February 1, 2018 at the redemption prices set forth in

54

the Unsecured Indenture, plus accrued and unpaid interest, if any. In addition, prior to February 1, 2018, CHS may redeem some or all of the 6 ⁷⁄₈% Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a “make-whole” premium, as set forth in the Unsecured Indenture. CHS is entitled to redeem up to 40% of the aggregate principal amount of the 6 ⁷⁄₈% Senior Notes until February 1, 2017 with the net proceeds from certain equity offerings at the redemption price set forth in the Unsecured Indenture. The Unsecured Indenture also contains covenants that, among other things, subject to various qualifications and exceptions, limit the ability of CHS, and certain of its subsidiaries to: incur or guarantee additional indebtedness; pay dividends or make other restricted payments; make certain investments; create or incur certain liens; sell assets and subsidiary stock; transfer all or substantially all of their assets or enter into merger or consolidation transactions; and enter into transactions with affiliates.

On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019, which were issued in a private placement. On March 21, 2012, CHS completed the secondary offering of $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%). The net proceeds from these issuances were used to finance the purchase of approximately $1.85 billion aggregate principal amount of CHS’ then outstanding 8 ⁷/₈% Senior Notes, to pay related fees and expenses and for general corporate purposes.

On July 18, 2012, CHS completed an underwritten public offering under our automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7 ¹/₈% Senior Notes due 2020. The net proceeds of the offering were used to finance the purchase or redemption of the then outstanding $934 million principal amount plus accrued interest of the 8 ⁷/₈% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes.

On August 17, 2012, CHS completed an underwritten public offering under our automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5 ¹/₈% Senior Secured Notes due 2018. The 5 ¹/₈% Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 5 ¹/₈% Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. The net proceeds of the offering, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses.

On March 21, 2012, through certain of its subsidiaries, CHS entered into an accounts receivable loan agreement, or the Receivables Facility, with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent. On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries also agreed to participate in the Receivables Facility as of that date. The existing and future non-self pay patient-related accounts receivable, or the Receivables, for certain hospitals of CHS and its subsidiaries serve as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread. Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on March 21, 2017, subject to customary termination events that could cause an early termination date. CHS maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of CHS’ subsidiaries to CHS, and CHS then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS. The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to CHS or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan. The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2015 totaled $623 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2015, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.3 billion and is included in patient accounts receivable on the condensed consolidated balance sheet.

As of March 31, 2015, we are currently a party to the following interest rate swap agreements to limit the effect of changes in interest rates on approximately 16.6% of our variable rate debt. On each of these swaps, we receive a variable rate of interest based on the three-month LIBOR, in exchange for the payment by us of a fixed rate of interest. We currently pay, on a quarterly basis, interest

55

on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 275 basis points. Loans in respect of the Term D Facility and the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 325 basis points. The Term D Facility is also subject to a 100 basis point LIBOR floor and a 200 basis point Alternate Base Rate floor.

Swap #	Notional Amount   (in millions)		Fixed Interest     Rate		Termination Date	Fair Value (in     millions)
1	$	300		3.447 %	August 6, 2016	$	12
2		100		3.401 %	August 19, 2016		4
3		200		3.429 %	August 19, 2016		8
4		200		3.500 %	August 30, 2016		8
5		100		3.005 %	November 30, 2016		4
6		200		2.055 %	July 25, 2019		5
7		200		2.059 %	July 25, 2019		5
8		400		1.882 %	August 30, 2019		1	(1)
9		200		2.515 %	August 30, 2019		5	(1)
10		200		2.613 %	August 30, 2019		6	(2)
11		300		2.041 %	August 30, 2020		1	(1)
12		300		2.738 %	August 30, 2020		10	(1)
13		300		2.892 %	August 30, 2020		12	(2)

(1) This interest rate swap becomes effective August 28, 2015.

(2) This interest rate swap becomes effective August 30, 2015.

The swaps that were in effect prior to the HMA merger remain in effect after the refinancing for the HMA merger and will continue to be used to limit the effects of changes in interest rates on portions of our amended credit facility.

56

The Credit Facility and/or our outstanding notes contain various covenants that limit our ability to take certain actions including; among other things, our ability to:

• incur, assume or guarantee additional indebtedness;

• issue redeemable stock and preferred stock;

• repurchase capital stock;

• make restricted payments, including paying dividends and making certain loans and investments;

• redeem debt that is subordinated in right of payment to our outstanding notes;

• create liens;

• sell or otherwise dispose of assets, including capital stock of subsidiaries;

• enter into agreements that restrict dividends from subsidiaries;

• merge, consolidate, sell or otherwise dispose of substantially all of our assets;

• enter into transactions with affiliates; and

• guarantee certain obligations.

In addition, our Credit Facility contains restrictive covenants and requires us to maintain specified financial ratios and satisfy other financial condition tests. Our ability to meet these restricted covenants and financial ratios and tests can be affected by events beyond our control, and we cannot assure you that we will meet those tests. A breach of any of these covenants could result in a default under our Credit Facility and/or our outstanding notes. Upon the occurrence of an event of default under our Credit Facility or our outstanding notes, all amounts outstanding under our Credit Facility and the notes may become immediately due and payable and all commitments under the Credit Facility to extend further credit may be terminated.

We believe that internally generated cash flows, availability for additional borrowings under our Credit Facility of $1.0 billion (consisting of a $1.0 billion Revolving Facility, of which $83 million is set aside for outstanding letters of credit and $62 million was outstanding at March 31, 2015) and our ability to amend the Credit Facility to provide for one or more tranches of term loans in an aggregate principal amount of $1.5 billion, and our continued access to the bank credit and capital markets will be sufficient to finance acquisitions, capital expenditures and working capital requirements during the next 12 months.

On May 24, 2012, we filed a universal automatic shelf registration statement on Form S-3ASR, as amended on June 7, 2012, that will permit us, from time to time, in one or more public offerings, to offer debt securities, common stock, preferred stock, warrants, depositary shares, or any combination of such securities. The shelf registration statement will also permit our subsidiary, CHS, to offer debt securities that would be guaranteed by us, from time to time in one or more public offerings. The terms of any such future offerings would be established at the time of the offering.

The ratio of earnings to fixed charges is a measure of our ability to meet our fixed obligations related to our indebtedness. The following table shows the ratio of earnings to fixed charges for the three months ended March 31, 2015:

	Three Months Ended
	March 31, 2015
Ratio of earnings to fixed charges (1)		1.56 x

(1) Fixed charges include interest expensed and capitalized during the year plus an estimate of the interest component of rent expense. There are no shares of preferred stock outstanding. See Exhibit 12.1 filed as part of this Report for the calculation of this ratio.

57

  Off-balance Sheet Arrangements

In the past, we have utilized operating leases as a financing tool for obtaining the operations of specified hospitals without acquiring, through ownership, the related assets of the hospital and without a significant outlay of cash at the front end of the lease. We utilize the same operating strategies to improve operations at those hospitals held under operating leases as we do at those hospitals that we own. We have not entered into any new operating leases for hospital operations since December 2000. At March 31, 2015, we operated two hospitals under operating leases that had an immaterial impact on our consolidated operating results from continuing operations. The terms of the two operating leases we currently have in place expire between December 2020 and June 2022, not including lease extension options. If we allow these leases to expire, we would no longer generate revenues nor incur expenses from these hospitals.

  Noncontrolling Interests

We have sold noncontrolling interests in certain of our subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. In conjunction with the HMA merger, we acquired 29 hospitals containing minority ownership interests ranging from less than 1% to 40%. We do not believe the minority ownership interests acquired in the HMA merger are material to our financial position or results of operations. In addition, effective November 1, 2014, we acquired from Novant Health, Inc., or Novant, its 30% noncontrolling interest in Lake Norman Regional Medical Center for $150 million pursuant to a change in control provision in the operating agreement that was triggered with the HMA merger. As of March 31, 2015, we have hospitals in 35 of the markets we serve, with noncontrolling physician ownership interests ranging from less than 1% to 40%, including one hospital that also has a non-profit entity as a partner. In addition, we have 9 other hospitals with noncontrolling interests owned by non-profit entities. Redeemable noncontrolling interests in equity of consolidated subsidiaries was $520 million and $531 million as of March 31, 2015 and December 31, 2014, respectively, and noncontrolling interests in equity of consolidated subsidiaries was $79 million and $80 million as of March 31, 2015 and December 31, 2014, respectively. The amount of net income attributable to noncontrolling interests was $20 million and $14 million for the three months ended March 31, 2015 and 2014, respectively. As a result of the change in the Stark Law “whole hospital” exception included in the Reform Legislation, we are not permitted to introduce physician ownership at any of our wholly-owned hospital facilities or increase the aggregate percentage of physician ownership in any of our existing hospital joint ventures in excess of the aggregate physician ownership level held at the time of the adoption of the Reform Legislation.

  Reimbursement, Legislative and Regulatory Changes

Ongoing legislative and regulatory efforts could reduce or otherwise adversely affect the payments we receive from Medicare and Medicaid. Within the statutory framework of the Medicare and Medicaid programs, including programs currently unaffected by the Reform Legislation, there are substantial areas subject to administrative rulings, interpretations and discretion which may further affect payments made under those programs, and the federal and state governments might, in the future, reduce the funds available under those programs or require more stringent utilization and quality reviews of hospital facilities. Additionally, there may be a continued rise in managed care programs and additional restructuring of the financing and delivery of healthcare in the United States. These events could cause our future financial results to decline. We cannot estimate the impact of Medicare and Medicaid reimbursement changes that have been enacted or are under consideration. We cannot predict whether additional reimbursement reductions will be made or whether any such changes would have a material adverse effect on our business, financial conditions, results of operations, cash flow, capital resources and liquidity.

  Inflation

The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. In addition, our suppliers pass along rising costs to us in the form of higher prices. We have implemented cost control measures, including our case and resource management program, to curb increases in operating costs and expenses. We have generally offset increases in operating costs by increasing reimbursement for services, expanding services and reducing costs in other areas. However, we cannot predict our ability to cover or offset future cost increases, particularly any increases in our cost of providing health insurance benefits to our employees as a result of the Reform Legislation.

58

  Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We believe that our critical accounting policies are limited to those described below.

  Third-party Reimbursement

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for treatment of patients covered by these programs are generally less than the standard billing rates. Contractual allowances are automatically calculated and recorded through our internally developed “automated contractual allowance system.” Within the automated system, actual Medicare DRG data and payors’ historical paid claims data are utilized to calculate the contractual allowances. This data is automatically updated on a monthly basis. All hospital contractual allowance calculations are subjected to monthly review by management to ensure reasonableness and accuracy. We account for the differences between the estimated program reimbursement rates and the standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at operating revenues (net of contractual allowances and discounts). The process of estimating contractual allowances requires us to estimate the amount expected to be received based on payor contract provisions. The key assumption in this process is the estimated contractual reimbursement percentage, which is based on payor classification and historical paid claims data. Due to the complexities involved in these estimates, actual payments we receive could be different from the amounts we estimate and record. If the actual contractual reimbursement percentage under government programs and managed care contracts differed by 1% at March 31, 2015 from our estimated reimbursement percentage, net income for the three months ended March 31, 2015 would have changed by approximately $80 million, and net accounts receivable at March 31, 2015 would have changed by $128 million. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net income by an insignificant amount in each of the three month periods ended March 31, 2015 and 2014.

  Allowance for Doubtful Accounts

Substantially all of our accounts receivable are related to providing healthcare services to patients at our hospitals and affiliated businesses. Collection of these accounts receivable is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to uninsured patients and outstanding patient balances for which the primary insurance payor has paid some but not all of the outstanding balance, with the remaining outstanding balance (generally deductibles and co-payments) owed by the patient. At the point of service, for patients required to make a co-payment, we generally collect less than 15% of the related revenue. For all procedures scheduled in advance, our policy is to verify insurance coverage prior to the date of the procedure. Insurance coverage is not verified in advance of procedures for walk-in and emergency room patients.

We estimate the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. For all other non-self-pay payor categories, we reserve 100% of all accounts aging over 365 days from the date of discharge. The percentage used to reserve for all self-pay accounts is based on our collection history. We believe that we collect substantially all of our third-party insured receivables, which include receivables from governmental agencies.

59

Collections are impacted by the economic ability of patients to pay and the effectiveness of our collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect our collection of accounts receivable and are considered in our estimates of accounts receivable collectability. If the actual collection percentage differed by 1% at March 31, 2015 from our estimated collection percentage as a result of a change in expected recoveries, net income for the three months ended March 31, 2015 would have changed by $46 million, and net accounts receivable at March 31, 2015 would have changed by $73 million. We also continually review our overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

With limited exceptions for recently acquired hospitals, our policy is to write-off gross accounts receivable if the balance is under $10.00 or when such amounts are placed with outside collection agencies. We believe this policy accurately reflects our ongoing collection efforts and is consistent with industry practices. We had approximately $4.1 billion and $4.0 billion at March 31, 2015 and December 31, 2014, respectively, being pursued by various outside collection agencies. We expect to collect less than 3%, net of estimated collection fees, of the amounts being pursued by outside collection agencies. As these amounts have been written-off, they are not included in our gross accounts receivable or our allowance for doubtful accounts. Collections on amounts previously written-off are recognized as a reduction to bad debt expense when received. However, we take into consideration estimated collections of these future amounts written-off in evaluating the reasonableness of our allowance for doubtful accounts.

All of the following information is derived from our hospitals, excluding clinics, unless otherwise noted.

Patient accounts receivable from our hospitals represent approximately 95% of our total consolidated accounts receivable.

Days revenue outstanding was 66 days at March 31, 2015 and 63 days at December 31, 2014. Our target range for days revenue outstanding is from 53 to 63 days.

Total gross accounts receivable (prior to allowance for contractual adjustments and doubtful accounts) was approximately $19.4 billion as of March 31, 2015 and approximately $18.0 billion as of December 31, 2014.

The approximate percentage of total gross accounts receivable (prior to allowances for contractual adjustments and doubtful accounts) summarized by payor is as follows:

	March 31,		December 31,
	2015		2014
Insured receivables		62.9 %		61.9 %
Self-pay receivables		37.1		38.1
Total		100.0 %		100.0 %

For the hospital segment, the combined total of the allowance for doubtful accounts for self-pay accounts receivable and related allowances for other self-pay discounts and contractuals, as a percentage of gross self-pay receivables, was approximately 87% at both March 31, 2015 and December 31, 2014. If the receivables that have been written-off, but where collections are still being pursued by outside collection agencies, were included in both the allowances and gross self-pay receivables specified above, the percentage of combined allowances to total self-pay receivables would have been approximately 91% at both March 31, 2015 and December 31, 2014.

60

  Goodwill and Other Intangibles

Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. We performed our last annual goodwill evaluation during the fourth quarter of 2014. No impairment was indicated by this evaluation, and based on the excess of fair value over the carrying value, none of our reporting units were at risk of goodwill impairment as of such date. The determination of fair value in step one of our goodwill impairment analysis is based on an estimate of fair value for each reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of our common stock, estimates of future revenue and expense growth, expected capital expenditures, income tax rates, and costs of invested capital. Future estimates of fair value could be adversely affected if the actual outcome of one or more of these assumptions changes materially in the future, including a decline in our stock price, lower than expected hospital volumes, or increased operating costs. The next annual goodwill evaluation will be performed during the fourth quarter of 2015.

  Impairment or Disposal of Long-Lived Assets

Whenever events or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, we project the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the reported amounts are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimate based on valuation techniques available in the circumstances.

  Professional Liability Claims

As part of our business of owning and operating hospitals, we are subject to legal actions alleging liability on our part. We accrue for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. We do not accrue for costs that are part of our corporate overhead, such as the costs of our in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, our historical claim reporting and payment patterns, the nature and level of our hospital operations, and actuarially determined projections. The actuarially determined projections are based on our actual claim data, including historic reporting and payment patterns which have been gathered over approximately a 20-year period. As discussed below, since we purchase excess insurance on a claims-made basis that transfers risk to third-party insurers, the liability we accrue does include an amount for the losses covered by our excess insurance. We also record a receivable for the expected reimbursement of losses covered by our excess insurance. Since we believe that the amount and timing of our future claims payments are reliably determinable, we discount the amount we accrue for losses resulting from professional liability claims using the risk-free interest rate corresponding to the timing of our expected payments.

The net present value of the projected payments was discounted using a weighted-average risk-free rate of 1.7%, 1.6% and 1.2% in 2014, 2013 and 2012, respectively. This liability is adjusted for new claims information in the period such information becomes known to us. Professional malpractice expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as paid excess insurance premiums, and is presented within other operating expenses in the accompanying condensed consolidated statements of income.

Our processes for obtaining and analyzing claims and incident data are standardized across all of our hospitals and have been consistent for many years. We monitor the outcomes of the medical care services that we provide and for each reported claim, we obtain various information concerning the facts and circumstances related to that claim. In addition, we routinely monitor current key statistics and volume indicators in our assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between four and five years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent less than 1.0% of the total liability at the end of any period.

61

For purposes of estimating our individual claim accruals, we utilize specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years, geography, and claims relating to the acquired HMA hospitals versus claims relating to our other hospitals. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses our company-specific historical claims data and other information. This company-specific data includes information regarding our business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data.

Based on these analyses, we determine our estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of management. Changes in reserving data or the trends and factors that influence reserving data may signal fundamental shifts in our future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since our methods and models use different types of data and we select our liability from the results of all of these methods, we typically cannot quantify the precise impact of such factors on our estimates of the liability. Due to our standardized and consistent processes for handling claims and the long history and depth of our company-specific data, our methodologies have produced reliably determinable estimates of ultimate paid losses.

We are primarily self-insured for these claims; however, we obtain excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of our self-insured retentions. Our excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of our professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 are self-insured up to $10 million per claim. Management, on occasion, has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future. Excess insurance for all hospitals has been purchased through commercial insurance companies and generally covers us for liabilities in excess of the self-insured retentions. The excess coverage consists of multiple layers of insurance, the sum of which totals up to $95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008 and up to $195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010. For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the self-insured retention will increase to $10 million per claim for any subsequent claims in that policy year until our total aggregate coverage is met.

Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary which are domiciled in the Cayman Islands and South Carolina, respectively. Those insurance subsidiaries, which are collectively referred to as the “Insurance Subsidiaries,” provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year.

62

Effective January 1, 2008, the former Triad Hospitals, Inc., or Triad, hospitals were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims occurring on or after January 1, 2002 and reported on or after January 1, 2008. Substantially all losses for the former Triad hospitals in periods prior to May 1, 1999 were insured through a wholly-owned insurance subsidiary of HCA Holdings, Inc., or HCA, Triad’s owner prior to that time, and excess loss policies maintained by HCA. HCA has agreed to indemnify the former Triad hospitals in respect of claims covered by such insurance policies arising prior to May 1, 1999. From May 1, 1999 through December 31, 2006, the former Triad hospitals obtained insurance coverage on a claims incurred basis from HCA’s wholly-owned insurance subsidiary with excess coverage obtained from other carriers that is subject to certain deductibles. Effective for claims incurred after December 31, 2006, Triad began insuring its claims from $1 million to $5 million through its wholly-owned captive insurance company, replacing the coverage provided by HCA. Substantially all claims occurring during 2007 were self-insured up to $10 million per claim.

There have been no significant changes in our estimate of the reserve for professional liability claims during the three months ended March 31, 2015.

  Income Taxes

We must make estimates in recording provision for income taxes, including determination of deferred tax assets and deferred tax liabilities and any valuation allowances that might be required against the deferred tax assets. We believe that future income will enable us to realize certain deferred tax assets, subject to the valuation allowance we have established.

The total amount of unrecognized benefit that would impact the effective tax rate, if recognized, was approximately $5 million as of March 31, 2015. A total of approximately $2 million of interest and penalties is included in the amount of liability for uncertain tax positions at March 31, 2015. It is our policy to recognize interest and penalties related to unrecognized benefits in our condensed consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute limitations and settlements with taxing authorities; however, we do not anticipate the change will have a material impact on our consolidated results of operations or consolidated financial position.

We, or one of our subsidiaries, file income tax returns in the United States federal jurisdiction and various state jurisdictions. We have extended the federal statute of limitations through December 31, 2015 for Triad for the tax periods ended December 31, 1, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, we are no longer subject to state income tax examinations for years prior to 2011. Our federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. We believe the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. We have extended the federal statute of limitations through December 31, 2015 for Community Health Systems, Inc. for the tax periods ended December 31, 2007 and 2008, through June 30, 2015 for the tax periods ended December 31, 2009 and 2010, and through September 6, 2015 for the tax period ended December 31, 2011.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that are recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. We adopted this ASU on January 1, 2015 and the adoption did not have a material impact on our consolidated financial position, results of operations and cash flows as of and for the three months ended March 31, 2015.

In May 2014, the FASB issued ASU 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years

63

beginning after December 15, 2016. However, the FASB recently decided to defer the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. We expect to adopt this ASU on January 1, 2018 and are currently evaluating our plan for adoption and the impact on our revenue recognition policies, procedures and control framework and the resulting impact on our consolidated financial position, results of operations and cash flows.

In April 2015, the FASB issued ASU 2015-03, which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with the accounting for debt discounts. The ASU did not change the measurement or recognition guidance for debt issuance costs. This ASU is effective for fiscal years beginning after December 31, 2015, with early adoption permitted. We plan to adopt this ASU on January 1, 2016, and do not anticipate that such adoption will have a material effect on our consolidated financial position, results of operations, or cash flows.

FORWARD-LOOKING STATEMENTS

Some of the matters discussed in this Report include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include the following:

• general economic and business conditions, both nationally and in the regions in which we operate,

• implementation, effect of, and changes to, adopted and potential federal and state healthcare reform legislation and other federal, state or local laws or regulations affecting the healthcare industry,

• the extent to which states support increases, decreases or changes in Medicaid programs, implement healthcare exchanges or alter the provision of healthcare to state residents through regulation or otherwise,

• risks associated with our substantial indebtedness, leverage and debt service obligations,

• demographic changes,

• changes in, or the failure to comply with, governmental regulations,

• potential adverse impact of known and unknown government investigations, audits, and Federal and State False Claims Act litigation and other legal proceedings,

• our ability, where appropriate, to enter into and maintain managed care provider arrangements and the terms of these arrangements,

• changes in, or the failure to comply with, managed care provider contracts, which could result in, among other things, disputes and changes in reimbursements, both prospectively and retroactively,

• changes in inpatient or outpatient Medicare and Medicaid payment levels,

• the effects related to the continued implementation of the sequestration spending reductions and the potential for future deficit reduction legislation,

• increases in the amount and risk of collectability of patient accounts receivable,

• the efforts of insurers, healthcare providers and others to contain healthcare costs,

• our ongoing ability to demonstrate meaningful use of certified electronic health record technology and recognize income for the related Medicare or Medicaid incentive payments,

• increases in wages as a result of inflation or competition for highly technical positions and rising supply costs due to market pressure from pharmaceutical companies and new product releases,

64

• liabilities and other claims asserted against us, including self-insured malpractice claims,

• competition,

• our ability to attract and retain, at reasonable employment costs, qualified personnel, key management, physicians, nurses and other healthcare workers,

• trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals,

• changes in medical or other technology,

• changes in U.S. GAAP,

• the availability and terms of capital to fund additional acquisitions or replacement facilities or other capital expenditures,

• our ability to successfully make acquisitions or complete divestitures,

• our ability to successfully integrate any acquired hospitals, including those of HMA, or to recognize expected synergies from acquisitions,

• the impact of the acquisition of HMA on third-party relationships,

• the impact of seasonal severe weather conditions,

• our ability to obtain adequate levels of general and professional liability insurance,

• timeliness of reimbursement payments received under government programs,

• effects related to outbreaks of infectious diseases, including Ebola,

• the impact of the external, criminal cyber-attack suffered by us in the second quarter of 2014, including potential reputational damage, the outcome of our investigation and any potential governmental inquiries, the outcome of litigation filed against us in connection with this cyber-attack, and the extent of remediation costs and additional operating or other expenses that we may continue to incur, and the impact of potential future cyber-attacks or security breaches, and

• the other risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014 and our other public filings with the SEC.

Although we believe that these forward-looking statements are based upon reasonable assumptions, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are made as of the date of this filing. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

65

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to interest rate changes, primarily as a result of our Credit Facility which bears interest based on floating rates. In order to manage the volatility relating to the market risk, we entered into interest rate swap agreements described under the heading “Liquidity and Capital Resources” in Part II, Item 7. We utilize risk management procedures and controls in executing derivative financial instrument transactions. We do not execute transactions or hold derivative financial instruments for trading purposes. Derivative financial instruments related to interest rate sensitivity of debt obligations are used with the goal of mitigating a portion of the exposure when it is cost effective to do so. As of March 31, 2015, our approximately $1.3 billion notional amount of interest rate swap agreements outstanding represented approximately 16.6% of our variable rate debt.

A 1% change in interest rates on variable rate debt in excess of that amount covered by interest rate swaps would have resulted in interest expense fluctuating approximately $17 million and $11 million for the three months ended March 31, 2015 and 2014, respectively.

Item 4. Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended), as of the end of the period covered by this report. Based on such evaluations, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective (at the reasonable assurance level) to ensure that the information required to be included in this report has been recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to ensure that the information required to be included in this report was accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2015 that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we receive inquiries or subpoenas from state regulators, state Medicaid Fraud Control units, fiscal intermediaries, the Centers for Medicare and Medicaid Services and the Department of Justice regarding various Medicare and Medicaid issues. In addition to the subpoenas discussed below, we are currently responding to subpoenas and administrative demands concerning (a) certain cardiology procedures, medical records and policies at a New Mexico hospital, (b) a civil investigative demand concerning cardiology devices at a Pennsylvania hospital, (c) a request for medical records at an Arizona hospital regarding transfers to a higher level of care, (d) a request for medical records concerning dialysis treatment at a Virginia hospital, and (e) a subpoena for financial arrangements and medical records related to wound care services at one of our Florida hospitals. In addition, we are subject to other claims and lawsuits arising in the ordinary course of our business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond our control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period. Settlements of suits involving Medicare and Medicaid issues routinely require both monetary payments as well as corporate integrity agreements. Additionally, qui tam or “whistleblower” actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act’s requirements for filing such suits. In September 2014, the Criminal Division of the United States Department of Justice, or DOJ, announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The Criminal Division has also frequently stated an intention to pursue corporations in criminal prosecutions. From time to time, we detect issues of non-compliance with Federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians. We avail ourselves of various mechanisms to address potential overpayments arising out of these issues, including repayment of claims, rebilling of claims, and participation in voluntary disclosure protocols offered by the Centers for Medicare and Medicaid Services and the Office of the Inspector General. Participating in voluntary repayments and voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.

66

The following legal proceedings are described in detail because, although they may not be required to be disclosed in this Part I, Item 3 under SEC rules, due to the nature of the business of the Company, we believe that the following discussion of these matters may provide useful information to security holders. This discussion does not include claims and lawsuits covered by medical malpractice, general liability or employment practices insurance and risk retention programs, none of which claims or lawsuits would in any event be required to be disclosed in this Part II, Item 1 under SEC rules. Certain of the matters referenced below are also discussed in the Notes to Condensed Consolidated Financial Statements at Part I, Item 1 under Note 16 “Contingencies.”

Community Health Systems, Inc. Legal Proceedings

Multi-provider National Department of Justice Investigations

Implantable Cardioverter Defibrillators (ICDs). We were first made aware of this investigation in September 2010, when we received a letter from the Civil Division of the DOJ. The letter advised us that an investigation was being conducted to determine whether certain hospitals have improperly submitted claims for payment for ICDs. The period of time covered by the investigation was 2003 to 2010. We continue to fully cooperate with the government in this investigation and have provided requested records and documents. On August 30, 2012, the DOJ issued a document entitled, “Medical Review Guidelines/Resolution Model,” which sets out, for the purposes of this investigation, the patient conditions and criteria for the medical necessity of the implantation of ICDs in Medicare beneficiaries and how the DOJ will enforce the repayment obligations of hospitals. We have reached an agreement in principle to settle this matter.

Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of our common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for our common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. Our motion to dismiss this case has been fully briefed and remains pending before the court. Case management has been set for May 11, 2015. We believe this consolidated matter is without merit and will vigorously defend this case.

Shareholder Derivative Actions. Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. Our motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part our motion to dismiss. On October 14, 2013, we filed for a Motion for Reconsideration of the Order Granting in Part and Denying in Part the Motion to Dismiss, a Motion to Stay Discovery, and an unopposed Motion for Extension of Time to File an Answer. Our motion to stay was denied and our motion for reconsideration was denied on December 12, 2014. An initial case management order was entered on November 11, 2014, but no trial date has been set. We believe all of the plaintiffs’ claims are without merit and will vigorously defend them.

Other Government Investigations

Hattiesburg, Mississippi – Allegiance Health Management, Inc. On February 23, 2012, our hospital in Hattiesburg, Mississippi received a document subpoena from OIG relating to its relationship with Allegiance Health Management, Inc., or Allegiance, a company that provides intensive outpatient psychiatric, or IOP, services to its patients. The subpoena seeks information concerning the hospital’s financial relationship with Allegiance, medical records of patients receiving IOP services, and other documents relating to Allegiance such as agreements, policies and procedures, audits, complaints, budgets, financial analyses and identities of those delivering services. We have reached an agreement in principle to settle this matter.

67

Dothan, Alabama – Independent Lab Billing. On February 12, 2015, our hospital in Dothan, Alabama received a Civil Investigative Demand, or CID, from the United States Department of Justice for information concerning its status as a “covered hospital” under certain lab billing regulations. These regulations discuss permissible billing of the technical component of lab tests performed for hospital patients by an independent laboratory. The CID seeks documentation and explanation whether the hospital qualifies as a covered hospital for billing purposes under the applicable regulations. We are cooperating fully with this investigation.

Qui Tam Cases – Government Declined Intervention

On June 2, 2011, an order was entered unsealing a relator’s qui tam complaint in the matter of U.S. ex rel. Wood M. Deming, MD, individually and on behalf of Regional Cardiology Consultants, PC v. Jackson-Madison County General Hospital, an Affiliate of West Tennessee Healthcare, Regional Hospital of Jackson, a Division of Community Health Systems Professional Services Corporation, James Moss, individually, Timothy Puthoff, individually, Joel Perchik, MD, individually, and Elie H. Korban, MD, individually. The action is pending in the Western District of Tennessee, Jackson Division. Regional Hospital of Jackson is an affiliated hospital and Mr. Puthoff is a former chief executive officer there. The Order recited that the United States had elected to intervene to a limited degree only concerning the claims against Dr. Korban for false and fraudulent billing for allegedly unnecessary stent procedures and for causing the submission of false claims by the hospitals. On July 28, 2011, we were served by the relator. On June 12, 2013, the government and Dr. Korban filed an advisory that they had reached a “handshake” settlement of all claims pled by the government. On December 17, 2013, the government filed a notice of settlement with Dr. Korban. A scheduling order has been entered with a trial date of September 28, 2015. We believe the claims against our hospital are without merit and we are vigorously defending this case.

On February 4, 2014, a redacted case then styled (Sealed Party) v. Pottstown Hospital Co., LLC d/b/a Pottstown Memorial Medical Center and Community Health Systems, Inc. was filed in the Eastern District of Pennsylvania. On May 6, 2014, the district court ordered the seal lifted. The relator is Alan E. Cooper, M.D. The complaint alleges the hospital traded on call agreements for referrals. There is no indication that the DOJ has intervened in this matter. This matter was previously reported in prior filings in the Legal Proceedings section as subpoenas to two Pennsylvania hospitals and one of our subsidiaries concerning on call agreements and physician directorships. On June 5, 2014, we filed motions to dismiss the complaint and on June 30, 2014 the relator filed his response. Oral argument occurred on October 15, 2014 and the matter was taken under advisement and discovery was stayed. Our motions to dismiss were granted with prejudice on March 13, 2015; the relator has filed an appeal. We will continue to vigorously defend this matter.

Commercial Litigation and Other Lawsuits

Becker v. Community Health Systems, Inc. d/b/a Community Health Systems Professional Services Corporation d/b/a Community Health Systems d/b/a Community Health Systems PSC, Inc. d/b/a Rockwood Clinic P.S. and Rockwood Clinic, P.S. (Superior Court, Spokane, Washington). This suit was filed on February 29, 2012, by a former chief financial officer at Rockwood Clinic in Spokane, Washington. Becker claims he was wrongfully terminated for allegedly refusing to certify a budget for Rockwood Clinic in 2012. On February 29, 2012, he also filed an administrative complaint with the Department of Labor, Occupational Safety and Health Administration alleging that he is a whistleblower under Sarbanes-Oxley, which was dismissed by the agency and has now been appealed to an administrative law judge for a hearing on January 19, 2016. At a hearing on July 27, 2012, the court dismissed Community Health Systems, Inc. from this case and subsequently certified the case for an interlocutory appeal of the denial to dismiss his employer and the management company. The appellate court accepted the interlocutory appeal, and it was argued on April 30, 2014. On August 14, 2014, the court denied our appeal. On October 20, 2014, we filed a petition to review the denial with the Washington Supreme Court. Our appeal was accepted and oral argument is set for June 9, 2015. We are vigorously defending this action.

Eliel Ntakirutimana, M.D. and Anesthesia Healthcare Partners of Laredo, P.A., Jose Berlioz, M.D. and Jose Berlioz, M.D., P.A. d/b/a Safari Pediatrics v. Laredo Texas Hospital Company, L.P. d/b/a Laredo Medical Center, CHS/Community Health Systems, Inc., Webb Hospital Corporation, Community Health Systems Professional Services Corporation, Community Health Systems, Inc., Abraham “Abe” Martinez, Argelia “Argie” Martinez, Michael Portacci, Wayne Smith, Timothy P. Adams, and Timothy Schmidt. On December 28, 2012, two physicians and each of their professional associations, who previously contracted as independent contractors with Laredo Medical Center under contracts that could be terminated without cause upon certain written notice, filed a first amended complaint. The first amended complaint alleged claims for breaches of contracts, unjust enrichment, violation of the Texas Theft Liability Act, negligence, breach of fiduciary duty, knowing participation in breach of fiduciary duty, defamation and business disparagement, R.I.C.O., economic duress/coercion, tortious interference with contracts or prospective business relations, conspiracy, respondent superior, actual and apparent authority, ratification, vice-principal liability, and joint enterprise liability. The first amended

68

complaint, in part, alleges facts concerning payments made by Dr. Eliel Ntakirutimana to former Laredo Medical Center CEO, Abe Martinez, who is also a defendant in the suit. On October 23, 2013, an Order staying the case until further notice was entered.

Cyber Attack. As previously disclosed on a Current Report on Form 8-K filed by us on August 18, 2014, our computer network was the target of an external, criminal cyber attack that we believe occurred between April and June, 2014. We and Mandiant (a FireEye Company), the forensic expert engaged by us in connection with this matter, believe the attacker was a foreign “Advanced Persistent Threat” group who used highly sophisticated malware and technology to attack our systems. The attacker was able to bypass our security measures and successfully copy and transfer outside the Company certain non-medical patient identification data (such as patient names, addresses, birthdates, telephone numbers and social security numbers), but not including patient credit card, medical or clinical information. We continue to work closely with federal law enforcement authorities in connection with their investigation and possible prosecution of those determined to be responsible for this attack. Mandiant has conducted a thorough investigation of this incident and continues to advise the Company regarding security and monitoring efforts. We are providing appropriate notification to affected patients and regulatory agencies as required by federal and state law. We are offering identity theft protection services to individuals affected by this attack.

We have incurred certain expenses to remediate and investigate this matter, and expect to continue to incur expenses of this nature in the foreseeable future. In addition, multiple purported class action lawsuits have been filed against the Company and certain subsidiaries. These lawsuits allege that sensitive information was unprotected and inadequately encrypted by the Company. The plaintiffs claim breach of contract and other theories of recovery, and are seeking damages, as well as restitution for any identity theft. On February 4, 2015, the United States Judicial Panel on Multidistrict Litigation ordered the transfer of the purported class actions pending outside of the District Court for the Northern District of Alabama to the District Court for the Northern District of Alabama for coordinated or consolidated pretrial proceedings and the plaintiffs now have until June 15, 2015 to file a consolidated complaint. At this time, we are unable to predict the outcome of this litigation or determine the potential impact, if any, that could result from this litigation, but we intend to vigorously defend these lawsuits. This matter may subject the Company to additional litigation, potential governmental inquiries, potential reputational damage, and additional remediation, operating and other expenses.

Certain Legal Proceedings Related to HMA

Medicare/Medicaid Billing Lawsuits

On January 11, 2010, HMA and one of its subsidiaries were named in a qui tam lawsuit entitled U.S. ex rel. J. Michael Mastej v. Health Management Associates, Inc. et al. in the United States District Court for the Middle District of Florida, Tampa Division. The plaintiff’s complaint alleged that, among other things, the defendants erroneously submitted claims to Medicare and that those claims were falsely certified to be in compliance with Section 1877 of the Social Security Act of 1935 (commonly known as the “Stark law”) and the Anti-Kickback Statute. The plaintiff’s complaint further alleged that the defendants’ conduct violated the False Claims Act. The plaintiff seeks recovery of all Medicare and Medicaid reimbursement that the defendants received as a result of the alleged false certifications and treble damages under the False Claims Act, as well as a civil penalty for each Medicare and Medicaid claim supported by such alleged false certifications. On August 18, 2010, the plaintiff filed a first amended complaint that was similar to the original complaint. On February 23, 2011, the case was transferred to the United States District Court for the Middle District of Florida, Fort Myers Division. On May 5, 2011, the plaintiff filed a second amended complaint, which was similar to the first amended complaint. On May 17, 2011, the defendants moved to dismiss the second amended complaint for failure to state a claim with the particularity required and failure to state a claim upon which relief can be granted. On January 26, 2012, the United States gave notice of its decision not to intervene in this lawsuit. On February 16, 2012, the court granted the defendants’ motion to dismiss, without prejudice. The court’s order permitted the plaintiff to file an amended complaint. On March 8, 2012, the plaintiff filed a third amended complaint, which was similar to the first amended complaint and the second amended complaint. On March 26, 2012, the defendants moved to dismiss the third amended complaint on the same bases set forth in earlier motions to dismiss. On March 19, 2013, the United States District Court for the Middle District of Florida, Tampa Division, dismissed the third amended complaint with prejudice. On March 28, 2013, the United States of America filed a motion to clarify that the dismissal with prejudice did not relate to the United States. On April 4, 2013, the defendants filed an opposition to the United States’ motion for clarification. The Government’s motion remains pending at this time. On April 16, 2013, the plaintiff filed a motion for relief from judgment and for leave to amend the complaint, and a proposed fourth amended complaint. On April 18, 2013, the plaintiff filed a notice of appeal. On May 2, 2013, the defendants filed an opposition to the plaintiff’s motion for relief from judgment and for leave to amend the complaint for the fourth time. On July 10, 2013, the court denied plaintiff’s motion for relief from judgment and for leave to amend the complaint for the fourth time. The case was appealed by Mastej to the Eleventh Circuit Court of Appeals and on October 30, 2014 the appellate court affirmed the dismissal of part of the case and reversed the dismissal of part of the case. The relator has sought further relief from the United States Supreme Court. We intend to vigorously defend HMA and its subsidiary against the allegations in this matter.

69

Beginning during the week of December 16, 2013 eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act. Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was recently settled; U.S. ex rel. Sandra Simmons, v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was recently partially settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions. On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation. On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, and again extended until May 27, 2015. We intend to defend against the allegations in these matters, but will also be cooperating with the government in the ongoing investigation of these allegations. We have been in discussions with the Civil Division of the DOJ regarding the resolution of these matters. We have recently been told that the Criminal Division is continuing to investigate former executive-level employees of HMA, as well as considering whether any HMA entities should be held criminally liable for the acts of the former HMA employees. We are voluntarily cooperating with these inquiries and have not been served with any subpoenas or other legal process.

Several HMA hospitals received letters during 2009 requesting information in connection with an investigation by the Civil Division of the DOJ, relating to kyphoplasty procedures. Kyphoplasty is a minimally invasive spinal procedure used to treat vertebral compression fractures. The DOJ is currently investigating hospitals and hospital operators in multiple states to determine whether certain Medicare claims for kyphoplasty were incorrect when billed as an inpatient service rather than as an outpatient service. The DOJ’s investigation originated with a False Claims Act lawsuit against Kyphon, Inc., the company that developed the kyphoplasty procedure. The requested information has been provided to the DOJ and we are cooperating with the investigation. Prior to the HMA merger, HMA determined that a liability for this claim was probable and an incremental liability was recorded by HMA during the quarter ended December 31, 2013, which was assumed as part of the HMA merger.

During September 2010, HMA received a letter from the DOJ indicating that an investigation was being conducted to determine whether certain HMA hospitals improperly submitted claims for the implantation of ICDs. The DOJ’s investigation covers the period commencing with Medicare’s expansion of coverage for ICDs in 2003 to the present. The letter from the DOJ further indicates that the claims submitted by HMA’s hospitals for ICDs and related services need to be reviewed to determine if Medicare coverage and payment was appropriate. During 2010, the DOJ sent similar letters and other requests to a large number of unrelated hospitals and hospital operators across the country as part of a nation-wide review of ICD billing under the Medicare program. We are cooperating with the DOJ in its ongoing investigation, which could potentially give rise to claims against HMA and/or certain of its subsidiary hospitals under the False Claims Act or other statutes, regulations or laws. Additionally, we are conducting an internal review of hospital medical records related to ICDs that are the subject of the DOJ investigation. We have reached an agreement in principle to settle this matter.

70

Securities and Exchange Commission Investigations

On April 25, 2013, HMA received a subpoena from the SEC, issued pursuant to an investigation, requesting documents related to accounts receivable, billing write-downs, contractual adjustments, reserves for doubtful accounts, and accounts receivable aging, and revenue from Medicare, Medicaid and from privately insured or uninsured patients. On June 5, 2013, HMA received a supplemental subpoena from the SEC which requests additional financial reports. Subsequent subpoenas have been directed to us, our accountants, the former accountants for HMA and certain individuals. On July 17, 2014, we received an additional subpoena from the SEC seeking numerous categories of documents relating to the financial statement adjustments taken in the fourth quarter of 2013 in the areas described above. This investigation is ongoing and we are unable to determine the potential impact, if any, of this investigation.

Class Action and Derivative Action Lawsuits

On April 30, 2012, two class action lawsuits that were brought against HMA and certain of its then executive officers, one of whom was at that time also a director, were consolidated in the United States District Court for the Middle District of Florida under the caption In Re: Health Management Associates, Inc., et al. and three pension fund plaintiffs were appointed as lead plaintiffs. On July 30, 2012, the lead plaintiffs filed an amended consolidated complaint purportedly on behalf of stockholders who purchased HMA’s common stock during the period from July 27, 2009, through January 9, 2012. The amended consolidated complaint (i) alleges that HMA made false and misleading statements in certain public disclosures regarding its business and financial results and (ii) asserts claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. Among other things, the plaintiffs claim that HMA inflated its earnings by engaging in fraudulent Medicare billing practices that entailed admitting patients to observation status when they should not have been admitted at all and to inpatient status when they should have been admitted to observation status. The plaintiffs seek unspecified monetary damages. On October 22, 2012, the defendants moved to dismiss the plaintiffs’ amended consolidated complaint for failure to state a claim or plead facts required by the Private Securities Litigation Reform Act. The plaintiffs filed an unopposed stipulation and proposed order to suspend briefing on the defendants’ motion to dismiss because they intended to seek leave of court to file a proposed second amended consolidated complaint. On December 15, 2012, the court entered an order approving the stipulation and providing a schedule for briefing with respect to the proposed amended pleadings. On February 25, 2013, the plaintiffs filed a second amended consolidated complaint, which asserted substantially the same claims as the amended consolidated complaint. As of August 15, 2013, the defendants’ motion to dismiss the second amended complaint for failure to state a claim and plead facts required by the Private Securities Litigation Reform Act was fully briefed and awaiting the Court’s decision. On May 22, 2014, the court granted the motion to dismiss and on June 20, 2014 the plaintiffs appealed to the Eleventh Circuit, where oral argument was heard on February 6, 2015. We intend to vigorously defend against the allegations in this lawsuit. We are unable to predict the outcome or determine the potential impact, if any, that could result from its final resolution.

Wrongful Termination Lawsuits

William J. Shoen vs. Health Management Associates, Inc. Schoen, former Chairman of the Board of HMA, filed suit against HMA on June 27, 2014 alleging breach of contract for a lump sum termination payment, certain airplane usage rights and underpayment of his SERP. He also seeks declaratory judgment that he and his spouse are entitled to lifetime health insurance benefits. On July 25, 2014, the matter was removed to the United States District Court for the Middle District of Florida. On September 22, 2014, we filed a motion to dismiss this matter, which has not yet been set for argument. We will vigorously defend this matter.

Jeffery D. Hamby, M.D. v. EmCare Physician Providers, Inc., et al. Circuit Court Crawford County, Arkansas. Hamby, who worked in the emergency department at HMA affiliate Summit Medical Center (AK) and was employed by independent contractor EmCare, filed suit alleging wrongful termination by EmCare at the behest of HMA. On January 13, 2014, the court granted HMA’s motion to dismiss which dismissal Hamby has now appealed. We will continue to vigorously defend this matter.

Management of Significant Legal Proceedings

In accordance with our governance documents, including our Governance Guidelines and the charter of the Audit and Compliance Committee, our management of significant legal proceedings is overseen by the independent members of the Board of Directors and, in particular, the Audit and Compliance Committee. The Audit and Compliance Committee is charged with oversight of compliance, regulatory and litigation matters, and enterprise risk management. Management has been instructed to refer all significant legal proceedings and allegations of financial statement fraud, error, or misstatement to the Audit and Compliance Committee for its oversight and evaluation. Consistent with New York Stock Exchange, NASDAQ and Sarbanes-Oxley independence requirements, the Audit and Compliance Committee is comprised entirely of individuals who are independent of Company management, and all three members of the Audit and Compliance Committee are “audit committee financial experts” as defined in the Exchange Act.

In addition, the Audit and Compliance Committee and the other independent members of the Board of Directors oversee the functions of the voluntary compliance program, including its auditing and monitoring functions and confidential disclosure program. In recent years,

71

the voluntary compliance program has addressed the potential for a variety of billing errors that might be the subject of audits and payment denials by the CMS Recovery Audit Contractors’ permanent project, including MS-DRG coding, outpatient hospital and physician coding and billing, and medical necessity for services (including a focus on hospital stays of very short duration). Efforts by management, through the voluntary compliance program, to identify and limit risk from these government audits have included significant policy and guidance revisions, training and education, and auditing. The Board of Directors now oversees and reviews periodic reports of the Company’s compliance with the Corporate Integrity Agreement, or CIA, that the Company entered into with the OIG during 2014. For additional information regarding the CIA, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 25, 2015.

For the past several years, our Board of Directors has met monthly to review the status of the lawsuits and investigations relating to allegations of improper billing for inpatient care at our hospitals and to oversee management in connection with our investigation and defense of these matters. Following the consummation of the HMA merger, these meetings have been expanded to include the review and oversight of the legal proceedings related to HMA that are covered by the CVR. The independent members of our Board of Directors remain fully engaged in the oversight of these matters.

Item 1A. Risk Factors

There have been no material changes with regard to the risk factors previously disclosed in our most recent annual report on Form 10-K.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

The following table contains information about our purchases of common stock during the three months ended March 31, 2015.

Period	Total Number of Shares Purchased (a)			Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(b)		Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs(b)
January 1, 2015 -
January 31, 2015		-	$		-		-		5,000,000
February 1, 2015 -
February 28, 2015		151,933			48.74		-		5,000,000
March 1, 2015 -
March 31, 2015		253,662			49.45		-		5,000,000
Total		405,595	$		49.18		-		5,000,000

(a) Includes 405,595 shares withheld to satisfy the payment of tax obligations related to the vesting of restricted stock awards.

(b) On December 10, 2014, we adopted a new open market repurchase program for up to 5,000,000 shares of our common stock, not to exceed $150 million in repurchases. The new repurchase program will expire at the earliest of three years from the commencement date, when the maximum number of shares has been repurchased, or when the maximum dollar amount has been expended. During the three month ended March 31, 2015, we did not repurchase and retire any shares under this program.

With the exception of a cash dividend of $0.25 per share paid by the Company in December 2012, historically, the Company has not paid any cash dividends. Our Credit Facility limits our ability to pay dividends and/or repurchase stock to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing our senior and senior secured notes also limit our ability to pay dividends and/or repurchase stock. As of March 31, 2015, under the most restrictive test under these agreements, we have approximately $461 million available with which to pay permitted dividends and/or repurchase shares of our stock or our notes.

72

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

73

Item 6. Exhibits

No.		Description
4.1	*	Tenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Notes due 2019, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as successor Trustee
4.2	*	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 7.125% Senior Notes due 2020, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
4.3	*	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2018, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
4.4	*	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
4.5	*	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
10.1	*	Fifth Amendment, dated February 28, 2015, to the Receivables Loan Agreement among CHS Receivables Funding, LLC, the lenders party thereto, the managing agents party thereto, Crédit Agricole Corporate and Investment Bank, as Administrative Agent, and CHSPSC, LLC, as Collection Agent, all dated as of March 21, 2012
10.2		Amendment No. 1 and Incremental Term Loan Assumption Agreement, dated as of March 9, 2015, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the subsidiary guarantors party thereto, the lenders party thereto and Credit Suisse AG, as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed March 10, 2015 (No. 001-15925))
10.3		Fourth Omnibus Amendment, dated March 31, 2015, to the Receivables Sale Agreement among CHS/Community Health Systems, Inc., the originators party thereto and CHSPSC, LLC, as Collection Agent, to the Receivables Purchase and Contribution Agreement among CHS/Community Health Systems, Inc., CHS Receivables Funding, LLC and CHSPSC, LLC, as Collection Agent, and to the Receivables Loan Agreement among CHS Receivables Funding, LLC, the lenders party thereto, the managing agents party thereto, Crédit Agricole Corporate and Investment Bank, as Administrative Agent, and CHSPSC, LLC, as Collection Agent, all dated as of March 21, 2012 (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 1, 2015 (No. 001-15925))
12.1	*	Computation of Ratio of Earnings to Fixed Charges
31.1	*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	*	XBRL Instance Document
101.SCH	*	XBRL Taxonomy Extension Schema
101.CAL	*	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	*	XBRL Taxonomy Extension Definition Linkbase
101.LAB	*	XBRL Taxonomy Extension Label Linkbase
101.PRE	*	XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith

** Furnished herewith

74

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMUNITY HEALTH SYSTEMS, INC. (Registrant)
By:	/s/    Wayne T. Smith
	Wayne T. Smith
	Chairman of the Board and
	Chief Executive Officer
	(principal executive officer)
By:	/s/    W. Larry Cash
	W. Larry Cash
	President of Financial Services, Chief
	Financial Officer and Director
	(principal financial officer)
By:	/s/    Kevin J. Hammons
	Kevin J. Hammons
	Senior Vice President and Chief
	Accounting Officer
	(principal accounting officer)

Date: May 6, 2015

75

Index to Exhibits

No.		Description
4.1	*	Tenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Notes due 2019, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as successor Trustee
4.2	*	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 7.125% Senior Notes due 2020, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
4.3	*	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2018, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
4.4	*	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent
4.5	*	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee
10.1	*	Fifth Amendment, dated February 28, 2015, to the Receivables Loan Agreement among CHS Receivables Funding, LLC, the lenders party thereto, the managing agents party thereto, Crédit Agricole Corporate and Investment Bank, as Administrative Agent, and CHSPSC, LLC, as Collection Agent, all dated as of March 21, 2012
10.2		Amendment No. 1 and Incremental Term Loan Assumption Agreement, dated as of March 9, 2015, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the subsidiary guarantors party thereto, the lenders party thereto and Credit Suisse AG, as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed March 10, 2015 (No. 001-15925))
10.3		Fourth Omnibus Amendment, dated March 31, 2015, to the Receivables Sale Agreement among CHS/Community Health Systems, Inc., the originators party thereto and CHSPSC, LLC, as Collection Agent, to the Receivables Purchase and Contribution Agreement among CHS/Community Health Systems, Inc., CHS Receivables Funding, LLC and CHSPSC, LLC, as Collection Agent, and to the Receivables Loan Agreement among CHS Receivables Funding, LLC, the lenders party thereto, the managing agents party thereto, Crédit Agricole Corporate and Investment Bank, as Administrative Agent, and CHSPSC, LLC, as Collection Agent, all dated as of March 21, 2012 (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 1, 2015 (No. 001-15925))
12.1	*	Computation of Ratio of Earnings to Fixed Charges
31.1	*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	*	XBRL Instance Document
101.SCH	*	XBRL Taxonomy Extension Schema
101.CAL	*	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	*	XBRL Taxonomy Extension Definition Linkbase
101.LAB	*	XBRL Taxonomy Extension Label Linkbase
101.PRE	*	XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith

** Furnished herewith

76

EX-4.1

Exhibit 4.1

TENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 31, 2015, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Issuer”), each of the parties identified as a New Subsidiary Guarantor on the signature pages hereto (each, a “New Subsidiary Guarantor” and collectively, the “New Subsidiary Guarantors”) and REGIONS BANK, as successor Trustee under the Indenture (the “Trustee”).

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an Indenture as amended, supplemented, waived or otherwise modified (the “Indenture”), dated as of November 22, 2011, providing for the issuance of the 8.000% Senior Notes due 2019 (the “Securities”);

WHEREAS, each of the undersigned New Subsidiary Guarantors has deemed it advisable and in its best interest to execute and deliver this Supplemental Indenture, and to become a New Subsidiary Guarantor under the Indenture; and

WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee, the Issuer and the New Subsidiary Guarantors are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the New Subsidiary Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture.

SECTION 2. Guaranties. Each New Subsidiary Guarantor hereby agrees to guarantee the Issuer’s obligations under the Securities on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture as a Subsidiary Guarantor.

SECTION 3. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, shall inure to the benefit of the Trustee and every Holder of Securities heretofore or hereafter authenticated and the Issuer, the Trustee and every Holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

1

SECTION 7. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction of this Supplemental Indenture.

[Signature page follows]

2

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of this 31^st day of March, 2015.

CHS/Community Health Systems, Inc., a Delaware corporation
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Blackwell HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Clinton HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Marshall County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Mayes County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Seminole HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

3

Regions Bank, as Trustee
By:	/s/ Paul Williams
	Paul Williams
	Vice President

4

EX-4.2

Exhibit 4.2

SEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 31, 2015, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Issuer”), each of the parties identified as a New Subsidiary Guarantor on the signature pages hereto (each, a “New Subsidiary Guarantor” and collectively, the “New Subsidiary Guarantors”) and REGIONS BANK, as Trustee under the Indenture (the “Trustee”).

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an Indenture as amended, supplemented, waived or otherwise modified (the “Indenture”), dated as of July 18, 2012, providing for the issuance of the 7.125% Senior Notes due 2020 (the “Securities”);

WHEREAS, each of the undersigned New Subsidiary Guarantors has deemed it advisable and in its best interest to execute and deliver this Supplemental Indenture, and to become a New Subsidiary Guarantor under the Indenture; and

WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee, the Issuer and the New Subsidiary Guarantors are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the New Subsidiary Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture.

SECTION 2. Guaranties. Each New Subsidiary Guarantor hereby agrees to guarantee the Issuer’s obligations under the Securities on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture as a Subsidiary Guarantor.

SECTION 3. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, shall inure to the benefit of the Trustee and every Holder of Securities heretofore or hereafter authenticated and the Issuer, the Trustee and every Holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

SECTION 7. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction of this Supplemental Indenture.

1

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of this 31^st day of March 2015.

CHS/Community Health Systems, Inc., a Delaware corporation
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Blackwell HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Clinton HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Marshall County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Mayes County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Seminole HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

2

Regions Bank, as Trustee
By:	/s/ Paul Williams
	Paul Williams
	Vice President

3

EX-4.3

Exhibit 4.3

SEVENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 31, 2015, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Issuer”), each of the parties identified as a New Subsidiary Guarantor on the signature pages hereto (each, a “New Subsidiary Guarantor” and collectively, the “New Subsidiary Guarantors”), REGIONS BANK, as Trustee under the Indenture (the “Trustee”) and Credit Suisse AG (the “Collateral Agent”).

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered to the Trustee an Indenture as amended, supplemented, waived or otherwise modified (the “Indenture”), dated as of August 17, 2012, providing for the issuance of the 5.125% Senior Secured Notes due 2018 (the “Securities”);

WHEREAS, each of the undersigned New Subsidiary Guarantors has deemed it advisable and in its best interest to execute and deliver this Supplemental Indenture, and to become a New Subsidiary Guarantor under the Indenture; and

WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee, the Collateral Agent, the Issuer and the New Subsidiary Guarantors are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the New Subsidiary Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture.

SECTION 2. Guaranties. Each New Subsidiary Guarantor hereby agrees to guarantee the Issuer’s obligations under the Securities on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture as a Subsidiary Guarantor.

SECTION 3. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, shall inure to the benefit of the Trustee and every Holder of Securities heretofore or hereafter authenticated and the Issuer, the Trustee and every Holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 4. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 5. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture.

SECTION 6. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

SECTION 7. Benefits Acknowledged. Each New Subsidiary Guarantor’s Note Guarantee is subject to the terms and conditions set forth in the Indenture. Each New Subsidiary Guarantor acknowledges that

1

it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Note Guarantee are knowingly made in contemplation of such benefits.

SECTION 8. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction of this Supplemental Indenture.

[Signature page follows]

2

IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of this 31^st day of March, 2015.

CHS/Community Health Systems, Inc., a Delaware corporation
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Blackwell HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Clinton HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Marshall County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Mayes County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Seminole HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

3

Regions Bank, as Trustee
By:	/s/ Paul Williams
	Paul Williams
	Vice President

4

Credit Suisse AG, as Collateral Agent
By:	/s/ Vipul Dhadda
	Name: Vipul Dhadda
	Title:   Authorized Signatory
By:	/s/ Karim Rahimtoola
	Name: Karim Rahimtoola
	Title:   Authorized Signatory

5

EX-4.4

Exhibit 4.4

FOURTH SUPPLEMENTAL INDENTURE, (this “Supplemental Indenture”) dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., a Delaware corporation (“Issuer”), the parties that are signatories hereto as Guarantors (each a “Guaranteeing Subsidiary”), Credit Suisse AG, as Collateral Agent, and Regions Bank, as Trustee under the Indenture referred to below.

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an indenture dated as of January 27, 2014 (as amended, supplemented, waived or otherwise modified, the “Indenture”), providing for the issuance on such date of an aggregate principal amount of $1,000,000,000 of 5.125% Senior Secured Notes due 2021 (the “Notes”) of the Issuer;

WHEREAS, the Indenture provides that the Guaranteeing Subsidiaries shall execute and deliver to the Trustee and the Collateral Agent a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the “Note Guarantee”), each on the terms and conditions set forth herein; and

WHEREAS, pursuant to Section 9.1 of the Indenture, the Issuer, any Guarantor and the Trustee are authorized to execute and deliver this Supplemental Indenture to amend or supplement the Indenture, without the consent of any Holder;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the benefit of the Trustee, the Collateral Agent and the Holders of the Notes as follows:

ARTICLE I

DEFINITIONS

SECTION 1.1. Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recitals hereto are used herein as therein defined. The words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

ARTICLE II

AGREEMENT TO BE BOUND; GUARANTEE

SECTION 2.1. Agreement to be Bound. Each of the Guaranteeing Subsidiaries hereby becomes a party to the Indenture as a “Guarantor” and as such will have all of the rights and be subject to all of the obligations and agreements of a “Guarantor” under the Indenture.

SECTION 2.2. Guarantee. Each of the Guaranteeing Subsidiaries agrees, on a joint and several basis with all the existing Guarantors, to fully, unconditionally and irrevocably Guarantee to each Holder of the Notes, the Trustee and the Collateral Agent the Guaranteed Obligations pursuant to Article X of the Indenture as and to the extent provided for therein.

1

ARTICLE III

MISCELLANEOUS

SECTION 3.1. Notices. All notices and other communications to the Guarantors shall be given as provided in the Indenture.

SECTION 3.2. Merger and Consolidation. Each Guaranteeing Subsidiary shall not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or merge with or into, another Person (other than the Issuer or any Restricted Subsidiary that is a Guarantor or becomes a Guarantor concurrently with the transaction) except in accordance with Section 4.1(e) of the Indenture.

SECTION 3.3. Release of Guarantee. The Note Guarantees hereunder may be released in accordance with Section 10.2 of the Indenture.

SECTION 3.4. Parties. Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained

SECTION 3.5. Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.

SECTION 3.6. Severability. In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.

SECTION 3.7. Benefits Acknowledged. Each Guaranteeing Subsidiary’s Note Guarantee is subject to the terms and conditions set forth in the Indenture. Each Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Note Guarantee are knowingly made in contemplation of such benefits.

SECTION 3.8. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 3.9. The Trustee and the Collateral Agent. Neither the Trustee nor the Collateral Agent make any representation or warranty as to the validity or sufficiency of this Supplemental Indenture or with respect to the recitals contained herein, all of which recitals are made solely by the other parties hereto.

SECTION 3.10. Counterparts. The parties hereto may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental

2

Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

SECTION 3.11. Execution and Delivery. Each Guaranteeing Subsidiary agrees that its Note Guarantee shall remain in full force and effect notwithstanding any absence on each Note of a notation of any such Note Guarantee.

SECTION 3.12. Headings. The headings of the Articles and the Sections in this Supplemental Indenture are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof.

[Signature page follows]

3

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

Blackwell HMA, LLC,
an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Clinton HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Marshall County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Mayes County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Seminole HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

4

Acknowledged by:
CHS/Community Health Systems, Inc.
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

5

Regions Bank,
as Trustee
By:	/s/ Paul Williams
	Paul Williams
	Vice President
Credit Suisse AG, as Collateral Agent
By:	/s/ Vipul Dhadda
	Name: Vipul Dhadda
	Title: Authorized Signatory
By:	/s/ Karim Rahimtoola
	Name: Karim Rahimtoola
	Title: Authorized Signatory

6

EX-4.5

Exhibit 4.5

FOURTH SUPPLEMENTAL INDENTURE, (this “Supplemental Indenture”) dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., a Delaware corporation (“Issuer”), the parties that are signatories hereto as Guarantors (each a “Guaranteeing Subsidiary”) and Regions Bank, as Trustee under the Indenture referred to below.

W I T N E S S E T H:

WHEREAS, each of the Issuer, the Guarantors and the Trustee have heretofore executed and delivered an indenture dated as of January 27, 2014 (as amended, supplemented, waived or otherwise modified, the “Indenture”), providing for the issuance on such date of an aggregate principal amount of $3,000,000,000 of 6.875% Senior Secured Notes due 2022 (the “Notes”) of the Issuer;

WHEREAS, the Indenture provides that the Guaranteeing Subsidiaries shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the “Note Guarantee”), each on the terms and conditions set forth herein; and

WHEREAS, pursuant to Section 9.1 of the Indenture, the Issuer, any Guarantor and the Trustee are authorized to execute and deliver this Supplemental Indenture to amend or supplement the Indenture, without the consent of any Holder;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Issuer, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the benefit of the Trustee and the Holders of the Notes as follows:

ARTICLE I

DEFINITIONS

SECTION 1.1. Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recitals hereto are used herein as therein defined. The words “herein,” “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof.

ARTICLE II

AGREEMENT TO BE BOUND; GUARANTEE

SECTION 2.1. Agreement to be Bound. Each of the Guaranteeing Subsidiaries hereby becomes a party to the Indenture as a “Guarantor” and as such will have all of the rights and be subject to all of the obligations and agreements of a “Guarantor” under the Indenture.

SECTION 2.2. Guarantee. Each of the Guaranteeing Subsidiaries agrees, on a joint and several basis with all the existing Guarantors, to fully, unconditionally and irrevocably Guarantee to each Holder of the Notes and the Trustee the Guaranteed Obligations pursuant to Article X of the Indenture as and to the extent provided for therein.

1

ARTICLE III

MISCELLANEOUS

SECTION 3.1. Notices. All notices and other communications to the Guarantors shall be given as provided in the Indenture.

SECTION 3.2. Merger and Consolidation. Each Guaranteeing Subsidiary shall not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or merge with or into, another Person (other than the Issuer or any Restricted Subsidiary that is a Guarantor or becomes a Guarantor concurrently with the transaction) except in accordance with Section 4.1(e) of the Indenture.

SECTION 3.3. Release of Guarantee. The Note Guarantees hereunder may be released in accordance with Section 10.2 of the Indenture.

SECTION 3.4. Parties. Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained

SECTION 3.5. Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.

SECTION 3.6. Severability. In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.

SECTION 3.7. Benefits Acknowledged. Each Guaranteeing Subsidiary’s Note Guarantee is subject to the terms and conditions set forth in the Indenture. Each Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Note Guarantee are knowingly made in contemplation of such benefits.

SECTION 3.8. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.

SECTION 3.9. The Trustee. The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture or with respect to the recitals contained herein, all of which recitals are made solely by the other parties hereto.

SECTION 3.10. Counterparts. The parties hereto may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or other electronic transmission shall be deemed to be their original signatures for all purposes.

2

SECTION 3.11. Execution and Delivery. Each Guaranteeing Subsidiary agrees that its Note Guarantee shall remain in full force and effect notwithstanding any absence on each Note of a notation of any such Note Guarantee.

SECTION 3.12. Headings. The headings of the Articles and the Sections in this Supplemental Indenture are for convenience of reference only and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof.

[Signature page follows]

3

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

Blackwell HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Clinton HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Marshall County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Mayes County HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer
Seminole HMA, LLC, an Oklahoma limited liability company
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

4

Acknowledged by:

CHS/Community Health Systems, Inc.
By:	/s/ James W. Doucette
	James W. Doucette
	Senior Vice President and Treasurer

5

Regions Bank, as Trustee
By:	/s/ Paul Williams
	Paul Williams
	Vice President

6

EX-10.1

Exhibit 10.1

FIFTH AMENDMENT TO RECEIVABLES LOAN AGREEMENT

This FIFTH AMENDMENT TO RECEIVABLES LOAN AGREEMENT is made as of February 28, 2015 (this “Amendment”), among CHS RECEIVABLES FUNDING, LLC, a Delaware limited liability company (“Receivables Funding”), as Borrower, THE BANK OF NOVA SCOTIA (“Scotia”), as a Committed Lender and as a Managing Agent, CRÉDIT AGRICOLE CORPORATE AND INVESTMENT BANK (“CA-CIB”), as a Committed Lender, as a Managing Agent and as Administrative Agent, THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. (“BTMU”), as a Committed Lender and as a Managing Agent, ATLANTIC ASSET SECURITIZATION LLC (“Atlantic”), as a Conduit Lender, LIBERTY STREET FUNDING LLC (“Liberty Street”), as a Conduit Lender, VICTORY RECEIVABLES CORPORATION (“Victory”), as a Conduit Lender, and CHSPSC, LLC (as successor-by-conversion to Community Health Systems Professional Services Corporation) (“Professional Services”), a Delaware limited liability company, as Collection Agent under the Receivables Loan Agreement, and is acknowledged and agreed by Receivables Funding, as the Company, Professional Services, as Collection Agent under each of the Contribution Agreement and the Sale Agreement, and as Authorized Representative (as defined in the Sale Agreement, the “Authorized Representative”), CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (“CHS”), as Transferor, as Buyer and individually (as the provider of a performance undertaking), and EACH OF THE OTHER PERSONS IDENTIFIED AS ORIGINATORS ON THE SIGNATURE PAGES HERETO AFFILIATED WITH CHS/COMMUNITY HEALTH SYSTEMS, INC., as Originators. All capitalized terms used herein without reference shall have the meanings assigned to such terms in the Receivables Loan Agreement (as defined below) after giving effect to this Amendment.

WHEREAS, Receivables Funding, as Borrower, Scotia, as a Committed Lender and as a Managing Agent, CA-CIB, as a Committed Lender, as a Managing Agent and as Administrative Agent, BTMU, as a Committed Lender and as a Managing Agent, the other Lenders party thereto and Professional Services, as Collection Agent, have entered into the Receivables Loan Agreement, dated as of March 21, 2012 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Receivables Loan Agreement”);

WHEREAS, CHS, as Transferor, Receivables Funding, as the Company, and Professional Services, as Collection Agent thereunder, have entered into the Receivables Purchase and Contribution Agreement, dated as of March 21, 2012 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Contribution Agreement”);

WHEREAS, the Originators, Professional Services, as Collection Agent and Authorized Representative thereunder, and CHS, as Buyer, have entered into the Receivables Sale Agreement, dated as of March 21, 2012 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Sale Agreement”);

WHEREAS, the parties hereto desire to amend certain provisions of the Receivables Loan Agreement pursuant to Section 10.01 of the Receivables Loan Agreement and take the other actions set forth herein, and have agreed to do so subject to the terms and conditions of this Amendment.

NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

SECTION 1. Amendment to Receivables Loan Agreement. Subject to all of the terms and conditions set forth in this Amendment, effective as of the last day of the Collection Period ended February 28, 2015, the definition of “Trigger Temporary Relief Period” in Section 1.01 of the Receivables Loan Agreement is hereby amended and restated in its entirety to read as follows:

“Trigger Temporary Relief Period” means the period comprised of the seven consecutive Collection Periods from August 2014 through and including February 2015.

SECTION 2. Conditions to Effectiveness. This Amendment shall become effective upon the date on which the following conditions have been satisfied (in form and substance reasonably acceptable to the Administrative Agent):

(a) The Administrative Agent shall have received counterparts of this Amendment duly executed by each of the Borrower, the Collection Agent, the Managing Agents, the Committed Lenders, the Conduit Lenders and the Administrative Agent and counterparts evidencing acknowledgment and agreement duly executed by each of the Company, the Collection Agent (as Collection Agent under each of the Contribution Agreement and the Sale Agreement), the Authorized Representative, the Transferor, the Buyer, CHS individually and the Originators.

(b) All fees and expenses required to be paid prior to an Advance under the Receivables Loan Agreement (as amended by this Amendment) pursuant to (i) the Receivables Loan Agreement (as amended by this Amendment) and (ii) the Fee Letter shall have been paid.

(c) Each Managing Agent and the Administrative Agent shall have completed satisfactory due diligence and obtained the requisite credit approvals.

SECTION 3. Representations and Warranties.

(a) Each of the Borrower and the Collection Agent represents and warrants as of the date hereof that (i) it has taken all necessary action to authorize the execution, delivery and performance of this Amendment and the performance of the Receivables Loan Agreement and the other Facility Documents, each as amended hereby, as applicable, and (ii) no consent, approval, authorization or order of, or filing, registration or qualification with, any court or governmental authority or third party is required in connection with the execution, delivery or performance by such Person of this Amendment other than such as has been met or obtained and are in full force and effect.

(b) Each of the Borrower and the Collection Agent represents and warrants as of the date hereof that each of this Amendment and each Facility Document (as amended by this Amendment or otherwise as of the date hereof, as applicable) constitutes such Person’s legal, valid and binding obligation, enforceable against such person in accordance with its terms,

2

except as such enforceability may be subject to (A) bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting creditors’ rights generally and (B) general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity).

(c) The Borrower hereby makes each of the representations and warranties contained in Sections 4.01 and 4.03 of the Receivables Loan Agreement as of the date hereof, in each case after giving effect to this Amendment, except for those representations and warranties that refer to specific dates, which are made as of the dates indicated therein.

(d) The Collection Agent hereby makes each of the representations and warranties contained in Section 4.02 of the Receivables Loan Agreement as of the date hereof, in each case after giving effect to this Amendment, except for those representations and warranties that refer to specific dates, which are made as of the dates indicated therein.

(e) Each of the Borrower and the Collection Agent further represents and warrants that, both before and after giving effect to this Amendment, no event has occurred and is continuing which constitutes an Event of Default, or would, with the passage of time or the giving of notice, constitute an Event of Default.

SECTION 4. Facility Document. This Amendment shall constitute a Facility Document under the terms of the Receivables Loan Agreement as amended hereby.

SECTION 5. Further Assurances. The Borrower and the Collection Agent agree to promptly take such action, upon the reasonable request of the Administrative Agent, as is necessary to carry out the intent of this Amendment.

SECTION 6. Confirmation of Agreement. On and after the date hereof, all references to the Receivables Loan Agreement in the Facility Documents and the other documents and instruments delivered pursuant to or in connection with such Facility Documents shall mean the Receivables Loan Agreement as amended by this Amendment, and as hereafter modified, amended or restated in accordance with its terms. Except as herein expressly amended, the Receivables Loan Agreement is ratified and confirmed in all respects and shall remain in full force and effect in accordance with its terms.

SECTION 7. Confirmation of Undertaking. CHS, as undertaking party under the Collection Agent Performance Undertaking, dated as of March 21, 2012 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Performance Undertaking”), in favor of CA-CIB as administrative agent on behalf of the Lenders, hereby consents to the amendment to the Receivables Loan Agreement set forth in Section 1 of this Amendment, and hereby confirms and agrees that, notwithstanding the effectiveness of this Amendment, the Performance Undertaking heretofore executed and delivered by it is, and shall continue to be, in full force and effect in accordance with its terms and shall apply to the Receivables Loan Agreement (as amended by this Amendment), the Contribution Agreement and the Sale Agreement and the Performance Undertaking is hereby so ratified and confirmed.

SECTION 8. GOVERNING LAW. THIS AMENDMENT SHALL, IN ACCORDANCE WITH SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF

3

THE STATE OF NEW YORK, BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. EACH OF THE PARTIES HERETO HEREBY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS OF THE UNITED STATES AND THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN NEW YORK COUNTY, NEW YORK IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AMENDMENT, ANY OTHER FACILITY DOCUMENT, ANY OTHER DOCUMENT DELIVERED PURSUANT HERETO OR THERETO, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH OF THE PARTIES HERETO HEREBY WAIVES ANY OBJECTION BASED ON FORUM NON CONVENIENS THE MAINTENANCE OF ANY SUCH ACTION OR PROCEEDING AND CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT.

SECTION 9. Execution in Counterparts. This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by facsimile or by electronic mail in portable document format (pdf) shall be effective as delivery of a manually executed counterpart of this Amendment.

SECTION 10. Severability of Provisions. Any provision of this Amendment which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.

SECTION 11. Headings. Section headings used herein are for convenience of reference only, are not part of this Amendment and shall not affect the construction of, or be taken into consideration in interpreting, this Amendment.

[Signature Pages Follow]

4

IN WITNESS WHEREOF, this Amendment has been duly executed as of the date first written above.

CHS RECEIVABLES FUNDING, LLC,
as Borrower
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Sr. VP Finance & Treasurer
CHS Receivables Funding, LLC
4000 Meridian Boulevard
Franklin, Tennessee 37067
Attention: Rachel A. Seifert
Telephone No: (615) 465-7000
Facsimile No: (615) 373-9704
Email: rachel_seifert@chs.net
CHSPSC, LLC, as Collection Agent under the Receivables Loan Agreement
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Sr. VP Finance & Treasurer
CHSPSC, LLC
4000 Meridian Boulevard
Franklin, Tennessee 37067
Attention: Rachel A. Seifert
Telephone No: (615) 465-7000
Facsimile No: (615) 373-9704
Email: rachel_seifert@chs.net

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

CRÉDIT AGRICOLE CORPORATE AND INVESTMENT BANK, as Administrative Agent, as a Managing Agent and as a Committed Lender
By:	/s/ Sam Pilcer
	Name:	Sam Pilcer
	Title:	Managing Director
By:	/s/ Kostantina Kourmpetis
	Name:	Kostantina Kourmpetis
	Title:	Managing Director
Crédit Agricole CIB
1301 Avenue of the Americas
New York, NY 10019
Attention: Sunny Gulrajani
Telephone No: (212) 261-7845
Facsimile No: (917) 849-5584
Email: sunny.gulrajani@ca-cib.com
ATLANTIC ASSET SECURITIZATION LLC,
as a Conduit Lender
By:	CRÉDIT AGRICOLE CORPORATE AND
	INVESTMENT BANK, as attorney-in-fact
By:	/s/ Sam Pilcer
	Name:	Sam Pilcer
	Title:	Managing Director
By:	/s/ Kostantina Kourmpetis
	Name:	Kostantina Kourmpetis
	Title:	Managing Director
Atlantic Asset Securitization
c/o Crédit Agricole CIB
1301 Avenue of the Americas
New York, NY 10019
Attention: Sunny Gulrajani
Telephone No: (212) 261-7845
Facsimile No: (917) 849-5584
Email: sunny.gulrajani@ca-cib.com

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

THE BANK OF NOVA SCOTIA, as a Managing
Agent and as a Committed Lender
By:	/s/ John Frazell
	Name:	John Frazell
	Title:	Director
LIBERTY STREET FUNDING LLC,
as a Conduit Lender
By:	/s/ Jill A. Russo
	Name:	Jill A. Russo
	Title:	Vice President

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., as a Managing Agent
By:	/s/ Van Dusenbury
	Name: Van Dusenbury
	Title:   Managing Director
THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., as a Committed Lender
By:	/s/ Brian McNany
	Name: Brian McNany
	Title:   Director
VICTORY RECEIVABLES CORPORATION, as a Conduit Lender
By:	/s/ David V. DeAngelis
	Name: David V. DeAngelis
	Title:   Vice President

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ACKNOWLEDGED AND AGREED:

CHS RECEIVABLES FUNDING, LLC, as Company
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Sr. VP Finance & Treasurer
CHS Receivables Funding, LLC
4000 Meridian Boulevard
Franklin, Tennessee 37067
Attention: Rachel A. Seifert
Telephone No: (615) 465-7000
Facsimile No: (615) 373-9704
Email: rachel_seifert@chs.net
CHSPSC, LLC, as Collection Agent under each of the Contribution Agreement and the Sale Agreement and as Authorized Representative
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Sr. VP Finance & Treasurer
CHSPSC, LLC
4000 Meridian Boulevard
Franklin, Tennessee 37067
Attention: Rachel A. Seifert
Telephone No: (615) 465-7000
Facsimile No: (615) 373-9704
Email: rachel_seifert@chs.net

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ACKNOWLEDGED AND AGREED:

CHS/COMMUNITY HEALTH SYSTEMS, INC., as Transferor, as Buyer and individually
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Sr. VP Finance & Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ACKNOWLEDGED AND AGREED:

ORIGINATORS:
AFFINITY HOSPITAL, LLC
BERWICK HOSPITAL COMPANY, LLC
BLUEFIELD HOSPITAL COMPANY, LLC
BLUFFTON HEALTH SYSTEM LLC
BULLHEAD CITY HOSPITAL CORPORATION
CARLSBAD MEDICAL CENTER, LLC
CLEVELAND TENNESSEE HOSPITAL COMPANY, LLC
COATESVILLE HOSPITAL CORPORATION
CRESTVIEW HOSPITAL CORPORATION
DEACONESS HEALTH SYSTEM, LLC
DHSC, LLC
DUKES HEALTH SYSTEM, LLC
DYERSBURG HOSPITAL CORPORATION
EMPORIA HOSPITAL CORPORATION
FOLEY HOSPITAL CORPORATION
FRANKLIN HOSPITAL CORPORATION
GADSDEN REGIONAL MEDICAL CENTER, LLC
GALESBURG HOSPITAL CORPORATION
GRANBURY HOSPITAL CORPORATION
GRANITE CITY ILLINOIS HOSPITAL COMPANY, LLC
GREENBRIER VMC, LLC
HOSPITAL OF MORRISTOWN, INC.
JACKSON, TENNESSEE HOSPITAL COMPANY, LLC
JOURDANTON HOSPITAL CORPORATION
KAY COUNTY OKLAHOMA HOSPITAL COMPANY, LLC
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

LAKE WALES HOSPITAL CORPORATION
LANCASTER HOSPITAL CORPORATION
LAS CRUCES MEDICAL CENTER, LLC
LEA REGIONAL HOSPITAL, LLC
MARTIN HOSPITAL CORPORATION
MARY BLACK HEALTH SYSTEM LLC
MCKENZIE-WILLAMETTE REGIONAL MEDICAL CENTER ASSOCIATES, LLC
MCNAIRY HOSPITAL CORPORATION
MCSA, L.L.C.
MOBERLY HOSPITAL COMPANY, LLC
NATIONAL HEALTHCARE OF LEESVILLE, INC.
NATIONAL HEALTHCARE OF MT. VERNON, INC.
NORTHAMPTON HOSPITAL COMPANY, LLC
NORTHWEST HOSPITAL, LLC
ORO VALLEY HOSPITAL, LLC
PAYSON HOSPITAL CORPORATION
PETERSBURG HOSPITAL COMPANY, LLC
PHOENIXVILLE HOSPITAL COMPANY, LLC
POTTSTOWN HOSPITAL COMPANY, LLC
PORTER HOSPITAL, LLC
QHG OF ENTERPRISE, INC.
QHG OF SOUTH CAROLINA, INC.
ROSWELL HOSPITAL CORPORATION
RUSTON LOUISIANA HOSPITAL COMPANY, LLC
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

SAN MIGUEL HOSPITAL CORPORATION
SCRANTON HOSPITAL COMPANY, LLC
SHELBYVILLE HOSPITAL CORPORATION
SILOAM SPRINGS ARKANSAS HOSPITAL COMPANY, LLC
SPOKANE VALLEY WASHINGTON HOSPITAL COMPANY, LLC
SPOKANE WASHINGTON HOSPITAL COMPANY, LLC
ST. JOSEPH HEALTH SYSTEM LLC
TOMBALL TEXAS HOSPITAL COMPANY, LLC
TOOELE HOSPITAL CORPORATION
WARREN OHIO HOSPITAL COMPANY, LLC
WARREN OHIO REHAB HOSPITAL COMPANY, LLC
WARSAW HEALTH SYSTEM LLC
WAUKEGAN ILLINOIS HOSPITAL COMPANY, LLC
WEATHERFORD TEXAS HOSPITAL COMPANY, LLC
WESLEY HEALTH SYSTEM, LLC
WEST GROVE HOSPITAL COMPANY, LLC
WILKES-BARRE HOSPITAL COMPANY, LLC
WOMEN & CHILDREN’S HOSPITAL, LLC
YOUNGSTOWN OHIO HOSPITAL COMPANY, LLC
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

ANNA HOSPITAL CORPORATION
AUGUSTA HOSPITAL, LLC
BIG BEND HOSPITAL CORPORATION
BIG SPRING HOSPITAL CORPORATION
BLUE RIDGE GEORGIA HOSPITAL COMPANY, LLC
CENTRE HOSPITAL CORPORATION
CLINTON HOSPITAL CORPORATION
DEMING HOSPITAL CORPORATION
EVANSTON HOSPITAL CORPORATION
FORREST CITY ARKANSAS HOSPITAL COMPANY, LLC
FORT PAYNE HOSPITAL CORPORATION
GREENVILLE HOSPITAL CORPORATION
HOSPITAL OF BARSTOW, INC.
HOSPITAL OF FULTON, INC.
HOSPITAL OF LOUISA, INC.
KIRKSVILLE MISSOURI HOSPITAL COMPANY, LLC
LEXINGTON HOSPITAL CORPORATION
LUTHERAN MUSCULOSKELETAL CENTER, LLC
MARION HOSPITAL CORPORATION
MCKENZIE TENNESSEE HOSPITAL COMPANY, LLC
MMC OF NEVADA, LLC
OAK HILL HOSPITAL CORPORATION
PHILLIPS HOSPITAL CORPORATION
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

RED BUD ILLINOIS HOSPITAL COMPANY, LLC
SALEM HOSPITAL CORPORATION
SCRANTON QUINCY HOSPITAL COMPANY, LLC
SUNBURY HOSPITAL COMPANY, LLC
WATSONVILLE HOSPITAL CORPORATION
WILLIAMSTON HOSPITAL CORPORATION
WOODWARD HEALTH SYSTEM, LLC
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

BROWNWOOD HOSPITAL, L.P.
By:	Brownwood Medical Center, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
COLLEGE STATION HOSPITAL, L.P.
By:	College Station Medical Center, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
IOM HEALTH SYSTEM, L.P.
By:	Lutheran Health Network Investors, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

LAREDO TEXAS HOSPITAL COMPANY, L.P.
By:	Webb Hospital Corporation
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
LONGVIEW MEDICAL CENTER, L.P.
By:	Regional Hospital of Longview, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
NAVARRO HOSPITAL, L.P.
By:	Navarro Regional, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

PINEY WOODS HEALTHCARE SYSTEM, L.P.
By:	Woodland Heights Medical Center, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
REHAB HOSPITAL OF FORT WAYNE GENERAL PARTNERSHIP
By:	Lutheran Health Network Investors, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
SAN ANGELO HOSPITAL, L.P.
By:	San Angelo Community Medical Center, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
VICTORIA OF TEXAS, L.P.
By:	Detar Hospital, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

ORIGINATORS (CONT.):

ARMC, L.P.
By:	Triad-ARMC, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer
CRESTWOOD HEALTHCARE, L.P.
By:	Crestwood Hospital, LLC
Its:	General Partner
By:	/s/ James W. Doucette
	Name: James W. Doucette
	Title:   Senior Vice President and Treasurer

62622207 Signature Page to Fifth Amendment to Receivables Loan Agreement

EX-12.1

Exhibit 12.1

STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(DOLLARS IN MILLIONS)

	Three Months Ended
	March 31, 2015
Earnings
Income from continuing operations before provision for income taxes	$	168
Income from equity investees		(18)
Distributed income from equity investees		3
Interest and amortization of deferred finance costs		241
Amortization of capitalized interest		5
Implicit rental interest expense		29
Total Earnings	$	428
Fixed Charges
Interest and amortization of deferred finance costs	$	241
Capitalized interest		4
Implicit rental interest expense		29
Total Fixed Charges	$	274
Ratio of Earnings to Fixed Charges		1.56	x

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Wayne T. Smith, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Community Health Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/  Wayne T. Smith

Wayne T. Smith

Chairman of the Board

and Chief Executive Officer

Date: May 6, 2015

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, W. Larry Cash, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Community Health Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/  W. Larry Cash

W. Larry Cash

President of Financial Services,

Chief Financial Officer and Director

Date: May 6, 2015

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Community Health Systems, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wayne T. Smith, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/  Wayne T. Smith

Wayne T. Smith

Chairman of the Board and

Chief Executive Officer

May 6, 2015

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Community Health Systems, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, W. Larry Cash, President of Financial Services and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/  W. Larry Cash

W. Larry Cash

President of Financial Services, Chief Financial

Officer and Director

May 6, 2015

XML

Equity Investments (Tables)

3 Months Ended

Mar. 31, 2015

Equity Investments [Abstract]

Schedule of Financial Information Related to Unconsolidated Entities Included in Consolidated Statement of Income

	Three Months Ended
	March 31,
	2015		2014
Revenues	$	375	$	332
Operating costs and expenses		315		294
Income from continuing operations before taxes		60		39

XML

Cost of Revenue (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cost of Revenue [Abstract]
Corporate Office Costs	$ 77	$ 77
Share-based Compensation	$ 14	$ 11

XML

Basis of Presentation and Significant Accounting Policies (Schedule of Operating Revenue, Net of Contractual Allowances and Discounts (But Before the Provision for Bad Debts)) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	$ 5,646	$ 4,875
Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	1,398	1,261
Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	586	459
Managed Care And Other Third Party Payors [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	2,946	2,450
Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Operating revenues (net of contractual allowances and discounts)	$ 716	$ 705

XML

Long-Term Debt (Schedule of Debt) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Debt	$ 16,969	$ 16,916
Current maturities of long-term debt	(229)	(235)
Long-term debt	16,740	16,681
Secured Debt [Member] | Credit Facility, Term Loan A [Member]
Debt Instrument [Line Items]
Debt	925	950
Secured Debt [Member] | Credit Facility, Term Loan D [Member]
Debt Instrument [Line Items]
Debt	4,544	4,555
Secured Debt [Member] | Credit Facility, Term Loan E [Member]
Debt Instrument [Line Items]
Debt		1,660
Secured Debt [Member] | Credit Facility, Term Loan F [Member]
Debt Instrument [Line Items]
Debt	1,700
Line of Credit [Member] | Credit Facility, Revolving Credit Loans [Member]
Debt Instrument [Line Items]
Debt	62
Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member]
Debt Instrument [Line Items]
Debt	2,017	2,018
Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt	1,200	1,200
Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member]
Debt Instrument [Line Items]
Debt	3,000	3,000
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Debt	1,600	1,600
Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member]
Debt Instrument [Line Items]
Debt	1,000	1,000
Receivables Facility [Member] | Receivables Facility, Name [Member]
Debt Instrument [Line Items]
Debt	623	614
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Debt	215	228
Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt	$ 83	$ 91

XML

Acquisitions and Divestitures (Acquisitions Narrative) (Details) (USD $)	3 Months Ended		0 Months Ended			1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Nov. 03, 2014	Oct. 01, 2014	Apr. 01, 2014	Jan. 27, 2014 item state	Dec. 31, 2014
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs	$ 3,000,000	$ 57,000,000
Business Acquisition, Purchase Price Allocation, Goodwill	8,954,000,000						8,951,000,000
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share	$ 1.00
Senior Secured Notes at 5.125, Due 2021 [Member] | Senior Secured Notes [Member]
Business Acquisition [Line Items]
Debt Instrument, Face Amount						1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage						5.125%
Senior Notes at 6.875, Due 2022 [Member] | Senior Notes [Member]
Business Acquisition [Line Items]
Debt Instrument, Face Amount						3,000,000,000
Debt Instrument, Interest Rate, Stated Percentage						6.875%
Lake Norman [Member]
Business Acquisition [Line Items]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent			150,000,000
Business Acquisition, Percentage of Voting Interests Acquired			30.00%
Upstate Carolina Medical Center [Member]
Business Acquisition [Line Items]
Business Acquisition, Number of Licensed Hospital or Facility Beds			125
Business Acquisition, Cost of Acquired Entity, Purchase Price			4,000,000
Business Acquisition, Purchase Price Allocation, Goodwill	0
Novant [Member]
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition	Nov. 03, 2014
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			5,000,000
Natchez Regional Medical Center [Member]
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition	Oct. 01, 2014
Business Acquisition, Number of Licensed Hospital or Facility Beds				179
Business Acquisition, Cost of Acquired Entity, Purchase Price				10,000,000
Prepayment of future property taxes				8,000,000
Period of prepayment for future property taxes will be applied to the tax liability				17 years
Business Acquisition, Purchase Price Allocation, Goodwill	0
Sharon Regional Health System [Member]
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition	Apr. 01, 2014
Business Acquisition, Number of Licensed Hospital or Facility Beds					258
Business Acquisition, Cost of Acquired Entity, Cash Paid for Fixed Assets					67,000,000
Business Acquisition, Cost of Acquired Entity, Cash Paid for Working Capital					1,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					9,000,000
Business Acquisition, Cost of Acquired Entity, Purchase Price					77,000,000
Business Acquisition, Purchase Price Allocation, Goodwill	8,000,000
Munroe Regional Medical Center [Member]
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition	Apr. 01, 2014
Business Acquisition, Number of Licensed Hospital or Facility Beds					421
Business Acquisition, Cost of Acquired Entity, Cash Paid for Fixed Assets					192,000,000
Business Acquisition, Cost of Acquired Entity, Cash Paid for Working Capital					4,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					11,000,000
Business Acquisition, Cost of Acquired Entity, Purchase Price					207,000,000
Business Acquisition, Purchase Price Allocation, Goodwill	11,000,000
Business Acquisition, Percentage of Voting Interests Acquired					95.00%
Business Combination, Assumed Noncontrolling Interest, Fair Value					10,000,000
Munroe Regional Medical Center [Member] | Affiliate of Regional Not-for-Profit Healthcare System [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					5.00%
Health Management Associates, Inc. [Member]
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition	Jan. 27, 2014
Business Acquisition, Purchase Price Allocation, Goodwill							4,500,000,000
Business Combination Consideration Transferred And Existing Indebtedness Assumed						7,300,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt						3,800,000,000
Payments to Acquire Businesses, Gross, Per Share						$ 10.50
Business Combination Consideration Transferred Equity Interests Issued, Per Share						0.06942
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Number Per Share						1
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share						$ 1.00
Business Acquisition, Number of Hospitals Acquired						71
Number of States in which Entity Operates						15
Physician Practices Clinics and Other Ancillary Businesses [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	12,000,000
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment	8,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 4,000,000

XML

Long-Term Debt (Schedule of Early Redemption Prices on 6.785% Senior Notes) (Details) (Senior Notes at 6.875, Due 2022 [Member], Senior Notes [Member])	3 Months Ended
	Mar. 31, 2015
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.438%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2018
Debt Instrument, Redemption Period, End Date	Jan. 31, 2019
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2019
Debt Instrument, Redemption Period, End Date	Jan. 31, 2020
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2020
Debt Instrument, Redemption Period, End Date	Jan. 31, 2022

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Income (Loss)) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	$ 5,646	$ 4,875
Provision for bad debts	735	699
Net operating revenues	4,911	4,176
Operating costs and expenses:
Salaries and benefits	2,257	1,992
Supplies	762	632
Other operating expenses	1,099	1,019
Government settlement and related costs	8
Electronic health records incentive reimbursement	(26)	(40)
Rent	116	98
Depreciation and amortization	296	255
Amortization of software to be abandoned		42
Total operating costs and expenses	4,512	3,998
Income from operations	399	178
Interest expense, net	241	224
Loss from early extinguishment of debt	8	73
Equity in earnings of unconsolidated affiliates	(18)	(11)
Impairment of long-lived assets		24
Income (loss) from continuing operations before income taxes	168	(132)
Provision for (benefit from) income taxes	56	(56)
Income (loss) from continuing operations	112	(76)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale	(11)	(4)
Impairment of hospitals sold or held for sale	(1)	(18)
Loss on sale, net	(1)
Loss from discontinued operations, net of taxes	(13)	(22)
Net income (loss)	99	(98)
Less: Net income attributable to noncontrolling interests	20	14
Net income (loss) attributable to Community Health Systems, Inc. stockholders	79	(112)
Parent Company [Member]
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates	(79)	112
Income (loss) from continuing operations before income taxes	79	(112)
Income (loss) from continuing operations	79	(112)
Discontinued operations, net of taxes:
Net income (loss)	79	(112)
Net income (loss) attributable to Community Health Systems, Inc. stockholders	79	(112)
Subsidiary Issuer [Member]
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	(5)	(4)
Net operating revenues	(5)	(4)
Operating costs and expenses:
Income from operations	(5)	(4)
Interest expense, net	21	40
Loss from early extinguishment of debt	8	73
Equity in earnings of unconsolidated affiliates	(104)	27
Income (loss) from continuing operations before income taxes	70	(144)
Provision for (benefit from) income taxes	(9)	(32)
Income (loss) from continuing operations	79	(112)
Discontinued operations, net of taxes:
Net income (loss)	79	(112)
Net income (loss) attributable to Community Health Systems, Inc. stockholders	79	(112)
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	3,488	3,119
Provision for bad debts	447	476
Net operating revenues	3,041	2,643
Operating costs and expenses:
Salaries and benefits	1,222	1,147
Supplies	492	417
Other operating expenses	708	663
Government settlement and related costs	8
Electronic health records incentive reimbursement	(17)	(30)
Rent	61	54
Depreciation and amortization	200	189
Amortization of software to be abandoned		26
Total operating costs and expenses	2,674	2,466
Income from operations	367	177
Interest expense, net	211	172
Equity in earnings of unconsolidated affiliates	(5)	23
Impairment of long-lived assets		24
Income (loss) from continuing operations before income taxes	161	(42)
Provision for (benefit from) income taxes	61	(16)
Income (loss) from continuing operations	100	(26)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		(3)
Impairment of hospitals sold or held for sale	(1)
Loss on sale, net	2
Loss from discontinued operations, net of taxes	1	(3)
Net income (loss)	101	(29)
Net income (loss) attributable to Community Health Systems, Inc. stockholders	101	(29)
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income (Unaudited)
Operating revenues (net of contractual allowances and discounts)	2,163	1,760
Provision for bad debts	288	223
Net operating revenues	1,875	1,537
Operating costs and expenses:
Salaries and benefits	1,035	845
Supplies	270	215
Other operating expenses	391	356
Electronic health records incentive reimbursement	(9)	(10)
Rent	55	44
Depreciation and amortization	96	66
Amortization of software to be abandoned		16
Total operating costs and expenses	1,838	1,532
Income from operations	37	5
Interest expense, net	9	12
Income (loss) from continuing operations before income taxes	28	(7)
Provision for (benefit from) income taxes	4	(8)
Income (loss) from continuing operations	24	1
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale	(11)	(1)
Impairment of hospitals sold or held for sale		(18)
Loss on sale, net	(3)
Loss from discontinued operations, net of taxes	(14)	(19)
Net income (loss)	10	(18)
Less: Net income attributable to noncontrolling interests	20	14
Net income (loss) attributable to Community Health Systems, Inc. stockholders	(10)	(32)
Consolidation, Eliminations [Member]
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates	170	(173)
Income (loss) from continuing operations before income taxes	(170)	173
Income (loss) from continuing operations	(170)	173
Discontinued operations, net of taxes:
Net income (loss)	(170)	173
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$ (170)	$ 173

XML

Supplemental Condensed Consolidating Financial Information (Tables)

3 Months Ended

Mar. 31, 2015

Supplemental Condensed Consolidating Financial Information [Abstract]

Schedule of Condensed Consolidating Statement of Income (Loss)

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(5)	$	3,488	$	2,163	$	-	$	5,646
Provision for bad debts		-		-		447		288		-		735
Net operating revenues		-		(5)		3,041		1,875		-		4,911
Operating costs and expenses:
Salaries and benefits		-		-		1,222		1,035		-		2,257
Supplies		-		-		492		270		-		762
Other operating expenses		-		-		708		391		-		1,099
Government settlement and related costs		-		-		8		-		-		8
Electronic health records incentive reimbursement		-		-		(17)		(9)		-		(26)
Rent		-		-		61		55		-		116
Depreciation and amortization		-		-		200		96		-		296
Total operating costs and expenses		-		-		2,674		1,838		-		4,512
Income from operations		-		(5)		367		37		-		399
Interest expense, net		-		21		211		9		-		241
Loss from early extinguishment of debt		-		8		-		-		-		8
Equity in earnings of unconsolidated affiliates		(79)		(104)		(5)		-		170		(18)
Income from continuing operations before income taxes		79		70		161		28		(170)		168
Provision for (benefit from) income taxes		-		(9)		61		4		-		56
Income from continuing operations		79		79		100		24		(170)		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		-		(11)		-		(11)
Impairment of hospitals sold or held for sale		-		-		(1)		-		-		(1)
Loss on sale, net		-		-		2		(3)		-		(1)
Loss from discontinued operations, net of taxes		-		-		1		(14)		-		(13)
Net income		79		79		101		10		(170)		99
Less: Net income attributable to noncontrolling interests		-		-		-		20		-		20
Net income attributable to Community Health Systems,
Inc. stockholders	$	79	$	79	$	101	$	(10)	$	(170)	$	79

Condensed Consolidating Statement of Loss
Three Months Ended March 31, 2014
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(4)	$	3,119	$	1,760	$	-	$	4,875
Provision for bad debts		-		-		476		223		-		699
Net operating revenues		-		(4)		2,643		1,537		-		4,176
Operating costs and expenses:
Salaries and benefits		-		-		1,147		845		-		1,992
Supplies		-		-		417		215		-		632
Other operating expenses		-		-		663		356		-		1,019
Electronic health records incentive reimbursement		-		-		(30)		(10)		-		(40)
Rent		-		-		54		44		-		98
Depreciation and amortization		-		-		189		66		-		255
Amortization of software to be abandoned		-		-		26		16		-		42
Total operating costs and expenses		-		-		2,466		1,532		-		3,998
Income from operations		-		(4)		177		5		-		178
Interest expense, net		-		40		172		12		-		224
Loss from early extinguishment of debt		-		73		-		-		-		73
Equity in earnings of unconsolidated affiliates		112		27		23		-		(173)		(11)
Impairment of long-lived assets		-		-		24		-		-		24
Income from continuing operations before income taxes		(112)		(144)		(42)		(7)		173		(132)
Provision for (benefit from) income taxes		-		(32)		(16)		(8)		-		(56)
Income from continuing operations		(112)		(112)		(26)		1		173		(76)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		(3)		(1)		-		(4)
Impairment of hospitals sold or held for sale		-		-		-		(18)		-		(18)
Loss from discontinued operations, net of taxes		-		-		(3)		(19)		-		(22)
Net loss		(112)		(112)		(29)		(18)		173		(98)
Less: Net income attributable to noncontrolling interests		-		-		-		14		-		14
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(112)	$	(112)	$	(29)	$	(32)	$	173	$	(112)

Schedule of Condensed Consolidating Statement of Comprehensive Income (Loss)

Condensed Consolidating Statement of Comprehensive Income
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net income	$	79	$	79	$	101	$	10	$	(170)	$	99
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		(9)		-		-		9		(9)
Net change in fair value of available-for-sale securities, net
of tax		1		1		1		-		(2)		1
Amortization and recognition of unrecognized pension
cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(7)		(7)		2		-		5		(7)
Comprehensive income		72		72		103		10		(165)		92
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		20		-		20
Comprehensive income (loss) attributable to Community
Health Systems, Inc. stockholders	$	72	$	72	$	103	$	(10)	$	(165)	$	72

Condensed Consolidating Statement of Comprehensive Loss
Three Months Ended March 31, 2014
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net loss	$	(112)	$	(112)	$	(29)	$	(18)	$	173	$	(98)
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		9		9		-		-		(9)		9
Net change in fair value of available-for-sale securities, net
of tax		-		-		-		-		-		-
Amortization and recognition of unrecognized pension
cost components, net of tax		-		-		-		-		-		-
Other comprehensive income (loss)		9		9		-		-		(9)		9
Comprehensive loss		(103)		(103)		(29)		(18)		164		(89)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		14		-		14
Comprehensive loss attributable to Community
Health Systems, Inc. stockholders	$	(103)	$	(103)	$	(29)	$	(32)	$	164	$	(103)

Schedule of Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet
March 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	37	$	185	$	-	$	222
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,430		2,176		-		3,606
Supplies		-		-		377		184		-		561
Deferred income taxes		341		-		-		-		-		341
Prepaid expenses and taxes		-		-		131		58		-		189
Other current assets		-		-		329		178		-		507
Total current assets		341		-		2,304		2,781		-		5,426
Intercompany receivable		1,257		16,512		3,314		6,131		(27,214)		-
Property and equipment, net		-		-		6,613		3,478		-		10,091
Goodwill		-		-		5,483		3,471		-		8,954
Other assets, net		6		303		1,817		1,164		(642)		2,648
Net investment in subsidiaries		3,361		18,435		7,643		-		(29,439)		-
Total assets	$	4,965	$	35,250	$	27,174	$	17,025	$	(57,295)	$	27,119
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	163	$	54	$	12	$	-	$	229
Accounts payable		-		1		873		318		-		1,192
Income tax payable		13		-		-		-		-		13
Deferred income taxes		23		-		-		-		-		23
Accrued interest		-		155		1		1		-		157
Accrued liabilities		4		-		1,051		492		-		1,547
Total current liabilities		40		319		1,979		823		-		3,161
Long-term debt		-		15,885		127		728		-		16,740
Intercompany payable		-		14,822		20,071		14,117		(49,010)		-
Deferred income taxes		844		-		-		-		-		844
Other long-term liabilities		-		862		1,113		361		(642)		1,694
Total liabilities		884		31,888		23,290		16,029		(49,652)		22,439
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		520		-		520
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,101		1,294		1,471		523		(3,288)		2,101
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(70)		(70)		(17)		-		87		(70)
Retained earnings		2,056		2,138		2,430		(126)		(4,442)		2,056
Total Community Health Systems, Inc.
stockholders’ equity		4,081		3,362		3,884		397		(7,643)		4,081
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		79		-		79
Total equity		4,081		3,362		3,884		476		(7,643)		4,160
Total liabilities and equity	$	4,965	$	35,250	$	27,174	$	17,025	$	(57,295)	$	27,119

Condensed Consolidating Balance Sheet
December 31, 2014
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	368	$	141	$	-	$	509
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,272		2,137		-		3,409
Supplies		-		-		373		184		-		557
Prepaid income taxes		30		-		-		-		-		30
Deferred income taxes		341		-		-		-		-		341
Prepaid expenses and taxes		-		-		138		54		-		192
Other current assets		-		-		356		172		-		528
Total current assets		371		-		2,507		2,688		-		5,566
Intercompany receivable		1,199		16,560		2,532		7,877		(28,168)		-
Property and equipment, net		-		-		6,548		3,621		-		10,169
Goodwill		-		-		5,480		3,471		-		8,951
Other assets, net		15		302		1,874		1,179		(635)		2,735
Net investment in subsidiaries		3,290		18,229		7,399		-		(28,918)		-
Total assets	$	4,875	$	35,091	$	26,340	$	18,836	$	(57,721)	$	27,421
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	163	$	61	$	11	$	-	$	235
Accounts payable		-		-		909		384		-		1,293
Deferred income taxes		23		-		-		-		-		23
Accrued interest		-		225		2		-		-		227
Accrued liabilities		4		-		1,249		558		-		1,811
Total current liabilities		27		388		2,221		953		-		3,589
Long-term debt		-		15,820		139		722		-		16,681
Intercompany payable		-		14,752		19,066		15,795		(49,613)		-
Deferred income taxes		845		-		-		-		-		845
Other long-term liabilities		-		841		1,140		346		(635)		1,692
Total liabilities		872		31,801		22,566		17,816		(50,248)		22,807
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		531		-		531
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,095		1,208		1,369		528		(3,105)		2,095
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(63)		(63)		(25)		5		83		(63)
Retained earnings		1,977		2,145		2,430		(124)		(4,451)		1,977
Total Community Health Systems, Inc.
stockholders’ equity		4,003		3,290		3,774		409		(7,473)		4,003
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		80		-		80
Total equity		4,003		3,290		3,774		489		(7,473)		4,083
Total liabilities and equity	$	4,875	$	35,091	$	26,340	$	18,836	$	(57,721)	$	27,421

Schedule of Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(10)	$	(123)	$	23	$	49	$	-	$	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(11)		(2)		-		(13)
Purchases of property and equipment		-		-		(199)		(42)		-		(241)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		4		58		-		62
Proceeds from sale of property and equipment		-		-		-		3		-		3
Purchases of available-for-sale securities		-		-		(22)		(37)		-		(59)
Proceeds from sales of available-for-sale securities		-		-		19		37		-		56
Increase in other investments		-		-		(30)		(9)		-		(39)
Net cash used in investing activities		-		-		(239)		8		-		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		-		-		-		-		17
Repurchase of restricted stock shares for payroll
tax withholding requirements		(20)		-		-		-		-		(20)
Deferred financing costs and other
debt-related costs		-		(20)		-		-		-		(20)
Redemption of noncontrolling investments in joint
ventures		-		-		-		(7)		-		(7)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(23)		-		(23)
Changes in intercompany balances with
affiliates, net		13		77		(101)		11		-		-
Borrowings under credit agreements		-		1,250		1		-		-		1,251
Issuance of long-term debt		-		-		-		-		-		-
Proceeds from receivables facility		-		-		-		75		-		75
Repayments of long-term indebtedness		-		(1,184)		(15)		(69)		-		(1,268)
Net cash provided by (used in) financing
activities		10		123		(115)		(13)		-		5
Net change in cash and cash equivalents		-		-		(331)		44		-		(287)
Cash and cash equivalents at beginning of period		-		-		368		141		-		509
Cash and cash equivalents at end of period	$	-	$	-	$	37	$	185	$	-	$	222

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2014
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	73	$	298	$	62	$	(368)	$	-	$	65
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(2,760)		(14)		-		(2,774)
Purchases of property and equipment		-		-		(143)		(38)		-		(181)
Purchases of available-for-sale securities		-		-		-		(78)		-		(78)
Proceeds from sales of available-for-sale securities		-		-		-		76		-		76
Increase in other investments		-		-		(75)		(24)		-		(99)
Net cash used in investing activities		-		-		(2,978)		(78)		-		(3,056)
Cash flows from financing activities:
Proceeds from exercise of stock options		6		-		-		-		-		6
Repurchase of restricted stock shares for payroll
tax withholding requirements		(11)		-		-		-		-		(11)
Deferred financing costs and other
debt-related costs		-		(269)		-		-		-		(269)
Excess tax benefit relating to
stock-based compensation		3		-		-		-		-		3
Redemption of noncontrolling investments in joint
ventures		-		-		-		(5)		-		(5)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(19)		-		(19)
Changes in intercompany balances with
affiliates, net		(71)		(3,417)		3,117		371		-		-
Borrowings under credit agreements		-		7,062		17		-		-		7,079
Issuance of long-term debt		-		4,000		-		-		-		4,000
Proceeds from receivables facility		-		-		-		133		-		133
Repayments of long-term indebtedness		-		(7,674)		(7)		(5)		-		(7,686)
Net cash provided by (used in) financing
activities		(73)		(298)		3,127		475		-		3,231
Net change in cash and cash equivalents		-		-		211		29		-		240
Cash and cash equivalents at beginning of period		-		-		239		134		-		373
Cash and cash equivalents at end of period	$	-	$	-	$	450	$	163	$	-	$	613

XML

Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2015

Basis of Presentation and Significant Accounting Policies [Abstract]

Schedule of Operating Revenues, Net of Contractual Allowances and Discounts (But Before the Provision for Bad Debts)

	Three Months Ended
	March 31,
	2015		2014
Medicare	$	1,398	$	1,261
Medicaid		586		459
Managed Care and other third-party payors		2,946		2,450
Self-pay		716		705
Total	$	5,646	$	4,875

XML

Long-Term Debt (8.0% Senior Notes, Due 2019 Narrative) (Details) (USD $)	1 Months Ended		12 Months Ended	3 Months Ended	1 Months Ended
	Jul. 18, 2012	Mar. 21, 2012	Dec. 31, 2011	Mar. 31, 2015	Nov. 22, 2011
Senior Notes at 8.875, Due 2015 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 934,000,000	$ 850,000,000	$ 1,000,000,000
Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date				Nov. 22, 2011
Debt Instrument, Maturity Date				Nov. 15, 2019
Debt Instrument, Face Amount					1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%			8.00%
Debt Instrument, Earliest Redemption Date				Nov. 15, 2015
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date				Mar. 21, 2012
Debt Instrument, Face Amount		$ 1,000,000,000
Debt Instrument, Premium Percentage		102.50%
Debt Instrument, Redemption, Period Two [Member] | Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage					100.00%
Debt Instrument, Redemption Period, Start Date				Nov. 15, 2014
Debt Instrument, Redemption Period, End Date				Nov. 15, 2015
Debt Instrument, Redemption, Description				plus a "make-whole" premium, as described in the 8% Senior Notes indenture
Minimum Period Notice for Redemption of Debt					30 days
Maximum Period Notice for Redemption of Debt					60 days

XML

Long-Term Debt (Credit Facility End of Period Disclosures Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015 item
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding amount	$ 62,000,000
Credit Facility, Name [Member] | Credit Facility, Type of Debt [Member]
Debt Instrument [Line Items]
Minimum Number of Additional Tranches Available in Future	1
Aggregate Principal Amount of Each Tranche Available in Future	1,500,000,000
Debt, Weighted Average Interest Rate	4.40%
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	1,000,000,000
Letters of Credit Outstanding, Amount	$ 83,000,000

XML

Fair Value of Financial Instruments (Narrative) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015
Fair Value of Financial Instruments [Abstract]
Interest expense arising from spread in fixed and floating rates of interest rate swap agreements that will be recognized in next 12 months	$ 48

XML

Acquisitions and Divestitures (Schedule of Net Operating Revenues and Income (Loss) and Assets and Liabilities Classified as Discontinued Operations) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Acquisitions And Divestitures [Abstract]
Net operating revenues	$ 56	$ 89
Loss from operations of entities sold or held for sale before income taxes	(17)	(7)
Impairment of hospitals held for sale before income taxes	(1)	(22)
Loss on sale, net	(1)
Loss from discontinued operations, before taxes	(19)	(29)
Income tax benefit	(6)	(7)
Loss from discontinued operations, net of taxes	$ (13)	$ (22)

XML

Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2018) (Details) (Senior Secured Notes At 5.125 Due 2018 [Member], Senior Secured Notes [Member])	3 Months Ended
	Mar. 31, 2015
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.563%
Debt Instrument, Redemption Period, Start Date	Aug. 15, 2015
Debt Instrument, Redemption Period, End Date	Aug. 14, 2016
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.281%
Debt Instrument, Redemption Period, Start Date	Aug. 15, 2016
Debt Instrument, Redemption Period, End Date	Aug. 14, 2017
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Aug. 15, 2017
Debt Instrument, Redemption Period, End Date	Aug. 15, 2018

XML

Long-Term Debt (Other Debt and Interest Payments Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Interest Paid on borrowing	$ 300,000,000	$ 175,000,000
Scenario, Previously Reported [Member]
Debt Instrument [Line Items]
Interest Paid on borrowing		280,000,000
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Derivative Liability, Number of Instruments Held	7
Interest Rate Swap, Currently Effective [Member]
Debt Instrument [Line Items]
Notional Amount, Liability	1,300,000,000
Interest Rate Swap, Not Yet Effective [Member]
Debt Instrument [Line Items]
Derivative Liability, Number of Instruments Held	6
Notional Amount, Liability	$ 1,700,000,000
Credit Facility, Revolving Credit Loans [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.75%
Credit Facility, Term Loan A [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	2.75%
Credit Facility, Term Loan D [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	3.25%
Credit Facility, Term Loan F [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Basis Spread on Variable Rate	3.25%
Secured Debt [Member] | Credit Facility, Term Loan D [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	1.00%
Secured Debt [Member] | Credit Facility, Term Loan D [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	2.00%

XML

Long-Term Debt (5.125% Senior Notes, Due 2018 Narrative) (Details) (USD $)	1 Months Ended	3 Months Ended
	Aug. 17, 2012	Mar. 31, 2015
Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date		Aug. 17, 2012
Debt Instrument, Face Amount	1,600,000,000
Debt Instrument, Interest Rate, Stated Percentage	5.125%
Debt Instrument, Earliest Redemption Date		Aug. 15, 2015
Secured Debt [Member] | Credit Facility, Term Loan B, Initial Funding [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	1,600,000,000
Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	105.125%
Debt Instrument, Redemption Period, End Date		Aug. 15, 2015
Debt Instrument, Redemption, Description		with the proceeds from certain public equity offerings
Debt Instrument, Redemption, Period Two [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date		Aug. 15, 2015
Debt Instrument, Redemption Period, End Date		Aug. 15, 2015
Debt Instrument, Redemption, Description		plus a "make-whole" premium, as described in the 2018 Senior Secured Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days
Maximum [Member] | Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Debt Instrument [Line Items]
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount	35.00%

XML

Fair Value of Financial Instruments (Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Assets:
Available-for-sale securities	$ 285	$ 280
Trading securities	58	55
Liabilities:
Contingent Value Right, Fair Value Disclosure	6	6
Carrying Amount Measurement [Member]
Assets:
Cash and cash equivalents	222	509
Available-for-sale securities	285	280
Trading securities	58	55
Liabilities:
Contingent Value Right, Fair Value Disclosure	6	6
Carrying Amount Measurement [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member]
Liabilities:
Credit Facility, Fair Value Disclosure	7,231	7,165
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	2,017	2,018
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,200	1,200
Carrying Amount Measurement [Member] | Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	3,000	3,000
Carrying Amount Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,600	1,600
Carrying Amount Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,000	1,000
Carrying Amount Measurement [Member] | Receivables Facility and Other Debt, Type [Member] | Receivables Facility and Unsecured Debt [Member]
Liabilities:
Other Liabilities, Fair Value Disclosure	706	705
Estimate of Fair Value Measurement [Member]
Assets:
Cash and cash equivalents	222	509
Available-for-sale securities	285	280
Trading securities	58	55
Liabilities:
Contingent Value Right, Fair Value Disclosure	6	6
Estimate of Fair Value Measurement [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member]
Liabilities:
Credit Facility, Fair Value Disclosure	7,249	7,143
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 8.0, Due 2019 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	2,129	2,139
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 7.125, Due 2020 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,277	1,282
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Senior Notes at 6.875, Due 2022 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	3,211	3,194
Estimate of Fair Value Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 5.125 Due 2018 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,655	1,655
Estimate of Fair Value Measurement [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125, Due 2021 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,034	1,041
Estimate of Fair Value Measurement [Member] | Receivables Facility and Other Debt, Type [Member] | Receivables Facility and Unsecured Debt [Member]
Liabilities:
Other Liabilities, Fair Value Disclosure	$ 706	$ 705

XML

Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2021) (Details) (Senior Secured Notes at 5.125, Due 2021 [Member], Senior Secured Notes [Member])	3 Months Ended
	Mar. 31, 2015
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.844%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2017
Debt Instrument, Redemption Period, End Date	Jan. 31, 2018
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.563%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2018
Debt Instrument, Redemption Period, End Date	Jan. 31, 2019
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.281%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2019
Debt Instrument, Redemption Period, End Date	Jan. 31, 2020
Debt Instrument, Redemption, Period Six [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2020
Debt Instrument, Redemption Period, End Date	Jan. 31, 2021

XML

Long-Term Debt (Credit Facility as Amended, Amendments and Modifications Narrative) (Details) (USD $)	Jan. 26, 2014	Jan. 27, 2014
Credit Facility, Term Loan B, Initial Funding [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Balance of Remaining Non-extended Term Loans	$ 60,000,000
Credit Facility, Term Loan A, March 6, 2012 Amendment [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Balance of Remaining Non-extended Term Loans	637,000,000
Credit Facility, Revolving Credit Loans, Third Amendment and Restatement [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		1,000,000,000
Credit Facility, Term Loan A, Third Amendment and Restatement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		1,000,000,000
Credit Facility, Term Loan D, Third Amendment and Restatement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		4,600,000,000
Credit Facility, Term Loan E, Third Amendment and Restatement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,700,000,000

XML

Basis of Presentation and Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2015

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Accounting, Policy

The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2015 and December 31, 2014 and for the three-month periods ended March 31, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of Health Management Associates, Inc. (“HMA”) are included from January 27, 2014, the date of the HMA merger. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2015. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2014, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2015.

Consolidation, Policy

Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets.

During the three months ended March 31, 2014, the Company made the decision to sell several smaller hospitals and entered into definitive agreements to sell two hospitals. Since March 31, 2014, the Company made the decision to sell two additional hospitals. The condensed consolidated statement of income for the three months ended March 31, 2014 has been restated to reclassify the results of operations for these hospitals that were owned or leased in 2014 to discontinued operations.

Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Allowance for Doubtful Accounts, Policy

Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses.

The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. For all other non-self-pay payor categories, the Company reserves 100% of all accounts aging over 365 days from the date of discharge. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2015 and 2014, were as follows (in millions):

	Three Months Ended
	March 31,
	2015		2014
Medicare	$	1,398	$	1,261
Medicaid		586		459
Managed Care and other third-party payors		2,946		2,450
Self-pay		716		705
Total	$	5,646	$	4,875

Electronic Health Records Incentive Reimbursement Policy

Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology.  The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

New Accounting Pronouncements, Policy

New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently decided to defer the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows.

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation Expense) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting for Stock-Based Compensation [Abstract]
Effect on income from continuing operations before income taxes	$ (14)	$ (11)
Effect on net income	$ (8)	$ (7)

XML

Fair Value (Tables)

3 Months Ended

Mar. 31, 2015

Fair Value [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

	March 31, 2015		Level 1		Level 2		Level 3
Available-for-sale securities	$	285	$	156	$	129	$	-
Trading securities		58		58		-		-
Total assets	$	343	$	214	$	129	$	-
Contingent Value Right (CVR)	$	6	$	6	$	-	$	-
CVR-related liability		256		-		-		256
Fair value of interest rate swap agreements		81		-		81		-
Total liabilities	$	343	$	6	$	81	$	256
	December 31, 2014		Level 1		Level 2		Level 3
Available-for-sale securities	$	280	$	151	$	129	$	-
Trading securities		55		55		-		-
Total assets	$	335	$	206	$	129	$	-
Contingent Value Right (CVR)	$	6	$	6	$	-	$	-
CVR-related liability		265		-		-		265
Fair value of interest rate swap agreements		68		-		68		-
Total liabilities	$	339	$	6	$	68	$	265

XML

Long-Term Debt (Schedule of Early Redemption Prices on 7.125% Senior Notes) (Details) (Senior Notes at 7.125, Due 2020 [Member], Senior Notes [Member])	3 Months Ended
	Mar. 31, 2015
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.563%
Debt Instrument, Redemption Period, Start Date	Jul. 15, 2016
Debt Instrument, Redemption Period, End Date	Jul. 14, 2017
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.781%
Debt Instrument, Redemption Period, Start Date	Jul. 15, 2017
Debt Instrument, Redemption Period, End Date	Jul. 14, 2018
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jul. 15, 2018
Debt Instrument, Redemption Period, End Date	Jul. 15, 2020

XML

Other Comprehensive Income (Schedule of Changes in Accumulated Other Comprehensive Income by Component) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	$ (63)	$ (67)
Other Comprehensive Income (Loss), before Reclassifications	(14)	(2)
Amounts reclassified from accumulated other comprehensive income (loss)	7	11
Other comprehensive (loss) income	(7)	9
Accumulated Other Comprehensive Income (Loss), Ending Balance	(70)	(58)
Change in Fair Value of Interest Rate Swaps [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	(43)	(56)
Other Comprehensive Income (Loss), before Reclassifications	(15)	(2)
Amounts reclassified from accumulated other comprehensive income (loss)	6	11
Other comprehensive (loss) income	(9)	9
Accumulated Other Comprehensive Income (Loss), Ending Balance	(52)	(47)
Change in Fair Value of Available for Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	7		7
Other Comprehensive Income (Loss), before Reclassifications	1
Other comprehensive (loss) income	1
Accumulated Other Comprehensive Income (Loss), Ending Balance	8	7	7
Change in Unrecognized Pension Cost Components [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	(27)		(18)
Amounts reclassified from accumulated other comprehensive income (loss)	1
Other comprehensive (loss) income	1
Accumulated Other Comprehensive Income (Loss), Ending Balance	$ (26)	$ (18)	$ (18)

XML

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share

	Three Months Ended
	March 31,
	2015		2014
Numerator:
Income (loss) from continuing operations, net of taxes	$	112	$	(76)
Less: Income from continuing operations attributable
to noncontrolling interests, net of taxes		20		14
Income (loss) from continuing operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	92	$	(90)
Loss from discontinued operations, net of taxes	$	(13)	$	(22)
Less: Loss from discontinued operations attributable
to noncontrolling interests, net of taxes		-		-
Loss from discontinued operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	(13)	$	(22)
Denominator:
Weighted-average number of shares outstanding — basic		114,419,590		106,601,997
Effect of dilutive securities:
Restricted stock awards		181,120		-
Employee stock options		452,659		-
Other equity-based awards		4,299		-
Weighted-average number of shares outstanding — diluted		115,057,668		106,601,997

Schedule of Antidilutive Securities

	Three Months Ended
	March 31,
	2015		2014
Dilutive securities outstanding not included in
the computation of earnings per
share because their effect is antidilutive:
Employee stock options and restricted stock awards		-		1,891,000

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Restricted Stock, Activity) (Details) (Restricted Stock [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	2,760,639
Granted, Shares	1,223,500
Vested, Shares	(1,115,006)
Ending Balance, Unvested Shares	2,869,133
Beginning of Period, Weighted Average Grant Date Fair Value	$ 39.82
Granted, Weighted Average Grant Date Fair Value	$ 47.72
Vested, Weighted Average Grant Date Fair Value	$ 37.45
End of Period, Weighted Average Grant Date Fair Value	$ 44.11

XML

Stockholders' Equity (Schedule of Impact of Noncontrolling Interest to Stockholders' Equity) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stockholders' Equity [Abstract]
Net loss attributable to Community Health Systems, Inc. stockholders	$ 79	$ (112)
Change to Community Health Systems, Inc. stockholders' equity from net loss attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$ 79

XML

Goodwill and Other Intangible Assets (Other Intangible Assets Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired during the year	$ 0
Finite-Lived Intangible Assets, Gross	76,000,000		76,000,000
Finite-Lived Intangible Assets, Net	35,000,000		39,000,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	128,000,000		131,000,000
Capitalized Computer Software, Gross	1,400,000,000		1,500,000,000
Capitalized Computer Software, Net	769,000,000		790,000,000
Capitalized Computer Software, Development Stage Costs	33,000,000
Impairment of long-lived assets		24,000,000
Amortization of software to be abandoned		42,000,000
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	4 years
Acquired Finite-lived Intangible Asset, Residual Value	0
Amortization expense	3,000,000	1,000,000
Amortization expense for remainder 2015	10,000,000
Amortization expense for 2016	13,000,000
Amortization expense for 2017	3,000,000
Amortization expense for 2018	2,000,000
Amortization expense for 2019	2,000,000
Amortization expense for 2020	2,000,000
Amortization expense thereafter	3,000,000
Capitalized Internal Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Asset, Residual Value	0
Amortization expense	53,000,000	84,000,000
Amortization expense for remainder 2015	146,000,000
Amortization expense for 2016	167,000,000
Amortization expense for 2017	103,000,000
Amortization expense for 2018	75,000,000
Amortization expense for 2019	68,000,000
Amortization expense for 2020	65,000,000
Amortization expense thereafter	$ 145,000,000
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	3 years
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	8 years
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life	10 years

XML

Basis of Presentation and Significant Accounting Policies (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Allowance for Doubtful Accounts, Policy [Abstract]
Percentage reserved for all non-self-pay payors accounts aging over 365 days from the date of discharge	100.00%
Number of days from the date of discharge over which all accounts are reserved 100%	365 days
Electronic Health Records Reimbursement, Policy [Abstract]
Electronic health records incentive reimbursement under HITECH	$ 26	$ 40
Electronic Health Records Incentive Reimbursement, Cash Received	54	62
Electronic Health Records Incentive Reimbursements [Member]
Electronic Health Records Reimbursement, Policy [Abstract]
Deferred Revenue	$ 75	$ 93

XML

Cost of Revenue

3 Months Ended

Mar. 31, 2015

Cost of Revenue [Abstract]

Cost of Revenue Disclosure

3.  COST OF REVENUE

Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office and Naples, Florida office, (which was the headquarters of HMA prior to the closing of the HMA merger), which collectively were $77 million for both the three months ended March 31, 2015 and 2014. During the three months ended March 31, 2015, corporate office costs from the Naples, Florida office were significantly lower than the three months ended March 31, 2014 due to the integration of the HMA corporate functions.  Included in these corporate office costs is stock-based compensation of $14 million and $11 million for the three months ended March 31, 2015 and 2014, respectively.

XML

Earnings Per Share (Schedule of Calculation of Numerator and Denominator in Earnings Per Share) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Income (loss) from continuing operations, net of taxes	$ 112	$ (76)
Less: Income from continuing operations attributable to noncontrolling interests	20	14
Income (loss) from continuing operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted	92	(90)
Loss from discontinued operations, net of taxes	(13)	(22)
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted	$ (13)	$ (22)
Denominator:
Weighted-average number of shares outstanding - basic	114,419,590	106,601,997
Effect of dilutive securities:
Restricted stock awards	181,120
Employee stock options	452,659
Other equity-based awards	4,299
Weighted-average number of shares outstanding - diluted	115,057,668	106,601,997

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2015

Segment Information [Abstract]

Schedule of Segment Reporting Information by Segment

	Three Months Ended March 31,
	2015		2014
Net operating revenues:
Hospital operations	$	4,857	$	4,124
Corporate and all other		54		52
Total	$	4,911	$	4,176
Income (loss) from continuing operations before income taxes:
Hospital operations	$	273	$	38
Corporate and all other		(105)		(170)
Total	$	168	$	(132)

XML

Fair Value of Financial Instruments (Policies)

3 Months Ended

Mar. 31, 2015

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments, Policy

The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 13.  The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation.  The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant. 

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). 

Available-for-sale securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. 

Trading securities.  Estimated fair value is based on closing price as quoted in public markets. 

Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions. 

8% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

7⅛% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

2018 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes. 

2021 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

Receivables Facility and other debt.  The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations. 

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. 

XML

Goodwill and Other Intangible Assets (Policies)

3 Months Ended

Mar. 31, 2015

Goodwill and Intangible Asset Impairment [Abstract]

Goodwill, Policy

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2015, the hospital operations reporting unit, the home care agency operations reporting unit, and the hospital management services reporting unit had approximately $8.9 billion, $44 million and $33 million, respectively, of goodwill. 

Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2014. No impairment was indicated by this evaluation.  The next annual goodwill evaluation will be performed during the fourth quarter of 2015. 

The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.  

XML

Contingencies (Impact of Legal Expenses Paid or Incurred to Date and Settlements Paid or Deemed Final) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Loss Contingencies [Line Items]
Beginning balance	$ 24
Settlements paid
Legal expenses incurred and/or paid during the three months ended March 31, 2015	3
Ending balance	27
Deductible [Member]
Loss Contingencies [Line Items]
Beginning balance	18
Settlements paid
Ending balance	18
CHS Responsibility at 10% [Member]
Loss Contingencies [Line Items]
Settlements paid
Legal expenses incurred and/or paid during the three months ended March 31, 2015	1
Ending balance	1
Reduction to Amount Owed to CVR Holders at 90% [Member]
Loss Contingencies [Line Items]
Beginning balance	6
Settlements paid
Legal expenses incurred and/or paid during the three months ended March 31, 2015	2
Ending balance	$ 8

XML

Acquisitions and Divestitures (Divestitures Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended	0 Months Ended
	Mar. 31, 2015 item	Mar. 01, 2015	Dec. 31, 2014	Feb. 01, 2015	Jan. 01, 2015 item
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of Hospitals Sold	4
Proceeds from Divestiture of Businesses, Net of Cash Divested	$ 62
Riverview Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date	Mar. 01, 2015
Number of licensed beds		281
Proceeds from Divestiture of Businesses, Net of Cash Divested		25
Carolina Pines Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date	Jan. 01, 2015
Number of licensed beds					116
Proceeds from Divestiture of Businesses, Net of Cash Divested			74
Williamson Memorial Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	76
Harris Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date	Feb. 01, 2015
Number of licensed beds				133
Proceeds from Divestiture of Businesses, Net of Cash Divested				5
Dallas Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Date	Mar. 01, 2015
Number of licensed beds		202
Proceeds from Divestiture of Businesses, Net of Cash Divested		$ 25

XML

Other Comprehensive Income (Tables)

3 Months Ended

Mar. 31, 2015

Stockholders' Equity [Abstract]

Schedule of Changes in Accumulated Other Comprehensive Income by Component

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2014	$	(43)	$	7	$	(27)	$	(63)
Other comprehensive (loss)
income before reclassifications		(15)		1		-		(14)
Amounts reclassified from
accumulated other
comprehensive income (loss)		6		-		1		7
Net current-period other
comprehensive income		(9)		1		1		(7)
Balance as of March 31, 2015	$	(52)	$	8	$	(26)	$	(70)

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2013	$	(56)	$	7	$	(18)	$	(67)
Other comprehensive (loss)
income before reclassifications		(2)		-		-		(2)
Amounts reclassified from
accumulated other
comprehensive income (loss)		11		-		-		11
Net current-period other
comprehensive income		9		-		-		9
Balance as of March 31, 2014	$	(47)	$	7	$	(18)	$	(58)

Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Income

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2015		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(9)	Interest expense, net
		3	Tax benefit
	$	(6)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		(1)	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2014		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(18)	Interest expense, net
		7	Tax benefit
	$	(11)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		-	Salaries and benefits
		-	Total before tax
		-	Tax benefit
	$	-	Net of tax

XML

Fair Value (Policies)

3 Months Ended

Mar. 31, 2015

Fair Value [Abstract]

Fair Value Measurement, Policy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). 

The inputs used to measure fair value are classified into the following fair value hierarchy: 

Level 1:  Quoted market prices in active markets for identical assets or liabilities. 

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data. 

Level 3:  Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. 

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were notransfers between levels during 2015 or 2014. 

XML

Contingencies (Policies)

3 Months Ended

Mar. 31, 2015

Contingencies [Abstract]

Legal Costs, Policy

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

XML

Accounting for Stock-Based Compensation

3 Months Ended

Mar. 31, 2015

Accounting for Stock-Based Compensation [Abstract]

Accounting for Stock-Based Compensation Disclosure

*

2.  ACCOUNTING FOR STOCK-BASED COMPENSATION

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. 2009 Stock Option and Award Plan, amended and restated as of March 19, 2014 (the “2009 Plan”).  

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock.  Persons eligible to receive grants under the 2000 Plan include the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 have a 10-year contractual term, options granted in 2005 through 2007 have an eight-year contractual term and options granted in 2008 through 2011 have a 10-year contractual term.  The Company has not granted stock option awards under the 2000 Plan since 2011.  Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan. 

The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term.  As of March 31, 2015, 3,192,176 shares of unissued common stock were reserved for future grants under the 2009 Plan. 

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date. 

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions): 

	Three Months Ended
	March 31,
	2015		2014
Effect on income from continuing operations before income taxes	$	(14)	$	(11)
Effect on net income	$	(8)	$	(7)

At March 31, 2015, $103 million of unrecognized stock-based compensation expense related to outstanding unvested restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 29 months. There is no expense to be recognized related to stock options. There were no modifications to awards during the three months ended March 31, 2015 and 2014.

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows (in millions, except share and per share data): 

				Weighted-	Aggregate
				Average	Intrinsic
		Weighted-		Remaining	Value as of
		Average		Contractual	March 31,
	Shares	Exercise Price		Term	2015
Outstanding at December 31, 2014	1,953,727	$	32.94
Granted	-		-
Exercised	(452,959)		38.77
Forfeited and cancelled	-		-
Outstanding at March 31, 2015	1,500,768	$	31.18	4.7 years	$	32
Exercisable at March 31, 2015	1,498,764	$	31.19	4.7 years	$	37

No stock options were granted during the three months ended March 31, 2015 and 2014.  The aggregate intrinsic value (the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($52.28) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on March 31, 2015. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the three months ended March 31, 2015 and 2014 was $5 million and $1 million, respectively.  The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. 

The Company has also awarded restricted stock under the 2000 Plan and the 2009 Plan to its directors and employees of certain subsidiaries. The restrictions on these shares generally lapse in one-third increments on each of the first three anniversaries of the award date. Certain of the restricted stock awards granted to the Company’s senior executives contain a performance objective that must be met in addition to any time-based vesting requirements. If the performance objective is not attained, the awards will be forfeited in their entirety.  Once the performance objective has been attained, restrictions will lapse in one-third increments on each of the first three anniversaries of the award date.  In addition, 835,000 restricted stock awards granted March 1, 2014 have a performance objective that is measured based on the realization of synergies related to the HMA merger over a two-year period that began on February 1, 2014.  The performance objective could be met in part in the first year or in whole or in part over such two-year period.  Depending on the degree of attainment of the performance objective, restrictions may lapse on a portion of the award grant over the first three anniversaries of the award date at a level dependent upon the amount of synergies realized. If the synergies related to the HMA merger did not reach a certain level, then the awards would have been forfeited in their entirety.  Based on the synergy levels attained in the first annual measurement period ending on January 31, 2015, the performance objective for the first measurement period was met, and one-third of the awards vested on March 1, 2015. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2000 Plan and the 2009 Plan will lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance standards that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied. 

Restricted stock outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows:  

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2014	2,760,639	$	39.82
Granted	1,223,500		47.72
Vested	(1,115,006)		37.45
Forfeited	-		-
Unvested at March 31, 2015	2,869,133		44.11

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2000 Plan and the 2009 Plan.  On February 27, 2013, each of the Company’s outside directors received a grant under the 2009 Plan of 3,596 RSUs. On March 1, 2014, each of the Company’s outside directors received a grant under the 2009 Plan of 3,614 RSUs. On March 1, 2015, each of the Company’s outside directors received a grant under the 2009 Plan of 3,504 RSUs. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date. 

RSUs outstanding under the 2000 Plan and the 2009 Plan as of March 31, 2015, and changes during the three-month period following December 31, 2014, were as follows: 

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2014	49,362	$	36.07
Granted	21,024		47.70
Vested	(27,708)		31.76
Forfeited	-		-
Unvested at March 31, 2015	42,678		44.59

XML

Supplemental Condensed Consolidating Financial Information (Policies)

3 Months Ended

Mar. 31, 2015

Supplemental Condensed Consolidating Financial Information [Abstract]

Guarantor Financial Information Policy

These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” 

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below: 

•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. 

•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net. 

•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. 

•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances. 

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 11.  The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation. 

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods are revised to reflect the status of guarantors or non-guarantors as of March 31, 2015.

XML

Long-Term Debt (6.785% Senior Notes, Due 2022 Narrative) (Details) (Senior Notes [Member], Senior Notes at 6.875, Due 2022 [Member], USD $)	1 Months Ended	3 Months Ended
	Jan. 27, 2014	Mar. 31, 2015
Debt Instrument [Line Items]
Debt Instrument, Offering Date		Jan. 27, 2014
Debt Instrument, Face Amount	3,000,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.875%
Debt Instrument, Earliest Redemption Date		Feb. 01, 2018
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	106.875%
Debt Instrument, Redemption Period, End Date		Feb. 01, 2018
Debt Instrument, Redemption, Description		proceeds from certain public equity offerings
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date		Feb. 01, 2017
Debt Instrument, Redemption Period, End Date		Feb. 01, 2018
Debt Instrument, Redemption, Description		plus a "make-whole" premium, as described in the 6⅞% Senior Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days
Maximum [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount	40.00%

XML

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2015

Debt Instrument [Line Items]

Schedule of Debt

	March 31,		December 31,
	2015		2014
Credit Facility:
Term A Loan	$	925	$	950
Term D Loan		4,544		4,555
Term E Loan		-		1,660
Term F Loan		1,700		-
Revolving credit loans		62		-
8% Senior Notes due 2019		2,017		2,018
7⅛% Senior Notes due 2020		1,200		1,200
5⅛% Senior Secured Notes due 2018		1,600		1,600
5⅛% Senior Secured Notes due 2021		1,000		1,000
6⅞% Senior Notes due 2022		3,000		3,000
Receivables Facility		623		614
Capital lease obligations		215		228
Other		83		91
Total debt		16,969		16,916
Less current maturities		(229)		(235)
Total long-term debt	$	16,740	$	16,681

Senior Notes at 8.0, Due 2019 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
November 15, 2015 to November 14, 2016	104.000	%
November 15, 2016 to November 14, 2017	102.000	%
November 15, 2017 to November 15, 2019	100.000	%

Senior Notes at 7.125, Due 2020 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
July 15, 2016 to July 14, 2017	103.563	%
July 15, 2017 to July 14, 2018	101.781	%
July 15, 2018 to July 15, 2020	100.000	%

Senior Secured Notes At 5.125 Due 2018 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
August 15, 2015 to August 14, 2016	102.563	%
August 15, 2016 to August 14, 2017	101.281	%
August 15, 2017 to August 15, 2018	100.000	%

Senior Secured Notes at 5.125, Due 2021 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 1, 2017 to January 31, 2018	103.844	%
February 1, 2018 to January 31, 2019	102.563	%
February 1, 2019 to January 31, 2020	101.281	%
February 1, 2020 to January 31, 2021	100.000	%

Senior Notes at 6.875, Due 2022 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 1, 2018 to January 31, 2019	103.438	%
February 1, 2019 to January 31, 2020	101.719	%
February 1, 2020 to January 31, 2022	100.000	%

XML

Accounting for Stock Based Compensation (Schedule of Share-based Compensation, Restricted Stock Units, Activity) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	49,362
Granted, Shares	21,024
Vested, Shares	(27,708)
Ending Balance, Unvested Shares	42,678
Beginning of Period, Weighted Average Grant Date Fair Value	$ 36.07
Granted, Weighted Average Grant Date Fair Value	$ 47.70
Vested, Weighted Average Grant Date Fair Value	$ 31.76
End of Period, Weighted Average Grant Date Fair Value	$ 44.59

XML

Long-Term Debt (Credit Facility Terms Narrative) (Details)	3 Months Ended
	Mar. 31, 2015
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Credit Facility, Term Loans [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Equivalent Percentage of Term Loan Facility Related to Net Cash Proceeds of Certain Asset Sales and Dispositions by Company and Its Subsidiaries	100.00%
Equivalent Percentage of Term Loan Facility Related to Net Cash Proceeds of Issuance of Certain Debt Obligations or Receivables Based Financing by Company and Its Subsidiaries	100.00%
Equivalent Percentage of Term Loan Facility Subject to Reduction to Lower Percentage Based on Company Leverage Ratio	50.00%
Alternate Base Rate [Member] | Credit Facility, Term Loan A [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Alternate Base Rate [Member] | Credit Facility, Term Loan D [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	2.00%
Alternate Base Rate [Member] | Credit Facility, Term Loan F [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Federal Funds Effective Rate [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.50%
LIBOR [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.00%
LIBOR [Member] | Credit Facility, Term Loan A [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.75%
LIBOR [Member] | Credit Facility, Term Loan D [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	1.00%
LIBOR [Member] | Credit Facility, Term Loan F [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.25%

XML

Condensed Consolidated Statements of Income (Loss) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Income (Loss) [Abstract]
Operating revenues (net of contractual allowances and discounts)	$ 5,646	$ 4,875
Provision for bad debts	735	699
Net operating revenues	4,911	4,176
Operating costs and expenses:
Salaries and benefits	2,257	1,992
Supplies	762	632
Other operating expenses	1,099	1,019
Government settlement and related costs	8
Electronic health records incentive reimbursement	(26)	(40)
Rent	116	98
Depreciation and amortization	296	255
Amortization of software to be abandoned		42
Total operating costs and expenses	4,512	3,998
Income from operations	399	178
Interest expense, net	241	224
Loss from early extinguishment of debt	8	73
Equity in earnings of unconsolidated affiliates	(18)	(11)
Impairment of long-lived assets		24
Income (loss) from continuing operations before income taxes	168	(132)
Provision (benefit) for income taxes	56	(56)
Income (loss) from continuing operations	112	(76)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale	(11)	(4)
Impairment of hospitals sold or held for sale	(1)	(18)
Loss on sale, net	(1)
Loss from discontinued operations, net of taxes	(13)	(22)
Net income (loss)	99	(98)
Less: Net income attributable to noncontrolling interests	20	14
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$ 79	$ (112)
Basic earnings (loss) per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	$ 0.80	$ (0.84)
Discontinued operations	$ (0.11)	$ (0.21)
Net income (loss)	$ 0.69	$ (1.05)
Diluted earnings (loss) per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	$ 0.79	$ (0.84)
Discontinued operations	$ (0.11)	$ (0.21)
Net income (loss)	$ 0.68	$ (1.05)
Weighted-average number of shares outstanding:
Basic	114,419,590	106,601,997
Diluted	115,057,668	106,601,997

XML

Contingencies (Tables)

3 Months Ended

Mar. 31, 2015

Contingencies [Abstract]

Impact of Legal Expenses Paid or Incurred to Date and Settlements Paid or Deemed Final

			Allocation of Expenses and Settlement Costs
							Reduction to
	Total Expenses				CHS		Amount Owed
	and Settlement				Responsibility		to CVR Holders
	Cost		Deductible		at 10%		at 90%
As of December 31, 2014	$	24	$	18	$	-	$	6
Settlements paid		-		-		-		-
Legal expenses incurred
and/or paid during
the three months ended
March 31, 2015		3		-		1		2
As of  March 31, 2015	$	27	$	18	$	1	$	8

Schedule Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies

	CVR Related		CVR Related Liability		Other
	Liability		for Probable		Probable
	at Fair Value		Contingencies		Contingencies
Balance as of December 31, 2014	$	265	$	29	$	125
Expense		(9)		(5)		15
Cash payments		-		-		(92)
Balance as of March 31, 2015	$	256	$	24	$	48

XML

Segment Information (Schedule of Segment Reporting Information by Segment) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Net operating revenues	$ 4,911	$ 4,176
Income (loss) from continuing operations before income taxes	168	(132)
Hospital operations [Member]
Segment Reporting Information [Line Items]
Net operating revenues	4,857	4,124
Income (loss) from continuing operations before income taxes	273	38
Corporate and All Other Reporting Units [Member]
Segment Reporting Information [Line Items]
Net operating revenues	54	52
Income (loss) from continuing operations before income taxes	$ (105)	$ (170)

XML

Condensed Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ 99	$ (98)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	296	302
Government settlement and related costs	8
Stock-based compensation expense	14	11
Loss on sale, net	1
Impairment of long-lived assets and hospitals sold or held for sale	2	42
Loss from early extinguishment of debt	8	73
Excess tax benefit relating to stock-based compensation		(3)
Other non-cash expenses, net	(7)	6
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable	(202)	(171)
Supplies, prepaid expenses and other current assets	14	14
Accounts payable, accrued liabilities and income taxes	(284)	(83)
Other	(10)	(28)
Net cash (used in) provided by operating activities	(61)	65
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(13)	(2,774)
Purchases of property and equipment	(241)	(181)
Proceeds from disposition of hospitals and other ancillary operations	62
Proceeds from sale of property and equipment	3
Purchases of available-for-sale securities	(59)	(78)
Proceeds from sales of available-for-sale securities	56	76
Increase in other investments	(39)	(99)
Net cash used in investing activities	(231)	(3,056)
Cash flows from financing activities:
Proceeds from exercise of stock options	17	6
Repurchase of restricted stock shares for payroll tax withholding requirements	(20)	(11)
Deferred financing costs and other debt-related costs	(20)	(269)
Excess tax benefit relating to stock-based compensation		3
Redemption of noncontrolling investments in joint ventures	(7)	(5)
Distributions to noncontrolling investors in joint ventures	(23)	(19)
Borrowings under credit agreements	1,251	7,079
Issuance of long-term debt		4,000
Proceeds from receivables facility	75	133
Repayments of long-term indebtedness	(1,268)	(7,686)
Net cash provided by financing activities	5	3,231
Net change in cash and cash equivalents	(287)	240
Cash and cash equivalents at beginning of period	509	373
Cash and cash equivalents at end of period	222	613
Supplemental disclosure of cash flow information:
Interest payments	(300)	(175)
Income tax (payments) refunds, net	$ (1)	$ 79

XML

Fair Value (Narrative) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Fair Value Disclosures [Line Items]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0	$ 0
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount	0	0
CVR-related legal liability	24
Interest Rate Swap [Member]
Fair Value Disclosures [Line Items]
Credit risk valuation adjustment, decrease in fair value of liability	5		4
Credit risk valuation adjustment, decrease in fair value of liability, net of tax	$ 3		$ 2

XML

Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 8,951
Goodwill acquired as part of acquisitions during current year	4
Consideration and purchase price allocation adjustments for prior year's acquisitions and other adjustments	(1)
Goodwill, Ending Balance	$ 8,954

XML

Contingencies (Contingencies Narrative) (Details) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015 item	Mar. 31, 2014	Jan. 27, 2014
Loss Contingencies [Line Items]
Business Combination Contingent Consideration Arrangements, Contingent Value Right, Amount Per Share	$ 1.00
Deductible related to litigation and contingent value right	$ 18
Contingent value right, percentage multiplier	90.00%
Number of contingent value rights outstanding	264,544,053
Amount which CVR holders are no longer entitled to payment	312
Contingent value right, period payable after final resolution	60 days
Business Combination, Contingent Consideration, Liability, Noncurrent	256		284
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(9)
Business Combination, Contingent Consideration, Liability, Current	24
Pending Litigation [Member] | Legal Matters Where Negative Outcome is Known or Probable [Member]
Loss Contingencies [Line Items]
Legal Fees	$ 4	$ 3
Class Action Shareholder Federal Securities Cases [Member] | Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member]
Loss Contingencies [Line Items]
Number of legal cases filed	3
Shareholder Derivative Actions [Member] | Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member]
Loss Contingencies [Line Items]
Number of legal cases filed	3

XML

Acquisitions and Divestitures (Tables)

3 Months Ended

Mar. 31, 2015

Acquisitions And Divestitures [Abstract]

Schedule of Net Operating Revenues and Income (Loss) and Assets and Liabilities Classified as Discontinued Operations

	Three Months Ended
	March 31,
	2015		2014
Net operating revenues	$	56	$	89
Loss from operations of entities sold or held for sale
before income taxes		(17)		(7)
Impairment of hospitals sold or held for sale		(1)		(22)
Loss on sale, net		(1)		-
Loss from discontinued operations, before taxes		(19)		(29)
Income tax benefit		(6)		(7)
Loss from discontinued operations, net of taxes	$	(13)	$	(22)

XML

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2012	Dec. 31, 2014
Class of Stock [Line Items]
Total capital stock, shares authorized	400,000,000		400,000,000
Common stock, shares authorized	300,000,000		300,000,000
Preferred stock, shares authorized	100,000,000		100,000,000
Common stock, par value per share	$ 0.01		$ 0.01
Preferred stock, par value per share	$ 0.01		$ 0.01
Preferred stock, shares outstanding	0
Common Stock, Dividends, Per Share, Cash Paid		$ 0.25
Maximum amount of dividends or stock repurchases permissable under the Credit Facility	$ 200,000,000
Annual amount of dividends or stock repurchases permissable under the Credit Facility	25,000,000
Amount available for dividend payments, stock repurchases or Senior Notes repurchases at period end	461,000,000
Open Market Repurchase Program for Common Stock, Adopted December 10, 2014 [Member]
Class of Stock [Line Items]
Maximum number of shares authorized for repurchase			5,000,000
Maximum value of shares authorized under repurchase program			$ 150,000,000

XML

Contingencies

3 Months Ended

Mar. 31, 2015

Contingencies [Abstract]

Commitments and Contingencies Disclosure

16.   CONTINGENCIES

The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

HMA Legal Matters and Related CVR

The CVR agreement entitles the holder to receive a one-time cash payment of up to $1.00 per CVR, subject to downward adjustment based on the final resolution of certain litigation, investigations (whether formal or informal, including subpoenas), or other actions or proceedings related to HMA or its affiliates existing on or prior to July 29, 2013 (the date of the Company’s merger agreement with HMA) as more specifically provided in the CVR agreement (all such matters are referred to as the “HMA Legal Matters”), which include, but are not limited to, investigation and litigation matters as previously disclosed by HMA in public filings with the SEC and described in more detail below. The adjustment reducing the ultimate amount paid to holders of the CVR is determined based on the amount of losses incurred by the Company in connection with the HMA Legal Matters as more specifically provided in the CVR agreement, which generally includes the amount paid for damages, costs, fees and expenses (including, without limitation, attorneys’ fees and expenses), and all fines, penalties, settlement amounts, indemnification obligations and other liabilities (all such losses are referred to as “HMA Losses”). If the aggregate amount of HMA Losses exceeds a deductible of $18 million, then the amount payable in respect of each CVR shall be reduced (but not below zero) by an amount equal to the quotient obtained by dividing: (a) the product of (i) all losses in excess of the deductible and (ii) 90%; by (b) the number of CVRs outstanding on the date on which final resolution of the existing litigation occurs. There are 264,544,053 CVRs outstanding as of the date hereof. If total HMA Losses (including HMA Losses that have occurred to date as noted in the table below) exceed approximately $312 million, then the holders of the CVRs will not be entitled to any payment in respect of the CVRs.

The CVRs do not have a finite payment date.  Any payments the Company makes under the CVR agreement will be payable within 60 days after the final resolution of the HMA Legal Matters. The CVRs are unsecured obligations of CHS and all payments under the CVRs will be subordinated in right of payment to the prior payment in full of all of the Company’s senior obligations (as defined in the CVR agreement), which include outstanding indebtedness of the Company (subject to certain exceptions set forth in the CVR agreement) and the HMA Losses. The CVR agreement permits the Company to acquire all or some of the CVRs, whether in open market transactions, private transactions or otherwise. As of March 31, 2015, the Company had acquired no CVRs.

The following table represents the impact of legal expenses paid or incurred to date and settlements paid or deemed final as of March 31, 2015 on the amounts owed to CVR holders (in millions):

			Allocation of Expenses and Settlement Costs
							Reduction to
	Total Expenses				CHS		Amount Owed
	and Settlement				Responsibility		to CVR Holders
	Cost		Deductible		at 10%		at 90%
As of December 31, 2014	$	24	$	18	$	-	$	6
Settlements paid		-		-		-		-
Legal expenses incurred
and/or paid during
the three months ended
March 31, 2015		3		-		1		2
As of  March 31, 2015	$	27	$	18	$	1	$	8

Amounts owed to CVR holders are dependent on the ultimate resolution of the HMA Legal Matters and determination of HMA Losses incurred. The settlement of any or all of the claims and expenses incurred on behalf of the Company in defending itself will (subject to the deductible) reduce the amounts owed to the CVR holders.

Underlying the CVR agreement are a number of claims included in the HMA Legal Matters asserted against HMA.  The Company has recorded a liability in connection with those claims as part of the acquired assets and liabilities at the date of acquisition pursuant to the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 805 “Business Combinations.”  For the estimate of the Company’s liabilities associated with the HMA Legal Matters that will be covered by the CVR and were not previously accrued by HMA, the Company recorded a liability of $284 million as part of the acquisition accounting for the HMA merger based on the Company’s estimate of fair value of such liabilities as of the date of acquisition.  The decrease in this liability during the three months ended March 31, 2015 was approximately $9 million and the fair value of $256 million is recorded in other long-term liabilities on the accompanying condensed consolidated balance sheet. The remaining portion of the estimated liability for claims underlying the CVR agreement had been previously recorded by HMA, as a probable contingency, and was reflected in the purchase accounting for HMA as an acquired liability.  This amount is $24 million at March 31, 2015 and is recorded in accrued liabilities on the accompanying condensed consolidated balance sheet.  In addition, although legal fees are not included in the amounts currently accrued, such legal fees are taken into account in determining HMA Losses under the CVR agreement. Certain significant HMA Legal Matters underlying these liabilities are discussed in greater detail below.

HMA Matters Recorded at Fair Value

Medicare/Medicaid Billing Lawsuits

Beginning during the week of December 16, 2013, eleven qui tam lawsuits filed by private individuals against HMA were unsealed in various United States district courts. The United States has elected to intervene in all or part of eight of these matters; namely U.S. ex rel. Craig Brummer v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Brummer”); U.S. ex rel. Ralph D. Williams v. Health Management Associates, Inc. et al. (Middle District Georgia) (“Williams”); U.S. ex rel. Scott H. Plantz, M.D. et al. v. Health Management Associates, Inc., et al. (Northern District Illinois) (“Plantz”); U.S. ex rel. Thomas L. Mason, M.D. et al. v. Health Management Associates, Inc. et al. (Western District North Carolina) (“Mason”); U.S. ex rel. Jacqueline Meyer, et al. v. Health Management Associates, Inc., Gary Newsome et al. (“Jacqueline Meyer”) (District of South Carolina); U.S. ex rel. George Miller, et al. v. Health Management Associates, Inc. (Eastern District of Pennsylvania) (“Miller”); U.S. ex rel. Bradley Nurkin v. Health Management Associates, Inc. et al. (Middle District of Florida) (“Nurkin”); and U.S. ex rel. Paul Meyer v. Health Management Associates, Inc. et al. (Southern District Florida) (“Paul Meyer”). The United States has elected to intervene with respect to allegations in these cases that certain HMA hospitals inappropriately admitted patients and then submitted reimbursement claims for treating those individuals to federal healthcare programs in violation of the False Claims Act or that certain HMA hospitals had inappropriate financial relationships with physicians which violated the Stark law, the Anti-Kickback Statute, and the False Claims Act.  Certain of these complaints also allege the same actions violated various state laws which prohibit false claims. The United States has declined to intervene in three of the eleven matters, namely U.S. ex rel. Anita France et al. v. Health Management Associates, Inc. (Middle District Florida) (“France”) which involved allegations of wrongful billing and was recently settled; U.S. ex rel. Sandra Simmons, v. Health Management Associates, Inc. et al. (Eastern District Oklahoma) (“Simmons”) which alleges unnecessary surgery by an employed physician and which was recently partially settled as to all allegations except alleged wrongful termination; and U.S. ex rel. David Napoliello, M.D. v. Health Management Associates, Inc. (Middle District Florida) (“Napoliello”) which alleges inappropriate admissions.  On April 3, 2014, the Multi District Litigation Panel ordered the transfer and consolidation for pretrial proceedings of the eight intervened cases, plus the Napoliello matter, to the District of the District of Columbia under the name In Re: Health Management Associates, Inc. Qui Tam Litigation.  On June 2, 2014, the court entered a stay of this matter until October 6, 2014, which was subsequently extended until February 27, 2015, and again extended until May 27, 2015. The Company intends to defend against the allegations in these matters, but will also be cooperating with the government in the ongoing investigation of these allegations. The Company has been in discussions with the Civil Division of the United States Department of Justice (“DOJ”)regarding the resolutions of these matters. The Company has recently been told that the Criminal Division is continuing to investigate former executive-level employees of HMA, as well as considering whether any HMA entities should be held criminally liable for the acts of the former HMA employees. The Company is voluntarily cooperating with these inquiries and has not been served with any subpoenas or other legal process.

During September 2010, HMA received a letter from the DOJ indicating that an investigation was being conducted to determine whether certain HMA hospitals improperly submitted claims for the implantation of implantable cardioverter defibrillators (“ICDs”). The DOJ’s investigation covers the period commencing with Medicare’s expansion of coverage for ICDs in 2003 to the present. The letter from the DOJ further indicates that the claims submitted by HMA’s hospitals for ICDs and related services need to be reviewed to determine if Medicare coverage and payment was appropriate. During 2010, the DOJ sent similar letters and other requests to a large number of unrelated hospitals and hospital operators across the country as part of a nation-wide review of ICD billing under the Medicare program. The Company is cooperating with the DOJ in its ongoing investigation, which could potentially give rise to claims against HMA and/or certain of its subsidiary hospitals under the False Claims Act or other statutes, regulations or laws. Additionally, the Company is conducting an internal review of hospital medical records related to ICDs that are the subject of the DOJ investigation. The Company has reached an agreement in principle to settle this matter.

Probable Contingencies – HMA 

OIG Investigation of Certain HMA Hospitals’ Relationships with Allegiance

On February 22, 2012 and February 24, 2012, the United States Department of Health and Human Services office of the Inspector General (“OIG”)served subpoenas on certain HMA hospitals relating to those hospitals’ relationships with Allegiance Health Management, Inc. (“Allegiance”). Allegiance, which is unrelated to HMA, is a post-acute healthcare management company that provides intensive outpatient psychiatric (“IOP”) services to patients. The HMA hospitals that were served subpoenas were: (i) Central Mississippi Medical Center in Jackson, Mississippi; (ii) Crossgates River Oaks Hospital in Brandon, Mississippi; (iii) Davis Regional Medical Center in Statesville, North Carolina; (iv) Lake Norman Regional Medical Center in Mooresville, North Carolina; (v) the Medical Center of Southeastern Oklahoma in Durant, Oklahoma; and (vi) Natchez Community Hospital in Natchez, Mississippi. Each of those hospitals has or had a contract with Allegiance. Among other things, the subpoenas seek: (i) documents related to the hospitals’ financial relationships with Allegiance; (ii) documents related to patients who received IOP services from Allegiance at the HMA hospitals, including their patient medical records; (iii) documents relating to complaints or concerns regarding Allegiance’s IOP services at the HMA hospitals; (iv) documents relating to employees, physicians and therapists who were involved with the IOP services provided by Allegiance at the HMA hospitals; and (v) other documents related to Allegiance, including leases, contracts, policies and procedures, training documents, budgets and financial analyses. The period of time covered by the subpoenas is January 1, 2008 through the date of subpoena compliance. The Company will continue to cooperate with the investigations. Prior to the HMA merger, HMA determined thata liability for this claim was probable and a liability was recorded by HMA during the quarter ended December 31, 2013, whichliability was assumed as part of the HMA merger. The Company has reached an agreement in principle to settle this matter.

Department of Justice Investigation of Kyphoplasty Procedures at Certain HMA Hospitals

Several HMA hospitals received letters during 2009 requesting information in connection with a DOJ investigation relating to kyphoplasty procedures. Kyphoplasty is a minimally invasive spinal procedure used to treat vertebral compression fractures. The DOJ is currently investigating hospitals and hospital operators in multiple states to determine whether certain Medicare claims for kyphoplasty were incorrect when billed as an inpatient service rather than as an outpatient service. The DOJ’s investigation originated with a False Claims Act lawsuit against Kyphon, Inc., the company that developed the kyphoplasty procedure. The requested information has been provided to the DOJ and the Company is continuing to cooperate with the investigation. Prior to the HMA merger, HMA determined that a liability for this claim was probable and an incremental liability was recorded by HMA during the quarter ended December 31, 2013, which liability was assumed as part of the HMA merger.

Probable Contingencies - CHS

Implantable Cardioverter Defibrillators (“ICDs”).  The Company was first made aware of this investigation in September 2010, when the Company received a letter from the Civil Division of the DOJ.  The letter advised the Company that an investigation was being conducted to determine whether certain hospitals have improperly submitted claims for payment for ICDs. The period of time covered by the investigation was 2003 to 2010. The Company continues to fully cooperate with the government in this investigation and has provided requested records and documents. On August 30, 2012, the DOJ issued a document entitled, “Medical Review Guidelines/Resolution Model,” which sets out, for the purposes of this investigation, the patient conditions and criteria for the medical necessity of the implantation of ICDs in Medicare beneficiaries and how the DOJ will enforce the repayment obligations of hospitals. The Company has reached an agreement in principle to settle this matter.

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the three months ended March 31, 2015with respect to the Company’s fair value determination in connection with HMA Legal Matters that were not previously accrued by HMA, the estimated liability in connection with HMA Legal Matters that were previously recorded by HMA as a probable contingency, and the remaining contingencies of the Company in respect of which an accrual has been recorded. In addition, future legal fees (which are expensed as incurred) and costs related to possible indemnification and criminal investigation matters associated with the HMA Legal Matters have not been accrued or included in the table below. Furthermore, although not accrued, such costs, if incurred, will be taken into account in determining the total amount of reductions applied to the amounts owed to CVR holders.

	CVR Related		CVR Related Liability		Other
	Liability		for Probable		Probable
	at Fair Value		Contingencies		Contingencies
Balance as of December 31, 2014	$	265	$	29	$	125
Expense		(9)		(5)		15
Cash payments		-		-		(92)
Balance as of March 31, 2015	$	256	$	24	$	48

With respect to the “Other Probable Contingencies” referenced in the chart above, in accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the condensed consolidated balance sheet and are included in the table above in the “Other Probable Contingencies” column. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount.

In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $4 million and $3 million for the three months ended March 31, 2015 and 2014, respectively, and are included in other operating expenses in the accompanying condensed consolidated statements of income.

Matters for which an Outcome Cannot be Assessed

For all of the legal matters below, the Company cannot at this time assess what the outcome may be and is further unable to determine any estimate of loss or range of loss.  Because the matters below are at a preliminary stage and other factors, there are not sufficient facts available to make these assessments. 

Class Action Shareholder Federal Securities Cases.  Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. The Company’s motion to dismiss this case has been fully briefed and remains pending before the court. Case management has been set for May 11, 2015. The Company believes this consolidated matter is without merit and will vigorously defend this case.

Shareholder Derivative Actions.  Three purported shareholder derivative actions have also been filed in the United States District Court for the Middle District of Tennessee; Plumbers and Pipefitters Local Union No. 630 Pension Annuity Trust Fund v. Wayne T. Smith, et al., filed May 24, 2011; Roofers Local No. 149 Pension Fund v. Wayne T. Smith, et al., filed June 21, 2011; and Lambert Sweat v. Wayne T. Smith, et al., filed October 5, 2011. These three cases allege breach of fiduciary duty arising out of allegedly improper inpatient admission practices, mismanagement, waste and unjust enrichment. These cases have been consolidated into a single, consolidated action. The plaintiffs filed an operative amended derivative complaint in these three consolidated actions on March 15, 2012. The Company’s motion to dismiss was argued on June 13, 2013. On September 27, 2013, the court issued an order granting in part and denying in part the Company’s motion to dismiss. On October 14, 2013, the Company filed for a Motion for Reconsideration of the Order Granting in Part and Denying in Part the Motion to Dismiss, a Motion to Stay Discovery, and an unopposed Motion for Extension of Time to File an Answer. The Company’s motion to stay was denied and the Company’s motion for reconsideration was denied on December 12, 2014.  An initial case management order was entered on November 11, 2014, but no trial date has been set. The Company believes all of the plaintiffs’ claims are without merit and will vigorously defend them.

XML

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2015

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill

Balance as of December 31, 2014	$	8,951
Goodwill acquired as part of acquisitions during current year		4
Consideration and purchase price allocation adjustments
for prior year’s acquisitions and other adjustments		(1)
Balance as of March 31, 2015	$	8,954

XML

Other Comprehensive Income (Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Income) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net	$ 241	$ 224
Income (loss) from continuing operations before income taxes	168	(132)
Tax benefit	(56)	56
Net income (loss) attributable to Community Health Systems, Inc. stockholders	79	(112)
Change in Fair Value of Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net	(9)	(18)
Tax benefit	3	7
Net income (loss) attributable to Community Health Systems, Inc. stockholders	(6)	(11)
Change in Unrecognized Pension Cost Components [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of defined benefit pension items - Actuarial losses	(1)
Change in Unrecognized Pension Cost Components [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income (loss) from continuing operations before income taxes	(1)
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$ (1)

XML

Supplemental Consolidating Financial Information

3 Months Ended

Mar. 31, 2015

Supplemental Condensed Consolidating Financial Information [Abstract]

Supplemental Condensed Consolidating Financial Information Disclosure

18.  SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Senior Notes due 2019, 2020 and 2022, which are senior unsecured obligations of CHS, and the 5⅛% Senior Secured Notes due 2018 and 2021 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries.  The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” 

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the condensed consolidated financial statements of the Company, except as noted below: 

•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. 

•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net. 

•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. 

•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances. 

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the Receivables Facility that is further discussed in Note 11.  The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation. 

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods are revised to reflect the status of guarantors or non-guarantors as of March 31, 2015.

Condensed Consolidating Statement of Income
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(5)	$	3,488	$	2,163	$	-	$	5,646
Provision for bad debts		-		-		447		288		-		735
Net operating revenues		-		(5)		3,041		1,875		-		4,911
Operating costs and expenses:
Salaries and benefits		-		-		1,222		1,035		-		2,257
Supplies		-		-		492		270		-		762
Other operating expenses		-		-		708		391		-		1,099
Government settlement and related costs		-		-		8		-		-		8
Electronic health records incentive reimbursement		-		-		(17)		(9)		-		(26)
Rent		-		-		61		55		-		116
Depreciation and amortization		-		-		200		96		-		296
Total operating costs and expenses		-		-		2,674		1,838		-		4,512
Income from operations		-		(5)		367		37		-		399
Interest expense, net		-		21		211		9		-		241
Loss from early extinguishment of debt		-		8		-		-		-		8
Equity in earnings of unconsolidated affiliates		(79)		(104)		(5)		-		170		(18)
Income from continuing operations before income taxes		79		70		161		28		(170)		168
Provision for (benefit from) income taxes		-		(9)		61		4		-		56
Income from continuing operations		79		79		100		24		(170)		112
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		-		(11)		-		(11)
Impairment of hospitals sold or held for sale		-		-		(1)		-		-		(1)
Loss on sale, net		-		-		2		(3)		-		(1)
Loss from discontinued operations, net of taxes		-		-		1		(14)		-		(13)
Net income		79		79		101		10		(170)		99
Less: Net income attributable to noncontrolling interests		-		-		-		20		-		20
Net income attributable to Community Health Systems,
Inc. stockholders	$	79	$	79	$	101	$	(10)	$	(170)	$	79

Condensed Consolidating Statement of Loss
Three Months Ended March 31, 2014
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(4)	$	3,119	$	1,760	$	-	$	4,875
Provision for bad debts		-		-		476		223		-		699
Net operating revenues		-		(4)		2,643		1,537		-		4,176
Operating costs and expenses:
Salaries and benefits		-		-		1,147		845		-		1,992
Supplies		-		-		417		215		-		632
Other operating expenses		-		-		663		356		-		1,019
Electronic health records incentive reimbursement		-		-		(30)		(10)		-		(40)
Rent		-		-		54		44		-		98
Depreciation and amortization		-		-		189		66		-		255
Amortization of software to be abandoned		-		-		26		16		-		42
Total operating costs and expenses		-		-		2,466		1,532		-		3,998
Income from operations		-		(4)		177		5		-		178
Interest expense, net		-		40		172		12		-		224
Loss from early extinguishment of debt		-		73		-		-		-		73
Equity in earnings of unconsolidated affiliates		112		27		23		-		(173)		(11)
Impairment of long-lived assets		-		-		24		-		-		24
Income from continuing operations before income taxes		(112)		(144)		(42)		(7)		173		(132)
Provision for (benefit from) income taxes		-		(32)		(16)		(8)		-		(56)
Income from continuing operations		(112)		(112)		(26)		1		173		(76)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-		-		(3)		(1)		-		(4)
Impairment of hospitals sold or held for sale		-		-		-		(18)		-		(18)
Loss from discontinued operations, net of taxes		-		-		(3)		(19)		-		(22)
Net loss		(112)		(112)		(29)		(18)		173		(98)
Less: Net income attributable to noncontrolling interests		-		-		-		14		-		14
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(112)	$	(112)	$	(29)	$	(32)	$	173	$	(112)

Condensed Consolidating Statement of Comprehensive Income
Three Months Ended March 31, 2015
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net income	$	79	$	79	$	101	$	10	$	(170)	$	99
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(9)		(9)		-		-		9		(9)
Net change in fair value of available-for-sale securities, net
of tax		1		1		1		-		(2)		1
Amortization and recognition of unrecognized pension
cost components, net of tax		1		1		1		-		(2)		1
Other comprehensive income (loss)		(7)		(7)		2		-		5		(7)
Comprehensive income		72		72		103		10		(165)		92
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		20		-		20
Comprehensive income (loss) attributable to Community
Health Systems, Inc. stockholders	$	72	$	72	$	103	$	(10)	$	(165)	$	72

Condensed Consolidating Statement of Comprehensive Loss
Three Months Ended March 31, 2014
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net loss	$	(112)	$	(112)	$	(29)	$	(18)	$	173	$	(98)
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		9		9		-		-		(9)		9
Net change in fair value of available-for-sale securities, net
of tax		-		-		-		-		-		-
Amortization and recognition of unrecognized pension
cost components, net of tax		-		-		-		-		-		-
Other comprehensive income (loss)		9		9		-		-		(9)		9
Comprehensive loss		(103)		(103)		(29)		(18)		164		(89)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		14		-		14
Comprehensive loss attributable to Community
Health Systems, Inc. stockholders	$	(103)	$	(103)	$	(29)	$	(32)	$	164	$	(103)

Condensed Consolidating Balance Sheet
March 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	37	$	185	$	-	$	222
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,430		2,176		-		3,606
Supplies		-		-		377		184		-		561
Deferred income taxes		341		-		-		-		-		341
Prepaid expenses and taxes		-		-		131		58		-		189
Other current assets		-		-		329		178		-		507
Total current assets		341		-		2,304		2,781		-		5,426
Intercompany receivable		1,257		16,512		3,314		6,131		(27,214)		-
Property and equipment, net		-		-		6,613		3,478		-		10,091
Goodwill		-		-		5,483		3,471		-		8,954
Other assets, net		6		303		1,817		1,164		(642)		2,648
Net investment in subsidiaries		3,361		18,435		7,643		-		(29,439)		-
Total assets	$	4,965	$	35,250	$	27,174	$	17,025	$	(57,295)	$	27,119
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	163	$	54	$	12	$	-	$	229
Accounts payable		-		1		873		318		-		1,192
Income tax payable		13		-		-		-		-		13
Deferred income taxes		23		-		-		-		-		23
Accrued interest		-		155		1		1		-		157
Accrued liabilities		4		-		1,051		492		-		1,547
Total current liabilities		40		319		1,979		823		-		3,161
Long-term debt		-		15,885		127		728		-		16,740
Intercompany payable		-		14,822		20,071		14,117		(49,010)		-
Deferred income taxes		844		-		-		-		-		844
Other long-term liabilities		-		862		1,113		361		(642)		1,694
Total liabilities		884		31,888		23,290		16,029		(49,652)		22,439
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		520		-		520
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,101		1,294		1,471		523		(3,288)		2,101
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(70)		(70)		(17)		-		87		(70)
Retained earnings		2,056		2,138		2,430		(126)		(4,442)		2,056
Total Community Health Systems, Inc.
stockholders’ equity		4,081		3,362		3,884		397		(7,643)		4,081
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		79		-		79
Total equity		4,081		3,362		3,884		476		(7,643)		4,160
Total liabilities and equity	$	4,965	$	35,250	$	27,174	$	17,025	$	(57,295)	$	27,119

Condensed Consolidating Balance Sheet
December 31, 2014
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	368	$	141	$	-	$	509
Patient accounts receivable, net of allowance
for doubtful accounts		-		-		1,272		2,137		-		3,409
Supplies		-		-		373		184		-		557
Prepaid income taxes		30		-		-		-		-		30
Deferred income taxes		341		-		-		-		-		341
Prepaid expenses and taxes		-		-		138		54		-		192
Other current assets		-		-		356		172		-		528
Total current assets		371		-		2,507		2,688		-		5,566
Intercompany receivable		1,199		16,560		2,532		7,877		(28,168)		-
Property and equipment, net		-		-		6,548		3,621		-		10,169
Goodwill		-		-		5,480		3,471		-		8,951
Other assets, net		15		302		1,874		1,179		(635)		2,735
Net investment in subsidiaries		3,290		18,229		7,399		-		(28,918)		-
Total assets	$	4,875	$	35,091	$	26,340	$	18,836	$	(57,721)	$	27,421
LIABILITIES AND EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	163	$	61	$	11	$	-	$	235
Accounts payable		-		-		909		384		-		1,293
Deferred income taxes		23		-		-		-		-		23
Accrued interest		-		225		2		-		-		227
Accrued liabilities		4		-		1,249		558		-		1,811
Total current liabilities		27		388		2,221		953		-		3,589
Long-term debt		-		15,820		139		722		-		16,681
Intercompany payable		-		14,752		19,066		15,795		(49,613)		-
Deferred income taxes		845		-		-		-		-		845
Other long-term liabilities		-		841		1,140		346		(635)		1,692
Total liabilities		872		31,801		22,566		17,816		(50,248)		22,807
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		531		-		531
Equity:
Community Health Systems, Inc. stockholders’
equity:
Preferred stock		-		-		-		-		-		-
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,095		1,208		1,369		528		(3,105)		2,095
Treasury stock, at cost		(7)		-		-		-		-		(7)
Accumulated other comprehensive loss		(63)		(63)		(25)		5		83		(63)
Retained earnings		1,977		2,145		2,430		(124)		(4,451)		1,977
Total Community Health Systems, Inc.
stockholders’ equity		4,003		3,290		3,774		409		(7,473)		4,003
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		80		-		80
Total equity		4,003		3,290		3,774		489		(7,473)		4,083
Total liabilities and equity	$	4,875	$	35,091	$	26,340	$	18,836	$	(57,721)	$	27,421

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2015
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(10)	$	(123)	$	23	$	49	$	-	$	(61)
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(11)		(2)		-		(13)
Purchases of property and equipment		-		-		(199)		(42)		-		(241)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		4		58		-		62
Proceeds from sale of property and equipment		-		-		-		3		-		3
Purchases of available-for-sale securities		-		-		(22)		(37)		-		(59)
Proceeds from sales of available-for-sale securities		-		-		19		37		-		56
Increase in other investments		-		-		(30)		(9)		-		(39)
Net cash used in investing activities		-		-		(239)		8		-		(231)
Cash flows from financing activities:
Proceeds from exercise of stock options		17		-		-		-		-		17
Repurchase of restricted stock shares for payroll
tax withholding requirements		(20)		-		-		-		-		(20)
Deferred financing costs and other
debt-related costs		-		(20)		-		-		-		(20)
Redemption of noncontrolling investments in joint
ventures		-		-		-		(7)		-		(7)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(23)		-		(23)
Changes in intercompany balances with
affiliates, net		13		77		(101)		11		-		-
Borrowings under credit agreements		-		1,250		1		-		-		1,251
Issuance of long-term debt		-		-		-		-		-		-
Proceeds from receivables facility		-		-		-		75		-		75
Repayments of long-term indebtedness		-		(1,184)		(15)		(69)		-		(1,268)
Net cash provided by (used in) financing
activities		10		123		(115)		(13)		-		5
Net change in cash and cash equivalents		-		-		(331)		44		-		(287)
Cash and cash equivalents at beginning of period		-		-		368		141		-		509
Cash and cash equivalents at end of period	$	-	$	-	$	37	$	185	$	-	$	222

Condensed Consolidating Statement of Cash Flows
Three Months Ended March 31, 2014
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	73	$	298	$	62	$	(368)	$	-	$	65
Cash flows from investing activities:
Acquisitions of facilities and other related
equipment		-		-		(2,760)		(14)		-		(2,774)
Purchases of property and equipment		-		-		(143)		(38)		-		(181)
Purchases of available-for-sale securities		-		-		-		(78)		-		(78)
Proceeds from sales of available-for-sale securities		-		-		-		76		-		76
Increase in other investments		-		-		(75)		(24)		-		(99)
Net cash used in investing activities		-		-		(2,978)		(78)		-		(3,056)
Cash flows from financing activities:
Proceeds from exercise of stock options		6		-		-		-		-		6
Repurchase of restricted stock shares for payroll
tax withholding requirements		(11)		-		-		-		-		(11)
Deferred financing costs and other
debt-related costs		-		(269)		-		-		-		(269)
Excess tax benefit relating to
stock-based compensation		3		-		-		-		-		3
Redemption of noncontrolling investments in joint
ventures		-		-		-		(5)		-		(5)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(19)		-		(19)
Changes in intercompany balances with
affiliates, net		(71)		(3,417)		3,117		371		-		-
Borrowings under credit agreements		-		7,062		17		-		-		7,079
Issuance of long-term debt		-		4,000		-		-		-		4,000
Proceeds from receivables facility		-		-		-		133		-		133
Repayments of long-term indebtedness		-		(7,674)		(7)		(5)		-		(7,686)
Net cash provided by (used in) financing
activities		(73)		(298)		3,127		475		-		3,231
Net change in cash and cash equivalents		-		-		211		29		-		240
Cash and cash equivalents at beginning of period		-		-		239		134		-		373
Cash and cash equivalents at end of period	$	-	$	-	$	450	$	163	$	-	$	613

XML

Equity Investments (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 488		$ 470
Equity in earnings of unconsolidated affiliates	$ 18	$ 11
Four Hospitals in Las Vegas, Nevada [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	27.50%
One Hospital in Las Vegas, Nevada [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	26.10%
Three Hospitals in Macon Georgia, [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	38.00%
HealthTrust [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	25.10%

XML

Basis of Presentation and Significant Accounting Policies

3 Months Ended

Mar. 31, 2015

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies Disclosure

1.  BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements of Community Health Systems, Inc. (the “Parent” or “Parent Company”) and its subsidiaries (the “Company”) as of March 31, 2015 and December 31, 2014 and for the three-month periods ended March 31, 2015 and 2014, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for such periods. All intercompany transactions and balances have been eliminated. The results of Health Management Associates, Inc. (“HMA”) are included from January 27, 2014, the date of the HMA merger. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2015. Certain information and disclosures normally included in the notes to condensed consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes the disclosures are adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2014, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2015.

Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity on the condensed consolidated balance sheets to distinguish between the interests of the Parent Company and the interests of the noncontrolling owners. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the condensed consolidated balance sheets.

During the three months ended March 31, 2014, the Company made the decision to sell several smaller hospitals and entered into definitive agreements to sell two hospitals. Since March 31, 2014, the Company made the decision to sell two additional hospitals. The condensed consolidated statement of income for the three months ended March 31, 2014 has been restated to reclassify the results of operations for these hospitals that were owned or leased in 2014 to discontinued operations.

Throughout these notes to the condensed consolidated financial statements, Community Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

Allowance for Doubtful Accounts. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated businesses.

The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. For all other non-self-pay payor categories, the Company reserves 100% of all accounts aging over 365 days from the date of discharge. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company’s collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company’s collection of accounts receivable and the estimates of the collectability of future accounts receivable and are considered in the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net revenue less provision for bad debts, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts), recognized during the three months ended March 31, 2015 and 2014, were as follows (in millions):

	Three Months Ended
	March 31,
	2015		2014
Medicare	$	1,398	$	1,261
Medicaid		586		459
Managed Care and other third-party payors		2,946		2,450
Self-pay		716		705
Total	$	5,646	$	4,875

Electronic Health Records Incentive Reimbursement. The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology.  The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

 The Company recognized approximately $26 million and $40 million for the three months ended March 31, 2015 and 2014, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology.  These incentive reimbursements are presented as a reduction of operating costs and expenses on the condensed consolidated statements of income.  The Company received cash related to the incentive reimbursement for HITECH incentives of approximately $54 million and $62 million for the three months ended March 31, 2015 and 2014, respectively. The Company recorded$75 million and $93 million as deferred revenue in connection with the receipt of these cash payments at March 31, 2015 and March 31, 2014, respectively, as all criteria for gain recognition had not been met. 

New Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2016. However, the FASB recently decided to defer the effective date by one year, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operations and cash flows.

XML

Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidated Statements of Comprehensive Income (Loss) [Abstract]
Net income (loss)	$ 99	$ (98)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(9)	9
Net change in fair value of available-for-sale securities, net of tax	1
Amortization and recognition of unrecognized pension cost components, net of tax	1
Other comprehensive (loss) income	(7)	9
Comprehensive income (loss)	92	(89)
Less: Comprehensive income attributable to noncontrolling interests	20	14
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	$ 72	$ (103)

XML

Long-Term Debt

3 Months Ended

Mar. 31, 2015

Long-term Debt [Abstract]

Long-Term Debt Disclosure

11.  LONG-TERM DEBT

Long-term debt consists of the following (in millions): 

	March 31,		December 31,
	2015		2014
Credit Facility:
Term A Loan	$	925	$	950
Term D Loan		4,544		4,555
Term E Loan		-		1,660
Term F Loan		1,700		-
Revolving credit loans		62		-
8% Senior Notes due 2019		2,017		2,018
7⅛% Senior Notes due 2020		1,200		1,200
5⅛% Senior Secured Notes due 2018		1,600		1,600
5⅛% Senior Secured Notes due 2021		1,000		1,000
6⅞% Senior Notes due 2022		3,000		3,000
Receivables Facility		623		614
Capital lease obligations		215		228
Other		83		91
Total debt		16,969		16,916
Less current maturities		(229)		(235)
Total long-term debt	$	16,740	$	16,681

Credit Facility

The Company’s wholly-owned subsidiary, CHS, has senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent. In connection with the HMA merger, the Company and CHS entered into a third amendment and restatement of its credit facility (the “Credit Facility”), providing for additional financing and recapitalization of certain of the Company’s term loans, including (i) the replacement of the revolving credit facility with a new $1.0 billion revolving facility maturing in 2019 (the “Revolving Facility”), (ii) the addition of a new $1.0 billion Term A facility due 2019 (the “Term A Facility”), (iii) a Term D facility in an aggregate principal amount equal to approximately $4.6 billion due 2021 (which includes certain term C loans that were converted into such Term D facility (collectively, the “Term D Facility”)), (iv) the conversion of certain term C loans into Term E Loans and the borrowing of new Term E Loans in an aggregate principal amount of approximately $1.7 billion due 2017 and (v) the addition of flexibility commensurate with the Company’s post-acquisition structure. In addition to funding a portion of the consideration in connection with the HMA merger, some of the proceeds of the Term A Facility and Term D Facility were used to refinance the outstanding $637 million existing term A facility due 2016 and the $60 million of term B loans due 2014, respectively. The Revolving Facility included a subfacility for letters of credit. On March 9, 2015, CHS entered into a first amendment and incremental term loan assumption agreement to refinance the existing Term E Loans due 2017 into Term F Loans due 2018, in an original aggregated principal amount of $1.7 billion dollars.

The loans under the Credit Facility bear interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the Federal Funds Effective Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR.  Loans in respect of the Revolving Facility and the Term A Facility will accrue interest at a rate per annum initially equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. In addition, the margin in respect of the Revolving Facility and the Term A Facility will be subject to adjustment determined by reference to a leverage-based pricing grid. Loans in respect of the Term D Facility and the Term F Facility will accrue interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate Borrowings. The Term D Facility will be subject to a 1.00% LIBOR floor and a 2.00%Alternate Base Rate floor.

The term loan facility must be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 50%, subject to reduction to a lower percentage based on the Company’s leverage ratio (as defined in the Credit Facility generally as the ratio of total debt on the date of determination to the Company’s EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions are permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements. 

The borrower under the Credit Facility is CHS. All of the obligations under the Credit Facility are unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees are secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries. 

CHS has agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to Eurodollar rate loans under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit will also receive a customary fronting fee and other customary processing charges. CHS is obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility.

The Credit Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s and its subsidiaries’ ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) make capital expenditures, (7) engage in mergers, acquisitions and asset sales, (8) conduct transactions with affiliates, (9) alter the nature of the Company’s businesses, (10) grant certain guarantees with respect to physician practices, (11) engage in sale and leaseback transactions or (12) change the Company’s fiscal year. The Company is also required to comply with specified financial covenants (consisting of a maximum secured net leverage ratio and an interest coverage ratio) and various affirmative covenants. 

Events of default under the Credit Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the credit agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to a grace period, (4) bankruptcy events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control, (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the administrative agent or lenders under the Credit Facility. 

As of March 31, 2015, the availability for additional borrowings under the Credit Facility, after consideration of the $62 million outstanding at that date, was approximately $1.0 billion pursuant to the Revolving Facility, of which $83 million was set aside for outstanding letters of credit. CHS has the ability to amend the Credit Facility to provide for one or more tranches of term loans or increases in the Revolving Facility in an aggregate principal amount of $1.5 billion, which CHS has not yet accessed. As of March 31, 2015, the weighted-average interest rate under the Credit Facility, excluding swaps, was 4.4%. 

8% Senior Notes due 2019 

On November 22, 2011, CHS completed its offering of $1.0 billion aggregate principal amount of 8% Senior Notes due 2019 (the “8% Senior Notes”), which were issued in a private placement.  The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes and related fees and expenses.  On March 21, 2012, CHS completed the secondary offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes, which were issued in a private placement (at a premium of 102.5%).  The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes, to pay related fees and expenses and for general corporate purposes.  The 8% Senior Notes bear interest at 8% per annum, payable semiannually in arrears on May 15 and November 15, commencing May 15, 2012. Interest on the 8% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. 

Except as set forth below, CHS is not entitled to redeem the 8% Senior Notes prior to November 15, 2015. 

Prior to November 15, 2015, CHS may redeem some or all of the 8% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 8% Senior Notes indenture. On and after November 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
November 15, 2015 to November 14, 2016	104.000	%
November 15, 2016 to November 14, 2017	102.000	%
November 15, 2017 to November 15, 2019	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 8% Senior Notes, as a result of an exchange offer made by CHS, substantially all of the 8% Senior Notes issued in November 2011 and March 2012 were exchanged in May 2012 for new notes (the “8% Exchange Notes”) having terms substantially identical in all material respects to the 8% Senior Notes (except that the 8% Exchange Notes were issued under a registration statement pursuant to the Securities Act of 1933, as amended (the “1933 Act”)). References to the 8% Senior Notes shall also be deemed to include the 8% Exchange Notes unless the context provides otherwise. 

7⅛% Senior Notes due 2020 

On July 18, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.2 billion aggregate principal amount of 7⅛% Senior Notes due 2020 (the “7⅛% Senior Notes”).  The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount plus accrued interest of CHS’ outstanding 8⅞% Senior Notes, to pay for consents delivered in connection therewith, to pay related fees and expenses, and for general corporate purposes. The 7⅛% Senior Notes bear interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15, commencing January 15, 2013. Interest on the 7⅛% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. 

Except as set forth below, CHS is not entitled to redeem the 7⅛% Senior Notes prior to July 15, 2016. 

Prior to July 15, 2015, CHS is entitled, at its option, to redeem a portion of the 7⅛% Senior Notes (not to exceed 35% of the outstanding principal amount) at a redemption price equal to 107.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings.  Prior to July 15, 2016, CHS may redeem some or all of the 7⅛% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 7⅛% Senior Notes indenture. On and after July 15, 2016, CHS is entitled, at its option, to redeem all or a portion of the 7⅛% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
July 15, 2016 to July 14, 2017	103.563	%
July 15, 2017 to July 14, 2018	101.781	%
July 15, 2018 to July 15, 2020	100.000	%

5⅛% Senior Secured Notes due 2018 

On August 17, 2012, CHS completed an underwritten public offering under its automatic shelf registration filed with the SEC of $1.6 billion aggregate principal amount of 5⅛% Senior Secured Notes due 2018 (the “2018 Senior Secured Notes”).  The net proceeds from this issuance, together with available cash on hand, were used to finance the prepayment of $1.6 billion of the outstanding term loans due 2014 under the Credit Facility and related fees and expenses.  The 2018 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on August 15 and February 15, commencing February 15, 2013. Interest on the 2018 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2018 Senior Secured Notes are secured by a first-priority lien subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2018 Senior Secured Notes on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. 

Except as set forth below, CHS is not entitled to redeem the 2018 Senior Secured Notes prior to August 15, 2015. 

Prior to August 15, 2015, CHS is entitled, at its option, to redeem a portion of the 2018 Senior Secured Notes (not to exceed 35% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings.  Prior to August 15, 2015, CHS may redeem some or all of the 2018 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2018 Senior Secured Notes indenture. On and after August 15, 2015, CHS is entitled, at its option, to redeem all or a portion of the 2018 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
August 15, 2015 to August 14, 2016	102.563	%
August 15, 2016 to August 14, 2017	101.281	%
August 15, 2017 to August 15, 2018	100.000	%

5⅛% Senior Secured Notes due 2021 

On January 27, 2014, CHS issued $1.0 billion aggregate principal amount of 5⅛% Senior Secured Notes due 2021 (the “2021 Senior Secured Notes”) in connection with the HMA merger, which were issued in a private placement.  The net proceeds from this issuance were used to finance the HMA merger.  The 2021 Senior Secured Notes bear interest at 5.125% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 2021 Senior Secured Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 2021 Senior Secured Notes are secured by a first-priority lien, subject to a shared lien of equal priority with certain other obligations, including obligations under the Credit Facility, and subject to prior ranking liens permitted by the indenture governing the 2021 Senior Secured Notes, on substantially the same assets, subject to certain exceptions, that secure CHS’ obligations under the Credit Facility. 

Except as set forth below, CHS is not entitled to redeem the 2021 Senior Secured Notes prior to February 1, 2017. 

Prior to February 1, 2017, CHS is entitled, at its option, to redeem a portion of the 2021 Senior Secured Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 105.125% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain equity offerings.  Prior to February 1, 2017, CHS may redeem some or all of the 2021 Senior Secured Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 2021 Senior Secured Notes indenture. On and after February 1, 2017, CHS is entitled, at its option, to redeem all or a portion of the 2021 Senior Secured Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
February 1, 2017 to January 31, 2018	103.844	%
February 1, 2018 to January 31, 2019	102.563	%
February 1, 2019 to January 31, 2020	101.281	%
February 1, 2020 to January 31, 2021	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 2021 Senior Secured Notes, as a result of an exchange offer made by CHS, all of the 2021 Senior Secured Notes issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 2021 Senior Secured Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act).  References to the 2021 Senior Secured Notes shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise.

6⅞% Senior Notes due 2022 

On January 27, 2014, CHS issued $3.0 billion aggregate principal amount of 6⅞% Senior Notes due 2022 (the “6⅞% Senior Notes”) in connection with the HMA merger, which were issued in a private placement.  The net proceeds from this issuance were used to finance the HMA merger.  The 6⅞% Senior Notes bear interest at 6.875% per annum, payable semiannually in arrears on February 1 and August 1, commencing August 1, 2014. Interest on the 6⅞% Senior Notes accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. 

Except as set forth below, CHS is not entitled to redeem the 6⅞% Senior Notes prior to February 1, 2018. 

Prior to February 1, 2018, CHS is entitled, at its option, to redeem a portion of the 6⅞% Senior Notes (not to exceed 40% of the outstanding principal amount) at a redemption price equal to 106.875% of the principal amount of the notes redeemed plus accrued and unpaid interest, with the proceeds from certain public equity offerings.  Prior to February 1, 2018, CHS may redeem some or all of the 6⅞% Senior Notes at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the 6⅞% Senior Notes indenture. On and after February 1, 2018, CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below: 

Period	Redemption Price
February 1, 2018 to January 31, 2019	103.438	%
February 1, 2019 to January 31, 2020	101.719	%
February 1, 2020 to January 31, 2022	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 6⅞% Senior Notes, as a result of an exchange offer made by CHS, all of the 6⅞% Senior Notes issued in January 2014 were exchanged in October 2014 for new notes (the “6⅞% Exchange Notes”) having terms substantially identical in all material respects to the 6⅞% Senior Notes (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act).  References to the 6⅞% Senior Notes shall be deemed to be the 6⅞% Exchange Notes unless the context provides otherwise.

Receivables Facility 

On March 21, 2012, CHS and certain of its subsidiaries entered into an accounts receivable loan agreement (the “Receivables Facility”) with a group of lenders and banks, Credit Agricolé Corporate and Investment Bank, as a managing agent and as the administrative agent, and The Bank of Nova Scotia, as a managing agent.  On March 7, 2013, CHS and certain of its subsidiaries amended the Receivables Facility to add an additional managing agent, The Bank of Tokyo-Mitsubishi UFJ, Ltd., to increase the size of the facility from $300 million to $500 million and to extend the scheduled termination date. Additional subsidiaries of the Company also agreed to participate in the Receivables Facility as of that date. On March 31, 2014, CHS and certain of its subsidiaries amended the Receivables Facility to increase the size of the facility from $500 million to $700 million and to extend the scheduled termination date. Additional subsidiaries of the Company also agreed to participate in the Receivables Facility as of that date. The existing and future non-self pay patient-related accounts receivable (the “Receivables”) for certain of the Company’s hospitals serves as collateral for the outstanding borrowings under the Receivables Facility. The interest rate on the borrowings is based on the commercial paper rate plus an applicable interest rate spread.  Unless earlier terminated or subsequently extended pursuant to its terms, the Receivables Facility will expire on March 21, 2017, subject to customary termination events that could cause an early termination date.  The Company maintains effective control over the Receivables because, pursuant to the terms of the Receivables Facility, the Receivables are sold from certain of the Company’s subsidiaries to CHS, which then sells or contributes the Receivables to a special-purpose entity that is wholly-owned by CHS.  The wholly-owned special-purpose entity in turn grants security interests in the Receivables in exchange for borrowings obtained from the group of third-party lenders and banks of up to $700 million outstanding from time to time based on the availability of eligible Receivables and other customary factors. The group of third-party lenders and banks do not have recourse to the Company or its subsidiaries beyond the assets of the wholly-owned special-purpose entity that collateralizes the loan.  The Receivables and other assets of the wholly-owned special-purpose entity will be available first and foremost to satisfy the claims of the creditors of such entity. The outstanding borrowings pursuant to the Receivables Facility at March 31, 2015 totaled $623 million and are classified as long-term debt on the condensed consolidated balance sheet. At March 31, 2015, the carrying amount of Receivables included in the Receivables Facility totaled approximately $1.3 billion and is included in patient accounts receivable on the condensed consolidated balance sheet. 

Loss from Early Extinguishment of Debt 

The financing transactions discussed above resulted in a loss from early extinguishment of debt of $8 million and $73 million for the three months ended March 31, 2015 and 2014, respectively, and an after-tax loss of $5 million and $45 million for the three months ended March 31, 2015 and 2014, respectively. 

Other Debt

As of March 31, 2015, other debt consisted primarily of the mortgage obligation on the Company’s corporate headquarters and other obligations maturing in various installments through 2020.

To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to seven separate interest swap agreements in effect at March 31, 2015, with an aggregate notional amount for currently effective swaps of $1.3 billion, and six forward-starting swap agreements with an aggregate notional amount of $1.7 billion. On each of these swaps, the Company receives a variable rate of interest based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. The Company currently pays, on a quarterly basis, interest on the Revolving Facility and the Term A Facility at a rate per annum equal to LIBOR plus 275 basis points. Loans in respect of the Term D Facility and the Term F Facility accrue interest at a rate per annum equal to LIBOR plus 325 basis points. The Term D Facility is also subject to a 100 basis point LIBOR floor and a 200 basis point Alternate Base Rate floor. See Note 12 for additional information regarding these swaps.

The Company paid interest of $300 million and $175 million on borrowings during the three months ended March 31, 2015 and 2014, respectively. Subsequent to the issuance of the Company’s 2014 Quarterly Report on Form 10-Q for the three-month period ended March 31, 2014, the Company determined that it had incorrectly reported cash paid for interest during the three months ended March 31, 2014 of $280 million instead of the correct amount of $175million. The Company concluded that this error was immaterial to its previously reported consolidated financial statements and had no impact on its consolidated financial position, results of operations, or cash flows. Correct amounts were reported in all subsequent quarterly and annual financial reports during 2014.

XML

Supplemental Condensed Consolidating Financial Information (Narrative) (Details)	3 Months Ended
	Mar. 31, 2015
Supplemental Condensed Consolidating Financial Information [Abstract]
Percentage of owned domestic subsidiaries which guaranteed senior notes	100.00%

XML

Fair Value (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$ 285	$ 280
Trading securities	58	55
Total assets	343	335
Contingent Value Right (CVR)	6	6
CVR-related legal liability	256	265
Fair value of interest rate swap agreements	81	68
Total liabilities	343	339
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	156	151
Trading securities	58	55
Total assets	214	206
Contingent Value Right (CVR)	6	6
Total liabilities	6	6
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	129	129
Total assets	129	129
Fair value of interest rate swap agreements	81	68
Total liabilities	81	68
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
CVR-related legal liability	256	265
Total liabilities	$ 256	$ 265

XML

Fair Value of Financial Instruments (Schedule of Effective Portion of the Pre-tax Loss Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income) (Details) (Interest Expense [Member], USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion)	$ 9	$ 18

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 29, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	COMMUNITY HEALTH SYSTEMS INC
Entity Central Index Key	0001108109
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Trading Symbol	CYH
Amendment Flag	false
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		118,034,114

XML

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2015

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments Disclosure

12.  FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of March 31, 2015 and December 31, 2014, and valuation methodologies considered appropriate. The estimates presented are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions): 

	March 31, 2015				December 31, 2014
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	222	$	222	$	509	$	509
Available-for-sale securities		285		285		280		280
Trading securities		58		58		55		55
Liabilities:
Contingent Value Right		6		6		6		6
Credit Facility		7,231		7,249		7,165		7,143
8% Senior Notes		2,017		2,129		2,018		2,139
7⅛% Senior Notes		1,200		1,277		1,200		1,282
2018 Senior Secured Notes		1,600		1,655		1,600		1,655
2021 Senior Secured Notes		1,000		1,034		1,000		1,041
6⅞% Senior Notes		3,000		3,211		3,000		3,194
Receivables Facility and other debt		706		706		705		705

The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 13.  The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation.  The Company utilizes the market approach and obtains indicative pricing from the administrative agent to the Credit Facility to determine fair values or through publicly available subscription services such as Bloomberg where relevant. 

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months). 

Available-for-sale securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques. 

Trading securities.  Estimated fair value is based on closing price as quoted in public markets. 

Contingent Value Right. Estimated fair value is based on the closing price as quoted on the public market where the CVR is traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions. 

8% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

7⅛% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

2018 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes. 

2021 Senior Secured Notes.  Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Notes.  Estimated fair value is based on the closing market price for these notes. 

Receivables Facility and other debt.  The carrying amount of the Receivables Facility and all other debt approximates fair value due to the nature of these obligations. 

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. 

The Company assesses the effectiveness of its hedge instruments on a quarterly basis. For the three months ended March 31, 2015 and 2014, the Company completed an assessment of the cash flow hedge instruments and determined the hedges to be highly effective. The Company has also determined that the ineffective portion of the hedges do not have a material effect on the Company’s consolidated financial position, operations or cash flows. The counterparties to the interest rate swap agreements expose the Company to credit risk in the event of nonperformance. However, at March 31, 2015, all of the swap agreements entered into by the Company were in a net liability position such that the Company would be required to make the net settlement payments to the counterparties; the Company does not anticipate nonperformance by those counterparties. The Company does not hold or issue derivative financial instruments for trading purposes. 

Interest rate swaps consisted of the following at March 31, 2015:  

Swap #	Notional Amount (in millions)		Fixed Interest Rate		Termination Date	Fair Value (in millions)
1	$	300	3.447	%	August 6, 2016	$	12
2		100	3.401	%	August 19, 2016		4
3		200	3.429	%	August 19, 2016		8
4		200	3.500	%	August 30, 2016		8
5		100	3.005	%	November 30, 2016		4
6		200	2.055	%	July 25, 2019		5
7		200	2.059	%	July 25, 2019		5
8		400	1.882	%	August 30, 2019		1	(1)
9		200	2.515	%	August 30, 2019		5	(1)
10		200	2.613	%	August 30, 2019		6	(2)
11		300	2.041	%	August 30, 2020		1	(1)
12		300	2.738	%	August 30, 2020		10	(1)
13		300	2.892	%	August 30, 2020		12	(2)

___________________

(1) This interest rate swap becomes effective August 28, 2015.

(2) This interest rate swap becomes effective August 30, 2015.

The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Interest rate swaps are entered into to manage interest rate fluctuation risk associated with the term loans in the Credit Facility. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the condensed consolidated statement of financial position. The Company designates its interest rate swaps as cash flow hedges. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. 

Assuming no change in March 31, 2015 interest rates, approximately $48 million of interest expense resulting from the spread between the fixed and floating rates defined in each interest rate swap agreement will be recognized during the next 12 months. If interest rate swaps do not remain highly effective as a cash flow hedge, the derivatives’ gains or losses resulting from the change in fair value reported through OCI will be reclassified into earnings. 

The following tabular disclosure provides the amount of pre-tax loss recognized as a component of OCI during the three months ended March 31, 2015 and 2014 (in millions): 

	Amount of Pre-Tax Loss Recognized in OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Three Months Ended March 31,
	2015		2014
Interest rate swaps	$	(22)	$	(3)

The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the condensed consolidated statements of income during the three months ended March 31, 2015 and 2014 (in millions):

	Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion)
Location of Loss Reclassified from AOCL into Income (Effective Portion)	Three Months Ended March 31,
	2015		2014
Interest expense, net	$	9	$	18

The fair values of derivative instruments in the condensed consolidated balance sheets as of March 31, 2015 and December 31, 2014 were as follows (in millions):

Asset Derivatives

Liability Derivatives

March 31, 2015

December 31, 2014

March 31, 2015

December 31, 2014

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

-

Other long-term liabilities

$

81

Other long-term liabilities

$

73

XML

Long-Term Debt (7.125% Senior Notes, Due 2020 Narrative) (Details) (Senior Notes [Member], USD $)	1 Months Ended		12 Months Ended	3 Months Ended
	Jul. 18, 2012	Mar. 21, 2012	Dec. 31, 2011	Mar. 31, 2015
Senior Notes at 8.875, Due 2015 [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 934,000,000	$ 850,000,000	$ 1,000,000,000
Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Offering Date				Jul. 18, 2012
Debt Instrument, Face Amount	$ 1,200,000,000
Debt Instrument, Interest Rate, Stated Percentage	7.125%
Debt Instrument, Earliest Redemption Date				Jul. 15, 2016
Debt Instrument, Redemption, Period One [Member] | Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	107.125%
Debt Instrument, Redemption Period, End Date				Jul. 15, 2015
Debt Instrument, Redemption, Description				with the proceeds from certain public equity offerings
Debt Instrument, Redemption, Period Two [Member] | Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date				Jul. 15, 2015
Debt Instrument, Redemption Period, End Date				Jul. 15, 2016
Debt Instrument, Redemption, Description				plus a "make-whole" premium, as described in the 7⅛% Senior Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days
Maximum [Member] | Debt Instrument, Redemption, Period One [Member] | Senior Notes at 7.125, Due 2020 [Member]
Debt Instrument [Line Items]
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount	35.00%

XML

Fair Value of Financial Instruments (Schedule of Pre-tax Gain (Loss) Recognized as a Component of Other Comprehensive Income) (Details) (Cash Flow Hedging [Member], Interest Rate Swap [Member], USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flow Hedging [Member] | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Pre-Tax Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	$ (22)	$ (3)

XML

Condensed Consolidated Balance Sheets (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 222	$ 509
Patient accounts receivable, net of allowance for doubtful accounts of $3,628 and $3,504 at March 31, 2015 and December 31, 2014, respectively	3,606	3,409
Supplies	561	557
Prepaid income taxes		30
Deferred income taxes	341	341
Prepaid expenses and taxes	189	192
Other current assets (including assets of hospitals held for sale of $7 and $38 at March 31, 2015 and December 31, 2014, respectively)	507	528
Total current assets	5,426	5,566
Property and equipment	14,400	14,264
Less accumulated depreciation and amortization	(4,309)	(4,095)
Property and equipment, net	10,091	10,169
Goodwill	8,954	8,951
Other assets, net (including assets of hospitals held for sale of $36 and $90 at March 31, 2015 and December 31, 2014, respectively)	2,648	2,735
Total assets	27,119	27,421
Current liabilities:
Current maturities of long-term debt	229	235
Accounts payable	1,192	1,293
Income tax payable	13
Deferred income taxes	23	23
Accrued interest	157	227
Accrued liabilities (including liabilities of hospitals held for sale of $2 and $10 at March 31, 2015 and December 31, 2014, respectively)	1,547	1,811
Total current liabilities	3,161	3,589
Long-term debt	16,740	16,681
Deferred income taxes	844	845
Other long-term liabilities	1,694	1,692
Total liabilities	22,439	22,807
Redeemable noncontrolling interests in equity of consolidated subsidiaries	520	531
Community Health Systems, Inc. stockholders' equity:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued
Common stock, $.01 par value per share, 300,000,000 shares authorized; 119,000,326 shares issued and 118,024,777 shares outstanding at March 31, 2015, and 117,701,087 shares issued and 116,725,538 shares outstanding at December 31, 2014	1	1
Additional paid-in capital	2,101	2,095
Treasury stock, at cost, 975,549 shares at March 31, 2015 and December 31, 2014	(7)	(7)
Accumulated other comprehensive loss	(70)	(63)
Retained earnings	2,056	1,977
Total Community Health Systems, Inc. stockholders' equity	4,081	4,003
Noncontrolling interests in equity of consolidated subsidiaries	79	80
Total equity	4,160	4,083
Total liabilities and equity	$ 27,119	$ 27,421

XML

Income Taxes

3 Months Ended

Mar. 31, 2015

Income Taxes [Abstract]

Income Taxes Disclosure

6.  INCOME TAXES

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $5 million as of March 31, 2015. A total of approximately $2 million of interest and penalties is included in the amount of the liability for uncertain tax positions at March 31, 2015. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its condensed consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position.

The Company, or one of its subsidiaries, files income tax returns in the United States federal jurisdiction and various state jurisdictions. The Company has extended the federal statute of limitations through December 31, 2015 for Triad Hospitals, Inc. for the tax periods ended December 31, 1999, December 31, 2000, April 30, 2001, June 30, 2001, December 31, 2001, December 31, 2002, December 31, 2003, December 31, 2004, December 31, 2005, December 31, 2006 and July 25, 2007. With few exceptions, the Company is no longer subject to state income tax examinations for years prior to 2011. The Company’s federal income tax returns for the 2009 and 2010 tax years are currently under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2015 for Community Health Systems, Inc. for the tax periods ended December 31, 2007 and 2008, through June 30, 2015 for the tax periods ended December 31, 2009 and 2010, and through September 6, 2016 for the tax period ended December 31, 2011.

The Company’s effective tax rates were 33.2% and 42.5% for the three months ended March 31, 2015 and 2014, respectively. The decrease in the Company’s effective tax rate for the three months ended March 31, 2015 is primarily impacted by the increase in income from continuing operations before income taxes, and the impact of non-deductible transaction costs associated with the HMA merger affecting the tax provision for the three months ended March 31, 2014.

Cash paid for income taxes, net of refunds received, resulted in net cash paid of $1 million and a net cash refund of $79 million during the three months ended March 31, 2015 and 2014, respectively.

XML

Acquisitions and Divestitures

3 Months Ended

Mar. 31, 2015

Acquisitions And Divestitures [Abstract]

Acquisitions and Divestitures Disclosure

5.  ACQUISITIONS AND DIVESTITURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree.  Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts.  Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition.  Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

Approximately $3 million and $57 million of acquisition and related integration costs related to prospective and closed acquisitions were expensed during the three months ended March 31, 2015 and 2014, respectively, and are included in other operating expenses on the condensed consolidated statements of income. 

Effective November 1, 2014, the Company entered into and closed on a restructuring agreement related to the joint venture between an affiliate of the Company and an affiliate of Novant Health, Inc. (“Novant”), the non-profit joint venture partner. Through this joint venture, Novant owned an indirect noncontrolling interest in Lake Norman Regional Medical Center (“Lake Norman”), one of the former HMA hospitals. The HMA merger triggered a change in control provision in the operating agreement of this joint venture, requiring the Company to purchase the 30% noncontrolling interest in Lake Norman held by Novant for the higher of fair value or $150 million. As part of the restructuring agreement, on November 3, 2014, the Company paid Novant (1) $150 million for its 30% noncontrolling interest in Lake Norman, (2) approximately $4 million to acquire Upstate Carolina Medical Center (125 licensed beds) in Gaffney, South Carolina, and (3) approximately $5 million to settle prior claims with Novant. The amounts paid to Novant to acquire the noncontrolling interest in Lake Norman and to settle prior claims were recognized as part of the opening balance sheet in the purchase accounting for HMA. Based upon our preliminary purchase price allocation relating to this acquisition as of March 31, 2015, no goodwill has been recorded related to the acquisition of Upstate Carolina Medical Center. The preliminary allocation of the purchase price has been determined by us based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material.

On October 1, 2014, one or more subsidiaries of the Company completed the acquisition of Natchez Regional Medical Center (179 licensed beds) in Natchez, Mississippi. The total cash consideration paid at closing for long-lived assets was $10 million. As part of the closing, the Company also paid $8 million as a prepayment for future property taxes that will be applied to the tax liability for the next 17 years. Based upon our preliminary purchase price allocation relating to this acquisition as of March 31, 2015, no goodwill has been recorded. The preliminary allocation of the purchase price has been determined by us based on available information and is subject to settling amounts related to purchased working capital and final appraisals of tangible and intangible assets. Adjustments to the purchase price allocation are not expected to be material.

Effective April 1, 2014, one or more subsidiaries of the Company completed the acquisition of Sharon Regional Health System in Sharon, Pennsylvania. This healthcare system includes Sharon Regional (258 licensed beds) and other outpatient and ancillary services. The total cash consideration paid for long-lived assets and working capital was approximately $67 million and $1 million, respectively, with additional consideration of $9 million assumed in liabilities, for a total consideration of $77 million. Based upon the Company’s purchase price allocation relating to this acquisition as of March 31, 2015, approximately $8 million of goodwill has been recorded.

Effective April 1, 2014, one or more subsidiaries of the Company completed the acquisition of a 95% interest in Munroe Regional Medical Center (421 licensed beds) in Ocala, Florida and its other outpatient and ancillary services through a joint venture arrangement with an affiliate of a regional not-for-profit healthcare system, which acquired the remaining 5% interest. The total cash consideration paid for long-lived assets plus prepaid rent on the leased property and working capital was approximately $192 million and $4 million, respectively, with additional consideration of $11 million assumed in liabilities, for a total consideration of $207 million. The value of the noncontrolling interest at acquisition was $10 million. Based upon the Company’s purchase price allocation relating to this acquisition as of March 31, 2015, approximately $11 million of goodwill has been recorded.

HMA Merger

On January 27, 2014, the Company completed the HMA merger by acquiring all the outstanding shares of HMA’s common stock for approximately $7.3 billion, including the assumption of approximately $3.8 billion of existing indebtedness, for consideration for each share of HMA’s common stock consisting of $10.50 in cash, 0.06942 of a share of the Company’s common stock, and one contingent value right (“CVR”). The CVR entitles the holder to receive a cash payment of up to $1.00 per CVR (subject to downward adjustment but not below zero), subject to the final resolution of certain legal matters pertaining to HMA, as defined in the CVR agreement. At the time of the completion of the HMA merger, HMA owned and operated 71 hospitals in 15 states in non-urban communities located primarily in the southeastern United States.

In connection with the HMA merger, the Company and CHS/Community Health Systems, Inc. (“CHS”) entered into a third amendment and restatement of its credit facility, providing for additional financing and recapitalization of certain of the Company’s term loans.  In addition, the Company and CHS also issued in connection with the HMA merger: (i) $1.0 billion aggregate principal amount of 5.125% Senior Secured Notes due 2021 and (ii) $3.0 billion aggregate principal amount of 6.875% Senior Notes due 2022.

The total consideration of the HMA merger has been allocated to the assets acquired and liabilities assumed based upon their respective fair values, resulting in $4.5 billion of goodwill resulting from the final purchase price allocation at December 31, 2014. The purchase price represented a premium over the fair value of the net tangible and identifiable intangible assets acquired for reasons such as:

· the expansion of the number of markets in which the Company operates in existing states;

· the extension and strengthening of the Company’s hospital and physician networks;

· the centralization of many support functions; and

· the elimination of duplicate corporate functions.

Other Acquisitions

During the three months ended March 31, 2015, the Company paid approximately $12 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during 2015, the Company allocated approximately $8 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill.

Discontinued Operations

Effective January 1, 2015, one or more subsidiaries of the Company sold Carolina Pines Regional Medical Center (116 licensed beds) in Hartsville, South Carolina and related outpatient services to Capella Healthcare for approximately $74 million in cash, which was received at the closing on December 31, 2014. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

Effective February 1, 2015, one or more subsidiaries of the Company sold Harris Hospital (133 licensed beds) in Newport, Arkansas and related healthcare services to White County Medical Center in Searcy, Arkansas for approximately $5 million in cash.

Effective March 1, 2015, one or more subsidiaries of the Company sold Riverview Regional Medical Center (281 licensed beds) in Gadsden, Alabama to Prime Healthcare Services, LLC. (“Prime”) for approximately $25 million in cash. This hospital was required to be divested by the Federal Trade Commission as a condition of its approval of the HMA merger.

Effective March 1, 2015, one or more subsidiaries of the Company sold Dallas Regional Medical Center (202 licensed beds) in Mesquite, Texas to Prime for approximately $25 million in cash.

During the year ended December 31, 2014, the Company made the decision to sell and began actively marketing several smaller hospitals, which are classified as held for sale at March 31, 2015. In addition, HMA entered into a definitive agreement to sell Williamson Memorial Hospital (76 licensed beds) located in Williamson, West Virginia prior to the HMA merger. In connection with management’s decision to sell these facilities and the sale of the four hospitals noted above during 2015, the Company has classified the results of operations of the above mentioned hospitals as discontinued operations in the accompanying condensed consolidated statements of income, and classified these hospitals as held for sale in the accompanying condensed consolidated balance sheet.

Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions):

	Three Months Ended
	March 31,
	2015		2014
Net operating revenues	$	56	$	89
Loss from operations of entities sold or held for sale
before income taxes		(17)		(7)
Impairment of hospitals sold or held for sale		(1)		(22)
Loss on sale, net		(1)		-
Loss from discontinued operations, before taxes		(19)		(29)
Income tax benefit		(6)		(7)
Loss from discontinued operations, net of taxes	$	(13)	$	(22)

Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment.

In April 2014, FASB issued ASU 2014-08, which changes the requirements for reporting discontinued operations. A discontinued operation continues to include a component of an entity or a group of components of an entity, or a business activity. However, in a shift reflecting stakeholder concerns that too many disposals of small groups of assets that are recurring in nature qualified for reporting as discontinued operations, a disposal of a component of an entity or a group of components of an entity will be required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. A business or nonprofit activity that, on acquisition, meets the criteria to be classified as held for sale will still be a discontinued operation. Additional disclosures will be required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU is effective for fiscal years beginning after December 15, 2014 and is to be applied on a prospective basis for disposals or components initially classified as held for sale after that date. The Company adopted this ASU on January 1, 2015 and the adoption did not have a material impact on the Company’s consolidated financial position, results of operations and cash flows as of and for the three months ended March 31, 2015.

XML

Subsequent Events

3 Months Ended

Mar. 31, 2015

Subsequent Events [Abstract]

Subsequent Events Disclosure

17.  SUBSEQUENT EVENTS 

The Company evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the condensed consolidated financial statements.

Effective April 1, 2015, one or more subsidiaries of the Company sold Chesterfield General Hospital (59 licensed beds) in Cheraw, South Carolina and Marlboro Park Hospital (102 licensed beds) in Bennettsville, South Carolina, and related outpatient services to M/C Healthcare, LLC for approximately $4 million in cash, which was received at the closing on March 31, 2015.

XML

Fair Value

3 Months Ended

Mar. 31, 2015

Fair Value [Abstract]

Fair Value Disclosure

13.  FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). 

The inputs used to measure fair value are classified into the following fair value hierarchy: 

Level 1:  Quoted market prices in active markets for identical assets or liabilities. 

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data. 

Level 3:  Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions. 

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were notransfers between levels during 2015 or 2014. 

The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 (in millions): 

	March 31, 2015		Level 1		Level 2		Level 3
Available-for-sale securities	$	285	$	156	$	129	$	-
Trading securities		58		58		-		-
Total assets	$	343	$	214	$	129	$	-
Contingent Value Right (CVR)	$	6	$	6	$	-	$	-
CVR-related liability		256		-		-		256
Fair value of interest rate swap agreements		81		-		81		-
Total liabilities	$	343	$	6	$	81	$	256
	December 31, 2014		Level 1		Level 2		Level 3
Available-for-sale securities	$	280	$	151	$	129	$	-
Trading securities		55		55		-		-
Total assets	$	335	$	206	$	129	$	-
Contingent Value Right (CVR)	$	6	$	6	$	-	$	-
CVR-related liability		265		-		-		265
Fair value of interest rate swap agreements		68		-		68		-
Total liabilities	$	339	$	6	$	68	$	265

Available-for-sale Securities

Available-for-sale securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale securities primarily consisted of: (i) bonds and notes issued by the United States government and its agencies, domestic and foreign corporations and foreign governments; and (ii) preferred securities issued by domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Contingent Value Right (CVR)

The CVR represents the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVR is listed on the NASDAQ and the valuation at March 31, 2015 is based on the quoted trading price for the CVR on the last day of the period. Changes in the estimated fair value of the CVR are recorded through the condensed consolidated statement of income.

CVR-related Liability

The CVR-related legal liability represents the Company’s estimate of fair value at March 31, 2015 of the liability associated with the legal matters assumed in the HMA merger that were not previously accrued by HMA. In addition, a liability of $24 million is recorded in accrued liabilities in the accompanying condensed consolidated balance sheet in respect of claims that were previously recorded by HMA as a probable contingency. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability.  The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company has classified the fair value measurement as a Level 3 measurement in the fair value hierarchy.

The fair value of the CVR-related legal liability will be measured each reporting period using similar measurement techniques, updated for the assumptions and facts existing at that date for each of the underlying legal matters. Changes in the fair value of the CVR related legal liability are recorded in future periods through the condensed consolidated statement of income.

Fair Value of Interest Rate Swap Agreements

The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged. 

The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements at March 31, 2015 resulted in a decrease in the fair value of the related liability of $5 million and an after-tax adjustment of $3 million to OCI. The CVA on the Company’s interest rate swap agreements at December 31, 2014 resulted in a decrease in the fair value of the related liability of $4 million and an after-tax adjustment of $2 million to OCI.   

The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy.

XML

Long-Term Debt (Receivables Facility Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 21, 2012	Mar. 07, 2013
Debt Instrument [Line Items]
Debt	$ 16,969,000,000	$ 16,916,000,000
Receivables Facility, Name [Member] | Receivables Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 21, 2012
Maximum Borrowing Capacity of Receivables Facility			300,000,000
Debt	623,000,000	614,000,000
Receivables Facility, March 7, 2013 Amendment [Member] | Receivables Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 07, 2013
Debt Instrument, Maturity Date	Mar. 21, 2017
Maximum Borrowing Capacity of Receivables Facility				500,000,000
Receivables Facility, March 31, 2014 Amendment [Member] | Receivables Facility [Member]
Debt Instrument [Line Items]
Maximum Borrowing Capacity of Receivables Facility	700,000,000
Debt	623,000,000
Receivables included in the Receivables Facility	$ 1,300,000,000

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity Disclosure

9.  STOCKHOLDERS’ EQUITY   

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of March 31, 2015, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

On December 10, 2014, the Company adopted a new open market repurchase program for up to 5,000,000 shares of the Company’s common stock, not to exceed $150 million in repurchases.  The repurchase program will expire at the earliest of three years from the commencement date, when the maximum number of shares has been repurchased, or when the maximum dollar amount of repurchases has been expended. During the three months ended March 31, 2015, the Company did not repurchase and retire any shares under this program.

With the exception of a cash dividend of $0.25 per share paid by the Company in December 2012, historically, the Company has not paid any cash dividends. The Company’s Credit Facility limits the Company’s ability to pay dividends and/or repurchase stock to an amount not to exceed $200 million in the aggregate plus an additional $25 million in any particular year plus the aggregate amount of proceeds from the exercise of stock options. The indentures governing the senior and senior secured notes also limit the Company’s ability to pay dividends and/or repurchase stock. As of March 31, 2015, under the most restrictive test under these agreements, the Company has approximately $461 million remaining available with which to pay permitted dividends and/or repurchase shares of stock or its senior and senior secured notes.

The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company, and equity attributable to the noncontrolling interests for the three-month period ended March 31, 2015 (in millions):

			Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interest		Common Stock		Additional Paid-In Capital		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Noncontrolling Interest		Total Stockholders’ Equity
Balance, December 31, 2014	$	531	$	1	$	2,095	$	(7)	$	(63)	$	1,977	$	80	$	4,083
Comprehensive income		16		-		-		-		(7)		79		4		76
Distributions to noncontrolling
interests, net of contributions		(17)		-		-		-		-		-		(6)		(6)
Purchase of subsidiary shares
from noncontrolling interests		(7)		-		-		-		-		-		-		-
Disposition of less-than-wholly
owned hospital		(8)		-		-		-		-		-		-		-
Other reclassifications of
noncontrolling interests		(1)		-		-		-		-		-		1		1
Adjustment to redemption
value of redeemable
noncontrolling interests		6		-		(6)		-		-		-		-		(6)
Issuance of common stock
in connection with the
exercise of stock options		-		-		18		-		-		-		-		18
Cancellation of restricted
stock for tax withholdings
on vested shares		-		-		(20)		-		-		-		-		(20)
Share-based compensation		-		-		14		-		-		-		-		14
Balance, March 31, 2015	$	520	$	1	$	2,101	$	(7)	$	(70)	$	2,056	$	79	$	4,160

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ equity (in millions): 

	Three Months Ended
	March 31, 2015
Net income attributable to Community Health Systems,
Inc. stockholders	$	79
Transfers to the noncontrolling interests:
Net decrease in Community Health Systems, Inc. paid-in
capital for  purchase of subsidiary partnership interests		-
Net transfers to the noncontrolling interests		-
Change to Community Health Systems, Inc. stockholders’ equity
from net income attributable to Community Health Systems,
Inc. stockholders and transfers to noncontrolling interests	$	79

XML

Goodwill and Other Intangible Assets (Goodwill Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Goodwill	$ 8,954,000,000	$ 8,951,000,000
Goodwill, Impairment Loss	0
Hospital operations [Member]
Goodwill [Line Items]
Goodwill	8,900,000,000
Home Care Agency Operations Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	44,000,000
Hospital Management Services Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	$ 33,000,000

XML

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2015

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Other Intangible Assets Disclosure

7.  GOODWILL AND OTHER INTANGIBLE ASSETS  

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2015 are as follows (in millions):

Balance as of December 31, 2014	$	8,951
Goodwill acquired as part of acquisitions during current year		4
Consideration and purchase price allocation adjustments
for prior year’s acquisitions and other adjustments		(1)
Balance as of March 31, 2015	$	8,954

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segments and hospital management services operations meet the criteria to be classified as reporting units. At March 31, 2015, the hospital operations reporting unit, the home care agency operations reporting unit, and the hospital management services reporting unit had approximately $8.9 billion, $44 million and $33 million, respectively, of goodwill. 

Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performed its last annual goodwill evaluation during the fourth quarter of 2014. No impairment was indicated by this evaluation.  The next annual goodwill evaluation will be performed during the fourth quarter of 2015. 

The Company estimates the fair value of the related reporting units using both a discounted cash flow model as well as an EBITDA multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.  

Intangible Assets

No intangible assets other than goodwill were acquired during the three months ended March 31, 2015.  The gross carrying amount of the Company’s other intangible assets subject to amortization was $76 million at both March 31, 2015 and December 31, 2014, and the net carrying amount was $35 million at March 31, 2015 and $39 million at December 31, 2014. The carrying amount of the Company’s other intangible assets not subject to amortization was $128 million and $131 million at March 31, 2015 and December 31, 2014, respectively. Other intangible assets are included in other assets, net on the Company’s condensed consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions. 

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately four years. There are noexpected residual values related to these intangible assets. Amortization expense on these intangible assets was $3 million and $1 million  during the three months ended March 31, 2015 and 2014, respectively.  Amortization expense on intangible assets is estimated to be $10 million for the remainder of 2015, $13 million in 2016, $3 million in 2017, $2 million in 2018, $2 million in 2019, $2 million in 2020 and $3 million thereafter.   

The gross carrying amount of capitalized software for internal use was approximately  $1.4 billion and  $1.5billion at March 31, 2015 and December 31, 2014, respectively, and the net carrying amount considering accumulated amortization was approximately $769 million and $790 million at March 31, 2015 and December 31, 2014, respectively. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, which is generally eight to ten years.  There is no expected residual value for capitalized internal-use software. At March 31, 2015, there was approximately $33 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use.  Amortization expense on capitalized internal-use software was $53 million and $84 million during the three months ended March 31, 2015 and 2014, respectively.   Amortization expense on capitalized internal-use software is estimated to be $146 million for the remainder of 2015, $167 million in 2016, $103 million in 2017, $75 million in 2018, $68 million in 2019, $65 million in 2020 and $145 million thereafter.

In connection with the HMA merger, the Company further analyzed its intangible assets related to internal-use software used in certain of its hospitals for patient and clinical systems, including software required to meet criteria for meaningful use attestation and ICD-10 compliance. This analysis resulted in management reassessing its usage of certain software products and rationalizing that, with the addition of the HMA hospitals in the first quarter of 2014, those software applications were going to be discontinued and replaced with new applications that better integrate meaningful use and ICD-10 compliance, are more cost effective and can be implemented at a greater efficiency of scale over future implementations. During the three months ended March 31, 2014, the Company recorded an impairment charge of approximately $24 million related to software in-process that was abandoned at March 31, 2014 and the acceleration of amortization of approximately $42 million related to shortening the remaining useful life of software abandoned by July 1, 2014.

XML

Earnings Per Share

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share Disclosure

8.  EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of basic and diluted earnings per share for income (loss) from continuing operations, discontinued operations and net income attributable to Community Health Systems, Inc. common stockholders (in millions, except share data):  

	Three Months Ended
	March 31,
	2015		2014
Numerator:
Income (loss) from continuing operations, net of taxes	$	112	$	(76)
Less: Income from continuing operations attributable
to noncontrolling interests, net of taxes		20		14
Income (loss) from continuing operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	92	$	(90)
Loss from discontinued operations, net of taxes	$	(13)	$	(22)
Less: Loss from discontinued operations attributable
to noncontrolling interests, net of taxes		-		-
Loss from discontinued operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	(13)	$	(22)
Denominator:
Weighted-average number of shares outstanding — basic		114,419,590		106,601,997
Effect of dilutive securities:
Restricted stock awards		181,120		-
Employee stock options		452,659		-
Other equity-based awards		4,299		-
Weighted-average number of shares outstanding — diluted		115,057,668		106,601,997

The Company generated a loss from continuing operations attributable to Community Health Systems, Inc. common stockholders for the three months ended March 31, 2014, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income from continuing operations during the three months ended March 31, 2014, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 578,587 shares.

	Three Months Ended
	March 31,
	2015		2014
Dilutive securities outstanding not included in
the computation of earnings per
share because their effect is antidilutive:
Employee stock options and restricted stock awards		-		1,891,000

XML

Equity Investments

3 Months Ended

Mar. 31, 2015

Equity Investments [Abstract]

Equity Investments Disclosure

10.  EQUITY INVESTMENTS

As of March 31, 2015, the Company owned equity interests of 27.5% in four hospitals in Las Vegas, Nevada, and 26.1% in one hospital in Las Vegas, Nevada, in which Universal Health Systems, Inc. owns the majority interest, and an equity interest of 38.0% in three hospitals in Macon, Georgia, in which HCA Holdings Inc. owns the majority interest.  

Summarized combined financial information for these unconsolidated entities in which the Company owns an equity interest is as follows (in millions): 

	Three Months Ended
	March 31,
	2015		2014
Revenues	$	375	$	332
Operating costs and expenses		315		294
Income from continuing operations before taxes		60		39

The summarized financial information was derived from the unaudited financial information provided to the Company by those unconsolidated entities. 

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As part of the HMA merger, the Company acquired HMA’s ownership in HealthTrust. As of March 31, 2015, the Company had a 25.1% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $488 million and $470 million at March 31, 2015 and December 31, 2014, respectively, and is included in other assets, net in the accompanying condensed consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $18 million and $11 million for the three months ended March 31, 2015 and 2014, respectively.

XML

Earnings Per Share (Schedule of Antidilutive Securities (Details)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]
Employee stock options and restricted stock awards	1,891,000

XML

Long-Term Debt (Loss from Early Extinguishment of Debt Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Extinguishment of Debt Disclosures [Abstract]
Loss from early extinguishment of debt	$ 8	$ 73
Loss on Extinguishment of Debt, Net of Tax	$ 5	$ 45

XML

Stockholders' Equity (Schedule of Stockholders' Equity) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity, beginning balance	$ 4,083
Redeemable Noncontrolling Interests, beginning balance	531
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests	76
Distributions to noncontrolling interests, net of contributions	(6)
Other reclassifications of noncontrolling interests	1
Adjustment to redemption value of redeemable noncontrolling interests	(6)
Issuance of common stock in connection with the exercise of stock options	18
Cancellation of restricted stock for tax withholdings on vested shares	(20)
Share-based compensation	14
Equity, ending balance	4,160
Redeemable Noncontrolling Interests, ending balance	520
Redeemable Noncontrolling Interests (Non- Equity) [Member]
Redeemable Noncontrolling Interests, beginning balance	531
Comprehensive income (loss) attributable to redeemable noncontrolling interest	16
Distributions to redeemable noncontrolling interests, net of contributions	(17)
Purchase of subsidiary shares from noncontrolling interests	(7)
Disposition of less-than-wholly owned hospital owned hospital	(8)
Other reclassifications of redeemable noncontrolling interests	(1)
Adjustment to redemption value of redeemable noncontrolling interests	6
Redeemable Noncontrolling Interests, ending balance	520
Common Stock [Member]
Equity, beginning balance		1
Equity, ending balance	1	1
Additional Paid-in Capital [Member]
Equity, beginning balance	2,095
Adjustment to redemption value of redeemable noncontrolling interests	(6)
Issuance of common stock in connection with the exercise of stock options	18
Cancellation of restricted stock for tax withholdings on vested shares	(20)
Share-based compensation	14
Equity, ending balance	2,101
Treasury Stock [Member]
Equity, beginning balance		(7)
Equity, ending balance	(7)	(7)
Accumulated Other Comprehensive (Loss) Income [Member]
Equity, beginning balance	(63)
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests	(7)
Equity, ending balance	(70)
Retained Earnings [Member]
Equity, beginning balance	1,977
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests	79
Equity, ending balance	2,056
Noncontrolling Interests [Member]
Equity, beginning balance	80
Comprehensive income (loss) including portion attributable to nonredeemable noncontrolling interests	4
Distributions to noncontrolling interests, net of contributions	(6)
Other reclassifications of noncontrolling interests	1
Equity, ending balance	$ 79

XML

Subsequent Events (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Apr. 01, 2015
Subsequent Event [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	$ 62
Chesterfield General Hospital and Marlboro Park Hospital [Member]
Subsequent Event [Line Items]
Disposal Date	Apr. 01, 2015
Subsequent Event [Member] | Chesterfield General Hospital [Member]
Subsequent Event [Line Items]
Number of licensed beds sold		59
Subsequent Event [Member] | Marlboro Park Hospital [Member]
Subsequent Event [Line Items]
Number of licensed beds sold		102
Subsequent Event [Member] | Chesterfield General Hospital and Marlboro Park Hospital [Member]
Subsequent Event [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested		$ 4

XML

Earnings Per Share (Narrative) (Details)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]
Increase in number of shares to diluted shares calculation if income from continuing operations would have been generated	578,587

XML

Fair Value of Financial Instruments (Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet) (Details) (Designated as Hedging Instrument [Member], Other Long-term Liabilities [Member], USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives designated as hedging instruments	$ 81	$ 73

XML

Accounting for Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2015

Accounting for Stock-Based Compensation [Abstract]

Schedule of Share-based Compensation Expense

	Three Months Ended
	March 31,
	2015		2014
Effect on income from continuing operations before income taxes	$	(14)	$	(11)
Effect on net income	$	(8)	$	(7)

Schedule of Share-based Compensation, Stock Options, Activity

				Weighted-	Aggregate
				Average	Intrinsic
		Weighted-		Remaining	Value as of
		Average		Contractual	March 31,
	Shares	Exercise Price		Term	2015
Outstanding at December 31, 2014	1,953,727	$	32.94
Granted	-		-
Exercised	(452,959)		38.77
Forfeited and cancelled	-		-
Outstanding at March 31, 2015	1,500,768	$	31.18	4.7 years	$	32
Exercisable at March 31, 2015	1,498,764	$	31.19	4.7 years	$	37

Schedule of Share-based Compensation, Restricted Stock, Activity

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2014	2,760,639	$	39.82
Granted	1,223,500		47.72
Vested	(1,115,006)		37.45
Forfeited	-		-
Unvested at March 31, 2015	2,869,133		44.11

Schedule of Share-based Compensation, Restricted Stock Units Award, Activity

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2014	49,362	$	36.07
Granted	21,024		47.70
Vested	(27,708)		31.76
Forfeited	-		-
Unvested at March 31, 2015	42,678		44.59

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Stock Options, Activity) (Details) (Employee Stock Option [Member], USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, shares	1,953,727
Granted, Shares	0	0
Exercised, Shares	(452,959)
Ending Balance, shares	1,500,768
Beginning of Period, Weighted Average Exercise Price	$ 32.94
Exercised, Weighted Average Exercise Price	$ 38.77
End of Period, Weighted Average Exercise Price	$ 31.18
Weighted Average Remaining Contractual Term	4 years 8 months 12 days
Aggregate Intrinsic Value	$ 32
Exercisable, Shares	1,498,764
Exercisable, Weighted Average Exercise Price	$ 31.19
Exercisable, Weighted Average Remaining Contractual Term	4 years 8 months 12 days
Exercisable, Aggregate Intrinsic Value	$ 37

XML

Other Comprehensive Income

3 Months Ended

Mar. 31, 2015

Stockholders' Equity [Abstract]

Other Comprehensive Income Disclosure

15. OTHER COMPREHENSIVE INCOME

The following tables present information about items reclassified out of accumulated other comprehensive income (loss) by component for the three months ended March 31, 2015 and 2014 (in millions, net of tax):

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2014	$	(43)	$	7	$	(27)	$	(63)
Other comprehensive (loss)
income before reclassifications		(15)		1		-		(14)
Amounts reclassified from
accumulated other
comprehensive income (loss)		6		-		1		7
Net current-period other
comprehensive income		(9)		1		1		(7)
Balance as of March 31, 2015	$	(52)	$	8	$	(26)	$	(70)

					Change in
	Change in Fair		Change in Fair		Unrecognized		Accumulated Other
	Value of Interest		Value of Available		Pension Cost		Comprehensive
	Rate Swaps		for Sale Securities		Components		Income (Loss)
Balance as of December 31, 2013	$	(56)	$	7	$	(18)	$	(67)
Other comprehensive (loss)
income before reclassifications		(2)		-		-		(2)
Amounts reclassified from
accumulated other
comprehensive income (loss)		11		-		-		11
Net current-period other
comprehensive income		9		-		-		9
Balance as of March 31, 2014	$	(47)	$	7	$	(18)	$	(58)

The following tables present a subtotal for each significant reclassification to net income out of accumulated other comprehensive income (loss) and the line item affected in the accompanying condensed consolidated statement of income for the three months ended March 31, 2015 and 2014 (in millions):

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2015		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(9)	Interest expense, net
		3	Tax benefit
	$	(6)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		(1)	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Three Months Ended		statement where net
comprehensive income (loss) components	March 31, 2014		income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(18)	Interest expense, net
		7	Tax benefit
	$	(11)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	-	Salaries and benefits
Actuarial losses		-	Salaries and benefits
		-	Total before tax
		-	Tax benefit
	$	-	Net of tax

XML

Use of Estimates (Policies)

3 Months Ended

Mar. 31, 2015

Use of Estimates [Abstract]

Use of Estimates, Policy

4.  USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

XML

Segment Information (Narrative) (Details)	3 Months Ended
	Mar. 31, 2015 segment
Segment Information [Abstract]
Number of Operating Segments	2

XML

Accounting for Stock-Based Compensation (Narrative) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 01, 2015	Mar. 01, 2014	Feb. 27, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Unrecognized Compensation Costs on Nonvested Awards	$ 103
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	29 months
Aggregate intrinsic value of options exercised	$ 5	$ 1
Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price	$ 52.28
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	one-third increments on each of the first three anniversaries of the award date
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	one-third increments on each of the first three anniversaries of the award date
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		835,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	2 years
Restricted Stock, Performance-Based Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	one-third increments on each of the first three anniversaries of the award date
Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	one-third increments on each of the first three anniversaries of the award date
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	one-third increments on each of the first three anniversaries of the award date
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,192,176
Plan 2009 [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Number of Shares Received by Each Director			3,504	3,614	3,596
Contractual Term of Option Granted Prior to 2005 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted	10 years
Contractual Term of Option Granted From 2005 Through 2007 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted	8 years
Contractual Term Of Option Granted From 2008 Through 2011 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted	10 years
Contractual Term of Option Granted in 2011 or Later [Member] | Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Contractual Term of Option Granted	10 years

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Comprehensive Income (Loss)) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income (loss)	$ 99	$ (98)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(9)	9
Net change in fair value of available-for-sale securities, net of tax	1
Amortization and recognition of unrecognized pension cost components, net of tax	1
Other comprehensive (loss) income	(7)	9
Comprehensive income (loss)	92	(89)
Less: Comprehensive income attributable to noncontrolling interests	20	14
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	72	(103)
Parent Company [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income (loss)	79	(112)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(9)	9
Net change in fair value of available-for-sale securities, net of tax	1
Amortization and recognition of unrecognized pension cost components, net of tax	1
Other comprehensive (loss) income	(7)	9
Comprehensive income (loss)	72	(103)
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	72	(103)
Subsidiary Issuer [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income (loss)	79	(112)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(9)	9
Net change in fair value of available-for-sale securities, net of tax	1
Amortization and recognition of unrecognized pension cost components, net of tax	1
Other comprehensive (loss) income	(7)	9
Comprehensive income (loss)	72	(103)
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	72	(103)
Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income (loss)	101	(29)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of available-for-sale securities, net of tax	1
Amortization and recognition of unrecognized pension cost components, net of tax	1
Other comprehensive (loss) income	2
Comprehensive income (loss)	103	(29)
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	103	(29)
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income (loss)	10	(18)
Other comprehensive (loss) income, net of income taxes:
Comprehensive income (loss)	10	(18)
Less: Comprehensive income attributable to noncontrolling interests	20	14
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	(10)	(32)
Consolidation, Eliminations [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net income (loss)	(170)	173
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	9	(9)
Net change in fair value of available-for-sale securities, net of tax	(2)
Amortization and recognition of unrecognized pension cost components, net of tax	(2)
Other comprehensive (loss) income	5	(9)
Comprehensive income (loss)	(165)	164
Comprehensive income (loss) attributable to Community Health Systems, Inc. stockholders	$ (165)	$ 164

XML

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2015

Fair Value of Financial Instruments [Abstract]

Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping

	March 31, 2015				December 31, 2014
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	222	$	222	$	509	$	509
Available-for-sale securities		285		285		280		280
Trading securities		58		58		55		55
Liabilities:
Contingent Value Right		6		6		6		6
Credit Facility		7,231		7,249		7,165		7,143
8% Senior Notes		2,017		2,129		2,018		2,139
7⅛% Senior Notes		1,200		1,277		1,200		1,282
2018 Senior Secured Notes		1,600		1,655		1,600		1,655
2021 Senior Secured Notes		1,000		1,034		1,000		1,041
6⅞% Senior Notes		3,000		3,211		3,000		3,194
Receivables Facility and other debt		706		706		705		705

Schedule of Interest Rate Swaps

Swap #	Notional Amount (in millions)		Fixed Interest Rate		Termination Date	Fair Value (in millions)
1	$	300	3.447	%	August 6, 2016	$	12
2		100	3.401	%	August 19, 2016		4
3		200	3.429	%	August 19, 2016		8
4		200	3.500	%	August 30, 2016		8
5		100	3.005	%	November 30, 2016		4
6		200	2.055	%	July 25, 2019		5
7		200	2.059	%	July 25, 2019		5
8		400	1.882	%	August 30, 2019		1	(1)
9		200	2.515	%	August 30, 2019		5	(1)
10		200	2.613	%	August 30, 2019		6	(2)
11		300	2.041	%	August 30, 2020		1	(1)
12		300	2.738	%	August 30, 2020		10	(1)
13		300	2.892	%	August 30, 2020		12	(2)

___________________

(1) This interest rate swap becomes effective August 28, 2015.

(2) This interest rate swap becomes effective August 30, 2015.

Schedule of Pre-tax Gain (Loss) Recognized as a Component of Other Comprehensive Income

	Amount of Pre-Tax Loss Recognized in OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Three Months Ended March 31,
	2015		2014
Interest rate swaps	$	(22)	$	(3)

Schedule of Effective Portion of the Pre-tax Loss Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income

	Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion)
Location of Loss Reclassified from AOCL into Income (Effective Portion)	Three Months Ended March 31,
	2015		2014
Interest expense, net	$	9	$	18

Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet

Asset Derivatives

Liability Derivatives

March 31, 2015

December 31, 2014

March 31, 2015

December 31, 2014

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

-

Other long-term liabilities

$

81

Other long-term liabilities

$

73

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Cash Flows) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net cash (used in) provided by operating activities	$ (61)	$ 65
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(13)	(2,774)
Purchases of property and equipment	(241)	(181)
Proceeds from disposition of hospitals and other ancillary operations	62
Proceeds from sale of property and equipment	3
Purchases of available-for-sale securities	(59)	(78)
Proceeds from sales of available-for-sale securities	56	76
Increase in other investments	(39)	(99)
Net cash used in investing activities	(231)	(3,056)
Cash flows from financing activities:
Proceeds from exercise of stock options	17	6
Repurchase of restricted stock shares for payroll tax withholding requirements	(20)	(11)
Deferred financing costs and other debt-related costs	(20)	(269)
Excess tax benefit relating to stock-based compensation		3
Redemption of noncontrolling investments in joint ventures	(7)	(5)
Distributions to noncontrolling investors in joint ventures	(23)	(19)
Borrowings under credit agreements	1,251	7,079
Issuance of long-term debt		4,000
Proceeds from receivables facility	75	133
Repayments of long-term indebtedness	(1,268)	(7,686)
Net cash provided by financing activities	5	3,231
Net change in cash and cash equivalents	(287)	240
Cash and cash equivalents at beginning of period	509	373
Cash and cash equivalents at end of period	222	613
Parent Company [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(10)	73
Cash flows from financing activities:
Proceeds from exercise of stock options	17	6
Repurchase of restricted stock shares for payroll tax withholding requirements	(20)	(11)
Excess tax benefit relating to stock-based compensation		3
Changes in intercompany balances with affiliates, net	13	(71)
Net cash provided by financing activities	10	(73)
Subsidiary Issuer [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(123)	298
Cash flows from financing activities:
Deferred financing costs and other debt-related costs	(20)	(269)
Changes in intercompany balances with affiliates, net	77	(3,417)
Borrowings under credit agreements	1,250	7,062
Issuance of long-term debt		4,000
Repayments of long-term indebtedness	(1,184)	(7,674)
Net cash provided by financing activities	123	(298)
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	23	62
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(11)	(2,760)
Purchases of property and equipment	(199)	(143)
Proceeds from disposition of hospitals and other ancillary operations	4
Purchases of available-for-sale securities	(22)
Proceeds from sales of available-for-sale securities	19
Increase in other investments	(30)	(75)
Net cash used in investing activities	(239)	(2,978)
Cash flows from financing activities:
Changes in intercompany balances with affiliates, net	(101)	3,117
Borrowings under credit agreements	1	17
Repayments of long-term indebtedness	(15)	(7)
Net cash provided by financing activities	(115)	3,127
Net change in cash and cash equivalents	(331)	211
Cash and cash equivalents at beginning of period	368	239
Cash and cash equivalents at end of period	37	450
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	49	(368)
Cash flows from investing activities:
Acquisitions of facilities and other related equipment	(2)	(14)
Purchases of property and equipment	(42)	(38)
Proceeds from disposition of hospitals and other ancillary operations	58
Proceeds from sale of property and equipment	3
Purchases of available-for-sale securities	(37)	(78)
Proceeds from sales of available-for-sale securities	37	76
Increase in other investments	(9)	(24)
Net cash used in investing activities	8	(78)
Cash flows from financing activities:
Redemption of noncontrolling investments in joint ventures	(7)	(5)
Distributions to noncontrolling investors in joint ventures	(23)	(19)
Changes in intercompany balances with affiliates, net	11	371
Proceeds from receivables facility	75	133
Repayments of long-term indebtedness	(69)	(5)
Net cash provided by financing activities	(13)	475
Net change in cash and cash equivalents	44	29
Cash and cash equivalents at beginning of period	141	134
Cash and cash equivalents at end of period	$ 185	$ 163

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets [Abstract]
Allowance for doubtful patient accounts	$ 3,628	$ 3,504
Other current assets of hospitals held for sale	7	38
Noncurrent assets of hospitals held for sale	36	90
Current liabilities of hospitals held for sale	$ 2	$ 10
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	119,000,326	117,701,087
Common stock, shares outstanding	118,024,777	116,725,538
Treasury stock, shares	975,549	975,549

XML

Fair Value of Financial Instruments (Schedule of Interest Rate Swaps) (Details) (Interest Rate Swap [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Interest Rate Swaps One [Member]
Derivative [Line Items]
Notional Amount, Liability	$ 300,000,000
Fixed Interest Rate	3.447%
Termination Date	Aug. 06, 2016
Fair Value of Liability	12,000,000
Interest Rate Swaps Two [Member]
Derivative [Line Items]
Notional Amount, Liability	100,000,000
Fixed Interest Rate	3.401%
Termination Date	Aug. 19, 2016
Fair Value of Liability	4,000,000
Interest Rate Swaps Three [Member]
Derivative [Line Items]
Notional Amount, Liability	200,000,000
Fixed Interest Rate	3.429%
Termination Date	Aug. 19, 2016
Fair Value of Liability	8,000,000
Interest Rate Swaps Four [Member]
Derivative [Line Items]
Notional Amount, Liability	200,000,000
Fixed Interest Rate	3.50%
Termination Date	Aug. 30, 2016
Fair Value of Liability	8,000,000
Interest Rate Swaps Five [Member]
Derivative [Line Items]
Notional Amount, Liability	100,000,000
Fixed Interest Rate	3.005%
Termination Date	Nov. 30, 2016
Fair Value of Liability	4,000,000
Interest Rate Swaps Six [Member]
Derivative [Line Items]
Notional Amount, Liability	200,000,000
Fixed Interest Rate	2.055%
Termination Date	Jul. 25, 2019
Fair Value of Liability	5,000,000
Interest Rate Swaps Seven [Member]
Derivative [Line Items]
Notional Amount, Liability	200,000,000
Fixed Interest Rate	2.059%
Termination Date	Jul. 25, 2019
Fair Value of Liability	5,000,000
Interest Rate Swaps Eight [Member]
Derivative [Line Items]
Notional Amount, Liability	400,000,000
Fixed Interest Rate	1.882%
Termination Date	Aug. 30, 2019
Fair Value of Liability	1,000,000	[1]
Interest Rate Swaps Nine [Member]
Derivative [Line Items]
Notional Amount, Liability	200,000,000
Fixed Interest Rate	2.515%
Termination Date	Aug. 30, 2019
Fair Value of Liability	5,000,000	[1]
Interest Rate Swaps Ten [Member]
Derivative [Line Items]
Notional Amount, Liability	200,000,000
Fixed Interest Rate	2.613%
Termination Date	Aug. 30, 2019
Fair Value of Liability	6,000,000	[2]
Interest Rate Swaps Eleven [Member]
Derivative [Line Items]
Notional Amount, Liability	300,000,000
Fixed Interest Rate	2.041%
Termination Date	Aug. 30, 2020
Fair Value of Liability	1,000,000	[1]
Interest Rate Swaps Twelve [Member]
Derivative [Line Items]
Notional Amount, Liability	300,000,000
Fixed Interest Rate	2.738%
Termination Date	Aug. 30, 2020
Fair Value of Liability	10,000,000	[1]
Interest Rate Swaps Thirteen [Member]
Derivative [Line Items]
Notional Amount, Liability	300,000,000
Fixed Interest Rate	2.892%
Termination Date	Aug. 30, 2020
Fair Value of Liability	$ 12,000,000	[2]

[1] This interest rate swap becomes effective August 28, 2015.

[2] This interest rate swap becomes effective August 30, 2015.

XML

Use of Estimates

3 Months Ended

Mar. 31, 2015

Use of Estimates [Abstract]

Use of Estimates Disclosure

4.  USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

XML

Income Taxes (Income Tax Contingency and Taxes Paid Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Contingency [Abstract]
Unrecognized benefit that would affect the effective tax rate	$ 5
Amount of interest and penalties included in liabilities for uncertain tax positions	2
Effective Income Tax Rate, Continuing Operations	33.20%	42.50%
Cash Paid for Income Taxes, Net of Refunds Received [Abstract]
Cash paid for income taxes (refunds received), net	$ 1	$ (79)

XML

Long-Term Debt (5.125% Senior Notes, Due 2021 Narrative) (Details) (Senior Secured Notes [Member], Senior Secured Notes at 5.125, Due 2021 [Member], USD $)	1 Months Ended	3 Months Ended
	Jan. 27, 2014	Mar. 31, 2015
Debt Instrument [Line Items]
Debt Instrument, Offering Date		Jan. 27, 2014
Debt Instrument, Face Amount	1,000,000,000
Debt Instrument, Interest Rate, Stated Percentage	5.125%
Debt Instrument, Earliest Redemption Date		Feb. 01, 2017
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	105.125%
Debt Instrument, Redemption Period, End Date		Feb. 01, 2017
Debt Instrument, Redemption, Description		proceeds from certain equity offerings
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date		Feb. 01, 2016
Debt Instrument, Redemption Period, End Date		Feb. 01, 2017
Debt Instrument, Redemption, Description		plus a "make-whole" premium, as described in the 2021 Senior Secured Notes indenture
Minimum Period Notice for Redemption of Debt	30 days
Maximum Period Notice for Redemption of Debt	60 days
Maximum [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Max Principal Redeemable Using Proceeds from a Public Equity Offering, as a Percentage of Principal Amount	40.00%

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Balance Sheet) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 222	$ 509	$ 613	$ 373
Patient accounts receivable, net of allowance for doubtful accounts	3,606	3,409
Supplies	561	557
Prepaid income taxes		30
Deferred income taxes	341	341
Prepaid expenses and taxes	189	192
Other current assets	507	528
Total current assets	5,426	5,566
Property and equipment, net	10,091	10,169
Goodwill	8,954	8,951
Other assets, net	2,648	2,735
Total assets	27,119	27,421
Current liabilities:
Current maturities of long-term debt	229	235
Accounts payable	1,192	1,293
Income tax payable	13
Deferred income taxes	23	23
Accrued interest	157	227
Accrued liabilities	1,547	1,811
Total current liabilities	3,161	3,589
Long-term debt	16,740	16,681
Deferred income taxes	844	845
Other long-term liabilities	1,694	1,692
Total liabilities	22,439	22,807
Redeemable noncontrolling interests in equity of consolidated subsidiaries	520	531
Community Health Systems, Inc. stockholders' equity:
Preferred stock
Common stock	1	1
Additional paid-in capital	2,101	2,095
Treasury stock, at cost	(7)	(7)
Accumulated other comprehensive loss	(70)	(63)	(58)	(67)
Retained earnings	2,056	1,977
Total Community Health Systems, Inc. stockholders' equity	4,081	4,003
Noncontrolling interests in equity of consolidated subsidiaries	79	80
Total equity	4,160	4,083
Total liabilities and equity	27,119	27,421
Parent Company [Member]
Current assets:
Prepaid income taxes		30
Deferred income taxes	341	341
Total current assets	341	371
Intercompany receivable	1,257	1,199
Other assets, net	6	15
Net investment in subsidiaries	3,361	3,290
Total assets	4,965	4,875
Current liabilities:
Income tax payable	13
Deferred income taxes	23	23
Accrued liabilities	4	4
Total current liabilities	40	27
Deferred income taxes	844	845
Total liabilities	884	872
Community Health Systems, Inc. stockholders' equity:
Common stock	1	1
Additional paid-in capital	2,101	2,095
Treasury stock, at cost	(7)	(7)
Accumulated other comprehensive loss	(70)	(63)
Retained earnings	2,056	1,977
Total Community Health Systems, Inc. stockholders' equity	4,081	4,003
Total equity	4,081	4,003
Total liabilities and equity	4,965	4,875
Subsidiary Issuer [Member]
Current assets:
Intercompany receivable	16,512	16,560
Other assets, net	303	302
Net investment in subsidiaries	18,435	18,229
Total assets	35,250	35,091
Current liabilities:
Current maturities of long-term debt	163	163
Accounts payable	1
Accrued interest	155	225
Total current liabilities	319	388
Long-term debt	15,885	15,820
Intercompany payable	14,822	14,752
Other long-term liabilities	862	841
Total liabilities	31,888	31,801
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	1,294	1,208
Accumulated other comprehensive loss	(70)	(63)
Retained earnings	2,138	2,145
Total Community Health Systems, Inc. stockholders' equity	3,362	3,290
Total equity	3,362	3,290
Total liabilities and equity	35,250	35,091
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	37	368	450	239
Patient accounts receivable, net of allowance for doubtful accounts	1,430	1,272
Supplies	377	373
Prepaid expenses and taxes	131	138
Other current assets	329	356
Total current assets	2,304	2,507
Intercompany receivable	3,314	2,532
Property and equipment, net	6,613	6,548
Goodwill	5,483	5,480
Other assets, net	1,817	1,874
Net investment in subsidiaries	7,643	7,399
Total assets	27,174	26,340
Current liabilities:
Current maturities of long-term debt	54	61
Accounts payable	873	909
Accrued interest	1	2
Accrued liabilities	1,051	1,249
Total current liabilities	1,979	2,221
Long-term debt	127	139
Intercompany payable	20,071	19,066
Other long-term liabilities	1,113	1,140
Total liabilities	23,290	22,566
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	1,471	1,369
Accumulated other comprehensive loss	(17)	(25)
Retained earnings	2,430	2,430
Total Community Health Systems, Inc. stockholders' equity	3,884	3,774
Total equity	3,884	3,774
Total liabilities and equity	27,174	26,340
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	185	141	163	134
Patient accounts receivable, net of allowance for doubtful accounts	2,176	2,137
Supplies	184	184
Prepaid expenses and taxes	58	54
Other current assets	178	172
Total current assets	2,781	2,688
Intercompany receivable	6,131	7,877
Property and equipment, net	3,478	3,621
Goodwill	3,471	3,471
Other assets, net	1,164	1,179
Total assets	17,025	18,836
Current liabilities:
Current maturities of long-term debt	12	11
Accounts payable	318	384
Accrued interest	1
Accrued liabilities	492	558
Total current liabilities	823	953
Long-term debt	728	722
Intercompany payable	14,117	15,795
Other long-term liabilities	361	346
Total liabilities	16,029	17,816
Redeemable noncontrolling interests in equity of consolidated subsidiaries	520	531
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	523	528
Accumulated other comprehensive loss		5
Retained earnings	(126)	(124)
Total Community Health Systems, Inc. stockholders' equity	397	409
Noncontrolling interests in equity of consolidated subsidiaries	79	80
Total equity	476	489
Total liabilities and equity	17,025	18,836
Consolidation, Eliminations [Member]
Current assets:
Intercompany receivable	(27,214)	(28,168)
Other assets, net	(642)	(635)
Net investment in subsidiaries	(29,439)	(28,918)
Total assets	(57,295)	(57,721)
Current liabilities:
Intercompany payable	(49,010)	(49,613)
Other long-term liabilities	(642)	(635)
Total liabilities	(49,652)	(50,248)
Community Health Systems, Inc. stockholders' equity:
Additional paid-in capital	(3,288)	(3,105)
Accumulated other comprehensive loss	87	83
Retained earnings	(4,442)	(4,451)
Total Community Health Systems, Inc. stockholders' equity	(7,643)	(7,473)
Total equity	(7,643)	(7,473)
Total liabilities and equity	$ (57,295)	$ (57,721)

XML

Equity Investments (Schedule of Financial Information Related to Unconsolidated Entities Included in Consolidated Statement of Income) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Equity Investments [Abstract]
Revenues	$ 375	$ 332
Operating costs and expenses	315	294
Income from continuing operations before taxes	$ 60	$ 39

XML

Acquisitions and Divestitures (Policies)

3 Months Ended

Mar. 31, 2015

Acquisitions And Divestitures [Abstract]

Business Combinations Policy

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree.  Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts.  Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded as of the date of acquisition.  Any material impact to comparative information for periods after acquisition, but before the period in which adjustments are identified, is reflected in those prior periods as if the adjustments were considered as of the acquisition date. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

XML

Long-Term Debt (Schedule of Early Redemption Prices on 8.0% Senior Notes) (Details) (Senior Notes at 8.0, Due 2019 [Member], Senior Notes [Member])	3 Months Ended
	Mar. 31, 2015
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	104.00%
Debt Instrument, Redemption Period, Start Date	Nov. 15, 2015
Debt Instrument, Redemption Period, End Date	Nov. 14, 2016
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.00%
Debt Instrument, Redemption Period, Start Date	Nov. 15, 2016
Debt Instrument, Redemption Period, End Date	Nov. 14, 2017
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Nov. 15, 2017
Debt Instrument, Redemption Period, End Date	Nov. 15, 2019

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2015

Stockholders' Equity [Abstract]

Schedule of Stockholders' Equity

			Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interest		Common Stock		Additional Paid-In Capital		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Noncontrolling Interest		Total Stockholders’ Equity
Balance, December 31, 2014	$	531	$	1	$	2,095	$	(7)	$	(63)	$	1,977	$	80	$	4,083
Comprehensive income		16		-		-		-		(7)		79		4		76
Distributions to noncontrolling
interests, net of contributions		(17)		-		-		-		-		-		(6)		(6)
Purchase of subsidiary shares
from noncontrolling interests		(7)		-		-		-		-		-		-		-
Disposition of less-than-wholly
owned hospital		(8)		-		-		-		-		-		-		-
Other reclassifications of
noncontrolling interests		(1)		-		-		-		-		-		1		1
Adjustment to redemption
value of redeemable
noncontrolling interests		6		-		(6)		-		-		-		-		(6)
Issuance of common stock
in connection with the
exercise of stock options		-		-		18		-		-		-		-		18
Cancellation of restricted
stock for tax withholdings
on vested shares		-		-		(20)		-		-		-		-		(20)
Share-based compensation		-		-		14		-		-		-		-		14
Balance, March 31, 2015	$	520	$	1	$	2,101	$	(7)	$	(70)	$	2,056	$	79	$	4,160

Schedule of Impact of Noncontrolling Interest to Stockholders' Equity

	Three Months Ended
	March 31, 2015
Net income attributable to Community Health Systems,
Inc. stockholders	$	79
Transfers to the noncontrolling interests:
Net decrease in Community Health Systems, Inc. paid-in
capital for  purchase of subsidiary partnership interests		-
Net transfers to the noncontrolling interests		-
Change to Community Health Systems, Inc. stockholders’ equity
from net income attributable to Community Health Systems,
Inc. stockholders and transfers to noncontrolling interests	$	79

XML

Segment Information

3 Months Ended

Mar. 31, 2015

Segment Information [Abstract]

Segment Information Disclosure

14.  SEGMENT INFORMATION

The Company operates in two distinct operating segments, represented by hospital operations (which includes its general acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services) and home care agency operations (which provide in-home outpatient care). 

Only the hospital operations segment meets the criteria as a separate reportable segment. The financial information for the home care agency segment does not meet the quantitative thresholds for a separate identifiable reportable segment and is combined into the corporate and all other reportable segment.

The distribution between reportable segments of the Company’s net operating revenues and income (loss) from continuing operations before income taxes is summarized in the following tables (in millions):

	Three Months Ended March 31,
	2015		2014
Net operating revenues:
Hospital operations	$	4,857	$	4,124
Corporate and all other		54		52
Total	$	4,911	$	4,176
Income (loss) from continuing operations before income taxes:
Hospital operations	$	273	$	38
Corporate and all other		(105)		(170)
Total	$	168	$	(132)

XML

Contingencies (Schedule of the Reconciliation of Accrued Liability Balances for Probable Contingencies) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Loss Contingency Accrual [Roll Forward]
Expense	$ 8
Pending Litigation [Member] | CVR Related Liability at Fair Value [Member]
Loss Contingency Accrual [Roll Forward]
Beginning Balance	265
Expense	(9)
Ending Balance	256
Pending Litigation [Member] | CVR Related Liability for Probably Contingencies [Member]
Loss Contingency Accrual [Roll Forward]
Beginning Balance	29
Expense	(5)
Ending Balance	24
Pending Litigation [Member] | Legal Matters Where Negative Outcome is Known or Probable [Member]
Loss Contingency Accrual [Roll Forward]
Beginning Balance	125
Expense	15
Cash payments	(92)
Ending Balance	$ 48